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Abstract:
Aberrant phosphorylation and pathological deposition of the microtubule associated protein tau
(tau protein) is associated with toxicity and cellular death in a number of neurodegenerative
diseases (tauopathies). Specific phosphorylation sites are of interest in the processes leading to
tau protein toxicity. One site of interest on tau protein is Thr175 (pThr175), which has been
identified in diseased brain tissue from individuals with amyotrophic lateral sclerosis with
cognitive impairment (ALSci) and Alzheimer’s disease. In vitro, pseudophosphorylation at this
residue has been shown to induce the formation of pathological tau fibrils and, apoptotic cell
death.
In my thesis, I have investigated the mechanism of cellular toxicity following
phosphorylation of tau protein at Thr175. After showing that Thr175 pseudophosphorylation alone
is insufficient to initiate tau protein fibrillization, I demonstrated that tau phosphorylation at
Thr175 directly leads to the induction of kinase glycogen synthase kinase-3β (GSK3β) which in
turn phosphorylates tau protein at Thr231. Both of these steps are necessary for the cytotoxicity
of pThr175 tau to be manifest. I have shown that the pharmacological inhibition of this process
leading to Thr231 phosphorylation prevents both fibril formation and cell death. To determine the
extent to which this pathological process of Thr231 phosphorylation was applicable across the
tauopathies in general, I characterized the presence of pThr175, activated GSK3β, pThr231tau and
oligomeric tau formation across multiple tauopathies. In doing so, I demonstrated that this
pathway may play an integral role in the generation of pathological tau deposition beyond that
discovered for ALSci.
I then characterized pThr175 tau protein pathology in the trauma-associated
neurodegenerative disease chronic traumatic encephalopathy (CTE) and CTE with amyotrophic
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lateral sclerosis (CTE-ALS), demonstrating the presence of pThr175 tau protein in pathology
associated with these diseases as well. In order to determine whether the induction of
pathological pThr175 tau was a primary event in the induction of this neuropathology, I used a rat
model of moderate traumatic brain injury in which I demonstrated that after a single cortical
impact, phosphorylation of endogenous tau protein at Thr175 was persistently elevated. pThr175
tau was present in axonal pathology as well as tau protein fibrillar neuronal pathology.
In order to definitively prove that pThr175tau was sufficient to induce tau pathology in
vivo, I undertook somatic gene transfer of a rAAV9 construct expressing pseudophosphorylated
human pThr175 tau (Thr175-Asp tau) in young adult rat hippocampus. I observed that one year
following the stereotactic inoculation of this modified viral vector, rats developed tau pathology
in construct-expressing hippocampal neurons along with caspase-3 cleavage. While the construct
was similarly expressed in control rats, including empty vector and wild-type human tau, none of
these latter rats developed pathology.
These findings indicate that phosphorylation of human tau at Thr175 triggers the
pathological phosphorylation of tau protein at Thr231 through activation of GSK3β, and that this
cascade leads to pathological fibril formation in vitro and in vivo. I have further demonstrated
that this pathological process may have broader applicability than to the pathogenesis of ALSci,
and includes a broad range of tauopathies in addition to CTE and CTE-ALS.

Keywords: Microtubule associated protein tau, phosphorylation, glycogen synthase kinase 3β,
tauopathy, amyotrophic lateral sclerosis, chronic traumatic encephalopathy, frontotemporal
dementia, Alzheimer’s disease, neurotoxicity.
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Chapter 1: Introduction

1.1 Tau protein
The microtubule associated protein tau (tau protein) is highly expressed in neurons where
it localizes mainly to the axon, acting as a microtubule binding protein. Human tau protein is
expressed as 6 isoforms encoded by a single gene encoded by 16 exons on chromosome 17 at
band position 17q21. The 6 isoforms of tau protein are the result of alternative splicing of exons
2, 3, and 10 (Andreadis, 2005; Goedert et al., 1989; Himmler, 1989; Himmler et al., 1989).
Although exon 1 is transcribed, it encodes for the promoter and is not translated (Andreadis et
al., 1996). Exons 2 and 3 encode for 29 amino acid inserts that incorporate a cassette which adds
to the N terminus of the protein. While exon 3 cannot be encoded without the inclusion of exon
2, exon 2 can be included in the absence of exon 3 (Andreadis2005). Exon 10 encodes a fourth
microtubule-binding repeat (MPR) domain. The nomenclature of tau protein isoforms is based
on the number of N terminal inserts (either absent (0N) or encoded by exons 2 and 3 (1N and 2N,
respectively) and MPR domains (either 3 or 4 (3R or 4R, respectively), the latter originating
from expression of exon 10) expressed in that isoform, giving 0N3R, 1N3R, 2N3R, 0N4R,
1N4R, and 2N4R isoforms (Buee and Delacourte, 1999). These are commonly referred to by
group as the 3R or 4R tau proteins.
These tau protein isoforms have characteristic molecular weights and isoelectric points,
making them differentiable by Western blot (Figure 1.1 A). In the healthy adult brain, the
expressed 3R:4R tau protein ratio is approximately 1:1 (D'Souza and Schellenberg, 2005).
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Figure 1.1: Tau protein isoforms and structure. A) Tau protein isoform is composed of 6 distinct
isoforms. Western blot for total tau protein isolated from human temporal pole. B) 2N4R tau
protein primary structure. C) 2N4R tau protein hairpin conformation.
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Tau protein exhibits very little secondary structure and is natively unfolded (Schweers et
al., 1994). The primary structure consists of an N-terminal acidic portion with an isoelectric
point of 3.8, a proline rich region followed by a series of 3 or 4 imperfect repeat regions which
functionally constitute the MPR domains, and a C-terminal basic tail (Figure 1.1 B) with an
isoelectric point of 10.8 (Sergeant et al., 2008). This primary structure makes tau protein a dipole
and which is crucial for interactions with binding partners and secondary structure.
Posttranslational modification of tau protein can modify this dipole, dramatically changing tau
protein secondary structure and its interaction with other proteins (Mietelska-Porowska et al.,
2014; Sergeant et al., 2008).
Although little secondary structure has been observed, a series of FRET and NMR studies
have shown that tau protein does in fact have a preferential secondary structure when in solution
in the form of a “global hairpin conformation” whereby the C-terminus folds over the
microtubule binding domain and the N-terminus folds over the C-terminus (Figure 1.1 C)
(Jeganathan et al., 2006). It is thought that this secondary structure is important in preventing tau
protein self-association when soluble such that any alteration to this structure is thought to
impact tau protein solubility, predisposing tau protein to self-associate and form fibrillar
structures (Bibow et al., 2011; Jeganathan et al., 2008b). Mutations (discussed in section 1.5.2.1)
and post translational modifications (section 1.4) have been shown to interfere with tau protein’s
ability to maintain the hairpin conformation and as a result this may be associated with tau
protein dysfunction (Bibow et al., 2011; Jeganathan et al., 2008a).
Functionally, tau protein’s N-terminal domain projects off the microtubule allowing tau
protein to interact with other proteins such as other cytoskeletal proteins or plasma membranes
(Figure 1.2) (Pooler and Hanger, 2010). The most extreme N-terminal domain of tau protein
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contains a 17 amino acid segment (aa 2-18) which has been implicated in fast axonal transport
through activation of a protein phosphatase-1 (PP1) - GSK3 mediated pathway (Section 1.2.1).
This segment has been termed the phosphatase activating domain (PAD) (Kanaan et al., 2011).
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Figure 1.2: Tau protein-microtubule binding. A) Tau protein interacts with microtubules through
its microtubule binding domain while the N-terminus projects away from microtubules. B)
Imperfect repeat sequence of the microtubule binding domains. Amino acids in red indicate
conservation across all four repeats.
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The MPR domains of tau protein are encoded by exons 9-12, and consist of imperfectly
repeated stretches of 18 highly conserved residues, separated by 13-14 amino acid spacers (Kar
et al., 2003) (Figure 1.2). The 18 amino acid repeats bind microtubules through a flexible series
of weakly attracted sites distributed through the binding domains (Butner and Kirschner, 1991).
4R tau protein promotes microtubule assembly more actively than 3R tau protein (Goedert and
Jakes, 1990). As such, adult brain tau protein, which consists of both 3R and 4R tau protein is
more effective at polymerizing microtubules than fetal rat brain tau protein which consists of
0N3R tau protein only (Kosik et al., 1989). The most potent microtubule polymerization region
is the inter-region between R1 and R2 (275KVQIINKK280) which exists in 4R tau protein only,
making it much more potent than 3R tau protein (Goode and Feinstein, 1994). This inter-region
is directly competed for by microtubules and protein phosphatase 2A (PP2A), with the preferred
interaction being between microtubules and the inter-region domain. Hence, when bound to
microtubules, this domain cannot be dephosphorylated by PP2A (Sontag et al., 1999). Therefore,
tau protein phosphorylation on the MPR and microtubule binding are mutually exclusive, as is
dephosphorylation of this domain, which requires tau protein to be off the microtubule to take
place.
Two MAPT gene haplotypes have been described (H1 and H2) (Baker et al.,
1999)resulting from an inversion of a 900 kb region spanning the entire MAPT gene (Stefansson
et al., 2005) but no change in amino acid sequence. The difference between haplotypes exists in
a set of single nucleotide polymorphisms (SNPs) and a 238 bp deletion in intron 9 in H2 (Koolen
et al., 2008). The H1 haplotype is associated with increased tau protein expression levels,
increased 4R tau protein relative to 3R and tauopathy (Caffrey and Wade-Martins, 2007) while
H2 haplotype is associated with decreased tau protein expression levels and is thought to be
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protective (Myers et al., 2007). Further analysis has linked a subhaplotype (H1c) to tauopathies
(Myers et al., 2007). It has been suggested that pathogenic effects associated with the H1
haplotype may be due to differences in transcription, splicing, posttranscriptional modifications,
transcript stability or localization, or rates of translation (Wolfe, 2012).
1.2 Physiological function
1.2.1 Microtubule binding protein
Tau protein was initially described as a microtubule binding protein (Weingarten et al.,
1975) and most of the research on its function has focused on this. As a microtubule binding
protein, tau protein localization within the neuron is overwhelmingly axonal in healthy adult
neurons (Binder et al., 1985). Microtubules are important for cell morphogenesis, cell division,
and intracellular trafficking where they provide a road for axonal transport (Morris and
Hollenbeck, 1995). Both anterograde (toward the synapse) and retrograde (toward the cell body)
axonal transport occur along the microtubule. Transport is carried out by motor proteins such as
kinesin (plus end directed) and dynein (minus end directed).
The microtubule is a cytoskeletal component whose function is to maintain neuronal
polarity and to act as a scaffold for motor protein based transport of cargo along the axons.
Composed of α and β tubulin dimers, the microtubule is itself a polarized structure which
undergoes dynamic instability. Microtubules are in constant turnover balanced by regulation of
polymerization and depolymerization, reviewed in (Conde and Caceres, 2009). Polymerization
occurs in the direction of the “plus end” of the microtubule while depolymerization occurs at the
opposite end, termed the “minus end”. The state of more depolymerization than polymerization
occurring in the microtubule is termed “catastrophe” while “rescue” is the state of
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polymerization occurring at a faster rate than depolymerization (Sept, 2007). Tau protein
supports microtubule polymerization by binding with tubulin through the imperfect repeat
regions of its microtubule binding domains, stabilizing the microtubule structure itself while
inhibiting katanin-induced severing of microtubules (Qiang et al., 2006).
Physiologically, tau protein may detach cargo from kinesin, modulating anterograde
transport by regulating the number of kinesin motors attached to cargo (Vershinin et al., 2007).
Tau protein has been shown to inhibit anterograde fast axonal transport (FAT) but not retrograde
FAT. This function has been shown to require an extreme N-terminal domain of the protein
termed the phosphatase activating (PAD) domain (Kanaan et al., 2011). Through a process by
which tau protein directly activates a protein phosphatase 1 (PP1) and glycogen synthase kinase3 (GSK) dependent pathway, tau protein initiates a process contributing to phosphorylation of
kinesin light chains (KLCs). GSK3β mediated phosphorylation of KLCs detaches calsyntenin-1,
the scaffold protein which binds to the KLCs and vesicles thereby stopping axonal transport
(Morfini et al., 2009; Vagnoni et al., 2011).
It has been suggested that abnormal exposure of the N terminus of tau protein leads to a
toxic inhibition of axonal transport (Morfini et al., 2009). In fact, tau protein-mediated
dysregulation of anterograde transport along microtubules has been shown to slow exocytosis
and may also lead to mitochondrial clustering near the microtubule organizing center (MTOC)
(Ebneth et al., 1998). The absence of mitochondria in the peripheral regions of axons can cause a
decrease in glucose metabolism and ATP synthesis leading to neuronal dysfunction (Schwarz,
2013)
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1.2.2 Non-microtubule functions
Beyond its role in the axonal transport and microtubule stabilization, tau protein has also
been shown to localize to the cytosol, plasma membrane, dendrites, and nucleus in much lower
amounts than its axonal concentration (Loomis et al., 1990; Papasozomenos and Binder, 1987).
These other localizations of tau protein suggest that it serves a function in neurons beyond
microtubule binding and related functions (Morris et al., 2011). Furthermore, its function may be
modified across development as isoform composition has been described to shift in the
developing brain where only the ON3R isoform is expressed compared to the adult brain where
all 6 isoforms are expressed (Kosik et al., 1989).
Overall, tau protein has been shown to interact with three types of non-microtubule
substrates which can be classified as other cytoskeletal elements (F-actin, neurofilament),
signaling molecules (Growth factor receptor based protein 2, P85α) and lipids
(phosphatidylinositol, phosphatidylinositol bisphosphate) (Flanagan et al., 1997; Reynolds et al.,
2008; Surridge and Burns, 1994). The other cytoskeletal element binding exhibited by tau
protein plays a role in maintaining a cytoskeletal network consisting of microtubules and other
elements such as actin filaments (Farias et al., 2002).
The role of tau protein in signaling could have widespread implications for cell function.
For instance, the proline-rich domain of tau protein binds to SH3 domains through any of 7
PXXP motifs contained within this region (Lau et al., 2016). One SH3 domain containing protein
is Fyn kinase, which is important in protein trafficking, and may be linked to NMDA receptors
(Zhang et al., 2016a). Increased NMDA receptor activation has been linked to increased GSK3β
activation, which is associated with widespread signaling changes including toxicity (De et al.,
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2006). Additionally, tau protein interaction with Fyn kinase has been shown to promote neurite
outgrowth, which is critical in nervous system development (Klein et al., 2002). Tau protein
interaction with lipid molecules may also relate to neurite outgrowth, as the association of the Nterminus (including the insert) of tau protein with plasma membrane phospholipids has been
shown to enhance growth cone formation in cell culture (Brandt et al., 1995). The role of tau
protein in lipid binding likely relates to widespread signaling as well, and many lipid binding
partners of tau protein are signaling lipids. For example, tau protein interacts with
phosphatidylinositol bisphosphate (PIP2) which is largely related to cytoskeletal dynamics (van
and Jalink, 2002), potassium channel modulation (Huang et al., 1998), as well as exocytosis
(Kabachinski et al., 2014). Furthermore, it has been suggested that tau protein may act as a
scaffold protein for signaling complexes and that tau protein binding can activate or inhibit
several enzymes (Morris et al., 2011).
As tau protein appears to have a role in many cellular molecular networks, dysfunction of
tau protein in any way could have widespread effects on the cell through any of these
mechanisms. Importantly, many of these functions are likely to occur through N-terminal
activities of tau protein, which is increased when global hairpin conformation is lost as observed
in several species of phosphorylated or mutated tau protein (Bibow et al., 2011; Jeganathan et al.,
2008a).
1.3 Tau protein in the stress response
When exposed to different kinds of physiological stress (ie: heat, osmotic stress, UV
radiation), neurons undergo a wide array of changes in transcription, translation and cell
signaling known as the stress response. One of the main objectives of the stress response is to
maintain homeostasis (Valenzuela et al., 2016). The balance of protein expression in the cell is
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closely regulated in a process known as proteostasis. Under stress conditions, the endoplasmic
reticulum (ER) can be overloaded by increased translation and misfolding of proteins leading to
ER stress, as observed in many neurodegenerative diseases (AD, PD, ALS). Additionally, ER
stress is observed after neuronal injury in traumatic brain injury.
To recover proteostasis after ER stress the unfolded protein response (UPR) is activated,
This occurs through proteins in the ER lumen, including inositol requiring enzyme-1 (IRE1),
protein kinase R-like endoplasmic reticulum kinase (PERK), activating transcription factor-6
(ATF6) (Schroder and Kaufman, 2005). The UPR stops translation of many proteins, increases
translation of chaperone proteins to increase proper protein folding, and activates protein
degradation pathways. One such protein degradation pathway is the ubiquitin-proteasome
pathway which tags and targets specific proteins for degradation and which is implicated in
clearing misfolded proteins in many neurodegenerative diseases. Aggregated tau protein has
been shown to inhibit proteasome activity through direct inhibitory binding of the 20S core
particle of the proteasome, slowing protein clearance and reducing the efficiency of the UPR
(Keck et al., 2003). When the UPR is active for a sustained period of time it can induce cellular
apoptosis (Fribley et al., 2009).
In addition to protein clearance in the stress response, priority is given to molecular
chaperone and repair enzyme synthesis, while translation of most mRNAs is paused until stress
conditions have passed. In this state, the mRNA is stored for future use within structures known
as stress granules (Anderson and Kedersha, 2006). Several proteins are associated with stress
granule formation and maintenance including Staufen, G3BP and TIA-1 (Anderson and
Kedersha, 2006) as well as RNA binding proteins such as Tar-DNA binding protein of 43 kDa
(TDP-43) and fused in sarcoma (FUS) (Aulas and Vande, 2015). Tau protein has been connected
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to the stress granule process through several means. First, tau protein may interact with RNA
species themselves and may serve a RNA binding function (Kampers et al., 1996). Second, tau
protein has been shown to interact with TIA-1, and may affect TIA-1 distribution in the cell as
well as its ability to interact with binding partners affecting stress-response dynamics at the stress
granule level (Vanderweyde et al., 2016). Furthermore, it has been shown that TIA-1 and tau
protein act synergistically to promote the formation of stress granules as well as the formation of
tau protein fibrils in primary hippocampal neurons (Vanderweyde et al., 2016).
There is evidence suggesting that the stress response is capable of inducing pathological
tau protein processes. Firstly, osmotic stress has been shown to induce caspase-3 cleavage of tau
protein, a process which is observed in AD and is associated with tau protein aggregate
formation and toxicity (Chong et al., 2006; Olivera-Santa et al., 2016). Additionally, abnormal
tau protein phosphorylation, another change associated with tau protein in disease can be induced
by the stress response when ER stress response pathways activate c-Jun N-terminal kinase and
other cell signaling cascades which may directly phosphorylate tau protein (Su et al., 2010;
Zhang et al., 2016b).
All of these data suggest that tau protein and the stress response are closely related and
dependent on each other to some degree for “normal” responses to stress. Abnormally long or
severe stress responses may initiate abnormal tau protein metabolism, while abnormal tau protein
metabolism may initiate neuronal stress responses.
1.4 Posttranslational modification
Tau protein activity is regulated by post-translational modification, and tau protein is
subject to at least 12 distinct types of post-translational modification (summarized in Table 1.1).
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These modifications can affect tau protein physiological function, tau protein toxicity to the cell,
and tau protein localization. Modifications may compete with one another, enhancing or
reducing other types of post-translational modification. These are described in detail below with
a specific focus on phosphorylation.
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Table 1.1: Tau protein post translational modifications
Modification

Definition

Phosphorylation

Adds a phosphate group to Thr, Ser, or Tyr
residue.

Glycation

Sugar added to any amino acid.

O-glycosylation

Adds a sugar to oxygen on Ser or Thr (multiple
subtypes depending on type of sugar added).
Sugar added to Asn residue nitrogen.
Ubiquitin added to protein at Lys residue.

N-glycosylation
Ubiquitination

Function to tau
Regulates microtubule interaction and
cellular processes. Implicated in toxicity
and aggregation.
Reduce tau-microtubule interactions.
Enhances fibrillization.
May inhibit tau phosphorylation
competing with Ser and Thr.
May promote tau phosphorylation.
Tag for proteasomal degradation.

SUMOylation

Small Ubiquitin-like Modifier protein covalently
attached to the protein at Lys residue.

Nitration

Addition of nitro group to protein.

Methylation

Addition of methyl group to Lys and Arg
residues.
Addition of acetyl group.

Nuclear-cytosolic transport,
transcriptional regulation, apoptosis,
protein stability, response to stress, and
progression through the cell cycle.
Competes for ubiquitin binding sites.
Conformational changes affecting
microtubule binding. May affect
aggregation.
Makes protein more alkaline. May
prevent/ reduce aggregation.
Decreases proteasomal tau degradation.

Prolyl
isomerisation

Covalently links glutamine and lysine residues.
Lysine dependent.
Converts cis to trans isomers of petide
bonds neughbouring Pro residues.

Promotion of protein cross-linking in
aggregate formation.
Enables PP2A to dephosphorylate tau at
Thr231.

Truncation

Cleavage of the protein into smaller fragments.

Involved in degradation but may also
produce toxic cleavage products.

Acetylation
Polyamination

Relation to tau
phosphorylation
Can increase further
phosphorylation.
Unknown.
Reduces phosphorylation.
Enhances phosphorylation.
Follows pathological
phosphorylation. Clears
tau.
Follows pathological
phosphorylation. Reduces
tau clearance.

References
(Ihara et al., 1986;
Lindwall and Cole,
1984)
(Wang et al., 1996;
Yan et al., 1994)
(Robertson et al.,
2004)
(Liu et al., 2002c)
(Bancher et al., 1991)

(Luo et al., 2014)

Unknown. May occur as
consequence of cellular
damage.

(Horiguchi et al.,
2003)

Unknown.

(Funk et al., 2014)

Reduces tau clearance.

(Min et al., 2010; Min
et al., 2015)
(Wang et al., 2008)

Occurs after
phosphorylation.
Reduces phosphorylation
by making Thr231 accessible
to phosphatases.
Occurs after
phosphorylation.

(Nakamura et al.,
2012)
(Ferreira and Bigio,
2011)
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1.4.1 Phosphorylation
Tau protein phosphorylation is balanced by kinase activity (addition of phosphates) and
phosphatase activity (removal of phosphates). Under physiological conditions tau protein is
phosphorylated as a means of modulating its activity, the most well studied being microtubule
binding. Sites of phosphorylation are referred to by the amino acid number in the longest tau
protein isoform (2N4R, 441 amino acids long).
Tau protein phosphorylation has been its most widely studied posttranslational
modification. Tau protein has 85 possible sites of phosphorylation and in the healthy adult brain
has a molar ratio of phosphates to tau protein of 3-4:1. In the fetal brain, the molar ratio of
phosphates to tau protein is much higher at 8:1 (Kenessey and Yen, 1993), indicating a
physiological role of phosphorylation in development, likely related to neurite outgrowth and
remodeling/ formation of synaptic connections (Esmaeli-Azad et al., 1994). The phosphorylation
of tau protein has an important role in regulating the interactions between it and microtubules,
with particularly relevant phosphorylation sites being those sites within the MPR domain and in
the adjacent N-terminus region (Jenkins and Johnson, 1999; Lin et al., 2007).
The 8:1 ratio of phosphates to tau protein in the fetal brain is mirrored in pathological
tauopathies where it is termed hyperphosphorylation (Kenessey and Yen, 1993). In the fetal
brain, many phosphoepitopes that have been considered pathologically associated with tauopathy
in the adult brain are observed as well (Hanger et al., 1998; Hanger, 2017; Reynolds et al., 2000).
It is important to note that the fetal brain only expresses one isoform of tau protein (0N3R) that
lacks the N-terminal inserts. Additionally, at this point the degree of phosphorylation is being
directed by developmental processes, so hyperphosphorylation is a physiologically “intended”
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state. In pathological states the balance of phosphorylation and dephosphorylation is
dysregulated, often with a shift towards the hyperphosphorylation typical of fetal tau protein.
Dysregulated (aberrant) tau protein phosphorylation has been shown to alter tau protein
global hairpin conformation. This conformation is thought to protect both the N-terminal domain
and the MPR domains from abnormal interactions. For example, the AT8 combination of
phosphorylation (Ser199/Ser202/Thr205) reduces folding of the N terminus over the rest of tau
protein, preventing global hairpin conformation (Jeganathan et al., 2006). This conformational
change affects tau protein solubility and interaction behaviour.
Studying the effects of tau protein phosphorylation directly in vitro has proven to be a
challenge. A common method used to investigate the effects of tau protein phosphoepitopes is
the use of pseudophosphorylation (Chang et al., 2011; Haase et al., 2004; Lin et al., 2007). In this
process, mutant constructs are generated in which the amino acid (Thr, Ser or Tyr) which would
be phosphorylated is mutated to an Asp or Glu, which have large and bulky, negatively charged
subgroups, mimicking a permanent, irreversible phosphorylation at this residue. These amino
acids only have a total charge of -1 compared to the -3 charge on an actual phosphate group.
Additionally, steric forces are different between phosphorylated amino acids and
phosphomimics. Despite these differences, a recent study showed that for the investigations of
tau protein pathological processes such as aggregation, pseudophosphorylation does in fact
mimic phosphorylated tau protein in terms of the aggregate products formed (Prokopovich et al.,
2017).
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1.4.1.1 Relevant individual sites of phosphorylation
1.4.1.1.1 MPR domain phosphorylation
Although there are 85 possible sites of phosphorylation on tau protein, and
hyperphosphorylation is associated with disease in the adult brain, individual sites of
phosphorylation may be important physiological regulators and mediators of pathogenicity on
their own when phosphorylation is dysregulated. A table of all currently known tau protein
phosphorylation sites has been compiled by Diane Hanger (Hanger2017). Here I will highlight
several phosphorylation sites that have significance to physiologic function and pathology
mediated by tau protein.
An important series of phosphoepitopes associated with a dramatic reduction in tau
protein ability to bind microtubules and associated with tau protein fibrillization includes Ser262,
Ser293, Ser324 and Ser356. These sites are located in equivalent positions in each of the four MPR
domains (Drewes et al., 1995). Due to their location on the MPR domain, phosphorylation is
likely to directly inhibit tau protein-microtubule interactions, and enhance self-association.
Phosphorylation at these sites is predicted to directly impair microtubule binding and mimic tau
protein mutations in these regions associated with disease (discussed in section 1.5.2.1).
1.4.1.1.2 Thr231
A physiologically and pathologically relevant phosphoepitope on tau protein is Thr231
(Luna-Munoz et al., 2005; Sengupta et al., 1998). Phosphorylation at this site is observed in fetal,
adult diseased brains, as well as adult control brain (Hanger et al., 1998; Reynolds et al., 2000).
The presence of pThr231 in both fetal and adult control brains suggests a physiological role in tau
protein regulation. Indeed, it has been shown that phosphorylation at this site alone is capable of
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preventing tau protein binding to microtubules, and that phosphorylation at this site causes the
N-terminus of the protein to push away from the C-terminus (opening the hairpin), allowing for
further access of the MPR domains by tau protein kinases (Lin et al., 2007). More recently, it has
been shown that Thr231 phosphorylation induces a salt bridge with Arg230 which directly inhibits
microtubule interaction (Schwalbe et al., 2015). Due to this potent inhibition of tau proteinmicrotubule interaction, under reversible circumstances phosphorylation of Thr231 is a highly
effective switch by which to remove tau protein from the microtubule or direct it back.
An effective means of modulating tau protein-microtubule interactions such as pThr231
would be crucial in physiological conditions when microtubules must be remodeled such as in
situations of neuronal damage, axon growth, or other plastic mechanisms. If enhanced, or locked
in place, however, phosphorylation at Thr231 could become pathological and has been proposed
to result in further phosphorylation of tau protein in the microtubule binding domain (Lin et al.,
2007). Furthermore pThr231 tau protein has been shown to be toxic in transiently transfected
CHO cells (Alonso et al., 2010). The state of phosphorylation at Thr231 has been shown to reduce
PP2A interaction with tau protein, possibly permitting an increased phosphorylation state of tau
protein by reducing phosphate removal (Sontag et al., 2012).
Thr231 phosphorylation is commonly observed at the same time as phosphorylation of
Ser235 which is considered to be a key site which, when phosphorylated, primes tau protein for
phosphorylation by GSKβ (Cho and Johnson, 2004). With respect to pathological processes,
pThr231 tau protein has been shown to be an early phosphoepitope in aggregate formation and
may be part of an initiating cascade of phosphorylation sites in this process (Luna-Munoz et al.,
2007).
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1.4.1.1.3 pThr175
Of particular relevance to this thesis, phosphorylation at Thr175 has been observed in both
Alzheimer’s disease and amyotrophic lateral sclerosis with cognitive impairment (discussed in
section 1.5.5) (Hanger et al., 1998; Reynolds et al., 2000; Strong et al., 2006; Yang and Strong,
2012). The observation that pThr175 is not present in fetal brain tissue (Hanger et al., 1998;
Reynolds et al., 2000) suggests that this phosphoepitope may be a key contributor to adult onset
tauopathy. Consistent with this, our lab had previously demonstrated that pThr175, expressed in
vitro as a pseudophosphorylation construct, is toxic (Gohar et al., 2009).
Pseudophosphorylation of tau protein on the proline rich domain has been shown to open
the global hairpin conformation (Jeganathan et al., 2006). This is relevant for pThr175 and pThr231
as both sites lie in this region.
1.4.1.2 Kinases involved in tau protein phosphorylation
There are at least 37 kinases that have been implicated in tau protein phosphorylation and
tau protein pathology (Hanger et al., 2009). Among these, mitogen activated protein kinase
(MAPK), glycogen synthase kinase-3 (GSK3), cyclin dependent kinase-5 (Cdk5), and casein
kinase-1 (CK1) have been robustly shown to be involved in tau protein phosphorylation, have
different substrate recognition motifs, and have been shown to phosphorylate many residues
(Table 1.2) (Hanger2017). GSK3β and Cdk5 have been determined as the likeliest candidate
kinases to contribute to pathological tau protein phosphorylation (Flaherty et al., 2000). As the
focus of my studies have been primarily amyotrophic lateral sclerosis, GSK3β was the kinase of
interest (discussed in section 1.5.5) and will be the only tau protein associated kinase discussed
in detail here.
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Table 1.2: Main kinases involved in tau protein phosphorylation
Kinase

Mitogen activated
protein kinase family
(MAPK)
Glycogen synthase
kinase 3 (GSK3)
Cyclin dependent
kinase 5 (cdk5)
Casein kinase 1 (CK1)
Protein kinase A (PKA)

Pro-X-Ser/Thr-Pro

No. of
pThr175?
phosphorylation
sites on tau
22
Yes

Yes

Ser/Thr-XXX-Ser/Thr(p)

37

Yes

Yes

Ser/Thr-Pro-X-Lys/Arg

12

No

Yes

Ser(p)-XX-Ser
Arg-XX-Ser/Thr

39
27

No
No

No
Yes

Preferred recognition
motif

pThr231?
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Glycogen synthase kinase 3 (GSK3) is a kinase consisting of 2 isoforms encoded by 2
separate genes sharing 85% similarity overall and 95% similarity within the catalytic domain
(Woodgett, 1990). The isoforms, GSK3α and GSK3β are regulated differently, expressed in
different cell populations and localize to different regions of the cell (Lau et al., 1999; Takahashi
et al., 1994; Uzbekova et al., 2009). GSK3β also has a higher expression level in the brain than
GSK3α (Lau et al., 1999; Yao et al., 2002). As such, they have different substrates and functions
despite their shared structure (Wang et al., 1994). GSK3β is a proline-directed kinase which
preferentially phosphorylates a Ser/Thr-XXX-Ser/Thr(p) motif for primed phosphorylation at the
former site (Lu et al., 2011). While enhanced by primed phosphorylation, its function does not
rely on this. Additionally, GSK3β can phosphorylate tau protein at Ser or Thr residues
irrespective of whether or not they are followed by a Pro residue, but prefers those residues
located N-terminally to a neighbouring Pro. GSK3β can phosphorylate tau protein at 37 sites
including Thr231 and Thr175. GSK3β has been implicated in abnormal tau protein phosphorylation
in neurodegenerative diseases including Alzheimer’s disease. Interestingly, tau protein may be
able to activate GSK3β, as the PAD domain activates the PP1-GSK3 pathway (Kanaan et al.,
2011). PP1 increases GSK3β activity by removing an inhibitory phosphate at Ser9 (McManus et
al., 2005). Therefore tau protein can directly induce GSK3 activity.
1.4.1.3 Phosphatases involved in tau protein dephosphorylation
The principal phosphatase involved in tau protein dephosphorylation is protein
phosphatase 2A (PP2A). PP2A is able to dephosphorylate abnormally phosphorylated tau protein
at residues Ser46, Ser199, Ser202, Ser396, and Ser404, but not Ser235 (Gong et al., 1994). Activity of
PP2A is inhibited by GSK3β, the activity of which can be enhanced by tau protein directly (Liu
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and Gotz, 2013). Additionally, endogenous inhibitor of PP2A (I2PP2A) is upregulated and
translocated from the nucleus to the cytosol in Alzheimer’s disease.
1.4.2 Other forms of posttranslational modification
In addition to tau protein phosphorylation, there are a plethora of other posttranslational
modifications that tau protein can undertake. These affect tau protein function directly, and many
also have implications for tau protein phosphorylation. Notably, some are associated with
increased phosphorylation, decreasing phosphorylation, or occur downstream of phosphorylation
in pathogenic processes.
1.4.2.1 Posttranslational modifications associated with tau protein phosphorylation
A number of posttranslational modifications have been associated with increased tau
protein phosphorylation status. These may act through decreasing tau protein clearance, such as
SUMOylation and acetylation, such that there is an increased retention of phosphorylated tau
protein which may become further phosphorylated by active kinases (Cohen et al., 2011; Guo et
al., 2017; Min et al., 2010). N-glycosylation reduces the rate of dephosphorylation (Liu et al.,
2002b) and enhances phosphorylation of tau protein by GSK3β (Liu et al., 2002a). Truncation is
associated with phosphorylated tau protein but appears to occur downstream of phosphorylation
events (Mondragon-Rodriguez et al., 2008; Rametti et al., 2004).
1.4.2.2 Posttranslational modifications reducing tau protein phosphorylation
A series of modifications are associated with reduced tau protein phosphorylation. These
include prolyl isomerisation, in which phosphate group orientation about a Ser/Thr-Pro bond
from cis to trans. Peptide-prolyl cis/trans isomerase NIMA-interacting 1 (PIN-1) isomerizes tau
protein from cis to trans conformation at pThr231 making tau protein accessible to PP2A for
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dephosphorylation (Zhou et al., 2000). Ubiquitination of tau protein results in increased
clearance of aberrantly phosphorylated tau protein by the ubiquitin-proteasome system reducing
cellular phosphorylated tau protein (David et al., 2002; Keller et al., 2000). Finally, Oglycosylation may be protective against tau protein phosphorylation (Li et al., 2006; Liu et al.,
2004). O-glcosylation occurs on Ser and Thr residues sterically hindering the addition of
phosphate groups to tau protein (Arnold et al., 1996).
1.4.2.3 Posttranslational modifications with unknown effect on tau protein phosphorylation
There are several types of posttranslational modification with unknown effect on tau
protein phosphorylation. Glycation, nitration and polyamination are all enhancers of aggregation
(Necula and Kuret, 2004; Wilhelmus et al., 2012; Zhang et al., 2005), while methylation appears
to decrease tau protein aggregation (Funk et al., 2014). These modifications may play a role in
the disease process but have yet to be described in greater detail.
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Table 1.3: Neuropathology of tauopathies (modified from Kovacs 2015)
Disease

Pathology region

AD

Entorhinal, cortical,
hippocampal, deeper
subcortical, late stages
widespread
Frontal, temporal,
hippocampus, caudate
nucleus, putamen

FTDP-17

Pathology Pathology phenotype
cell type
Neuronal
NCI, NFT, DNs

Neuronal,
glial

Variable

Isoform
composition
68, 64, 60 kDa
(major)
72 kDa (minor)
PHF motif
Variable

PSP

Variable cortical and
subcortical

Neuronal,
glial

NFT, NCIs, DNs, coiled
bodies, tufted astrocytes

64 and 68 kDa
bands (4R
isoforms)

CBD

Variable cortical and
subcortical

Neuronal,
glial

Pick’s
disease

Frontal and temporal
cortex

Neuronal,
glial

Astrocytic plaques, NFTs,
NCIs, DNs, coiled bodies,
astrocytic plaques
Pick bodies, ramified
astrocytes

64 and 68 kDa
bands (4R
isoforms)
60 and 64 kDa
bands (3R
isoforms)

AGD

Temporal, entorhinal
cortex, hippocampus,
amygdala
Prefrontal, temporal
parietal cortices, ACC,
subcortical
Internal capsule,
putamen

Neuronal,
glial

NCI, coiled bodies, granular
astrocytic immunoreactivity

Neuronal,
glial

NFT, thorny astrocytes,
coiled bodies

Neuronal,
glial

Granular neuronal, glial
cytoplasmic inclusions (GCI)

63, 68 kDa
bands (4R
isoforms)
3R+4R
(neuronal)
4R (glial)
4R

DLBD

MSA

Phosphorylation

References

45 sites shown

(Braak et al., 2006;
Hanger2017; Wang et al.,
2013)

Thr181, Ser202, Thr205,
Thr212, Ser214, Thr231,
Ser235, Ser262, Ser356,
Ser404, Ser422
Ser46, Thr181, Ser202,
Thr217, Thr231, Ser235,
Ser396, Ser400, Thr403,
Ser404
Ser202, Thr205, Ser396,
Ser404, Thr231

(Ingram and Spillantini,
2002)

Thr231, Ser235, Ser202,
Thr205, Thr181, Ser396,
Ser404

(Buee and Delacourte,
1999; Dickson et al., 2011;
Irwin et al., 2016; Probst
et al., 1996)
(Tolnay et al., 1997;
Tolnay and Clavaguera,
2004)
(Howlett et al., 2015; Iseki
et al., 2003; Ishizawa et
al., 2003)

Thr181, Ser202, Thr205,
Thr231, Ser253, Ser356,
Ser396, Ser262, Ser404
Ser202, Thr205,Thr231,
Ser235, Ser202, Ser404,
Ser396
Ser202, Thr205

(Dickson et al., 2011;
Wray et al., 2008)

(Dickson et al., 2011;
Feany et al., 1995)

(Nagaishi et al., 2011)
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PART

ALS
(cognitive
impaired)

CTE

Temporal cortex,
hippocampus basal
forebrain, brainstem,
olfactory
Frontal, temporal,
entorhinal cortex,
hippocampus,
amygdala, ACC,
substantia nigra, basal
ganglia
Entorhinal, cortical,
perivascular/
periventricular, spinal
cord, brainstem

Neuronal,
glial

NFT, DNs, coiled bodies,
thorny astrocytes

Neuronal,
glial

NFT, threads, diffuse NC IR,
coiled bodies

Neuronal,
glial

NFT, DNs, NCI, NC IR
astrocytic tangles, thorny
astrocytes, tufted astrocytes

68, 64, 60 kDa
(major)
72 kDa (minor)
PHF motif
All 6

Ser202, Thr205

(Crary et al., 2014)

pThr175, Thr231,
Thr181, Thr199, Ser202,
Ser205, Thr217, Ser396,
Ser404, Ser208, Ser210

(Strong et al., 2006; Yang
and Strong, 2012)

3R + 4R

Ser202, Thr205, Ser396,
Ser404

(McKee et al., 2009;
McKee et al., 2010;
McKee et al., 2013)

Abbreviations used: NCI= neuronal cytoplasmic inclusion, NFT= neurofibrillary tangles, DNs= dystrophic neurites, NC IR= diffuse neuronal
cytoplasmic immunoreactivity, GCI= glial cytoplasmic inclusions, ACC= anterior cingulate cortex, AD= Alzheimer’s disease, FTDP-17=
frontotemporal dementia with Parkinsonism linked to chromosome 17, PSP= progressive supranuclear pasly, CBD= corticobasal denegeration,
AGD= argyrophilic grains disease, DLBD= diffuse Lewy body dementia, MSA= multiple system atrophy, PART= primary age-related tauopathy,
ALS= amyotrophic lateral sclerosis, CTE= chronic traumatic encephalopathy
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1.5 Tau protein in neurodegenerative diseases
Tau protein pathology has been observed in a host of different neurodegenerative
diseases collectively, collectively termed “tauopathies” (Spillantini et al., 1997a). Primary
tauopathies such as FTDP-17 are diseases in which tau protein metabolism dysfunction is
thought to be the initial insult causing neuronal toxicity whereas secondary tauopathies are
neurodegenerative diseases where tau protein metabolism dysfunction is thought to be the result
of some other insult leading to tau protein dysfunction. Regardless, tau protein dysfunction
appears to be toxic when it occurs, and it is likely that once induced, tau protein pathology is
self-perpetuating and contributes to neuronal death (Guo and Lee, 2013).
1.5.1 Alzheimer’s disease
The neurofibrillary tangle (NFT), consisting primarily of phosphorylated tau protein was
identified by Alois Alzheimer in his initial description of Alzheimer’s disease (AD) (Alzheimer
et al., 1995) and has been a disease defining pathology since (Hippius and Neundorfer, 2003).
Tau protein pathology in AD is primarily neuronal and is observed in the form of
neurofibrillary tangles, neuronal cytoplasmic inclusions, threads and dystrophic neurites. By
electron microscopy, the ultrastructure of the 8-20 nm wide filamentous inclusions of NFTs in
AD forms a regular helical turn at 85-nm intervals known as the paired helical filament (Wischik
et al., 1988). A second morphology of the inclusions in AD is the straight filament, which lacks
the helical regularity of the PHF and is approximately 15 nm wide (Crowther, 1991). Aggregated
tau protein in AD consists of both 3R and 4R tau protein isoforms and when isolated and run on
a western blot reveals bands at 68, 64, and 60 kDa with a minor band at 72 kDa. This triplet
motif is known as the paired helical filament motif (PHF).
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Tau protein phosphorylation has been observed as the major distinguishing modification
to tau protein in the AD tauopathic process (Crowther et al., 1989; Goedert et al., 1992;
Grundke-Iqbal et al., 1986; Hanger et al., 2009). Indeed, tau protein is hyperphosphorylated in
AD, showing a shift in molar ratio from ~2:1 to ~9:1 (Kopke et al., 1993). To date, tau protein
has been shown to exhibit phosphorylation at 45 sites in this disease state (Hanger et al., 2009;
Hanger2017) many of which are shared with fetal tau protein (Hanger2017; MorishimaKawashima et al., 1995; Reynolds et al., 2000).
1.5.2 Frontotemporal lobar dementia
Frontotemporal lobar dementia (FTLD) is a neuropathologically diagnosed group of
neurodegenerative disorders characterized by neuronal death primarily in the frontal and
temporal lobes. FTLD therefore is an umbrella term for a number of neurodegenerative diseases
which are defined by the underlying neuropathology. The location of pathology and neuronal
death determines the clinical manifestation of the underlying disorder, known as frontotemporal
dementia, which may present as behavioural disinhibition, semantic dementia, nonfluent aphasia,
Parkinsonism, or motor system dysfunction (Neary et al., 1998). Broadly FTLD is subdivided
into 2 main classifications, FTLD-U (50%) and FTLD-Tau (40%). FTLD-U is characterized by
tau-negative, ubiquitin positive inclusions composed primarily of TAR DNA binding protein of
43 kDa (TDP-43). Therefore it is referred to as FTLD-TDP. The group of FTLDs comprising
FTLD-Tau is further subdivided based on the molecular nature of the tau pathology observed
into 3R, 4R and 3R/4R tauopathies. 3R FTLD tauopathies include Pick’s disease and some cases
of FTDP-17 while 4R tauopathies include corticobasal degeneration (CBD), progressive
supranuclear palsy (PSP), argyrophilic grains disease (AGD) and some cases of FTDP-17. 3R/4R
tauopathies include FTDP-17. Depending on the subtype of FTLD-Tau, tau pathology inclusions
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are variable in morphology and cell type. The characteristics of tau pathology of the FTLD
subtypes are summarized in Table 1.3.
1.5.2.1 Frontotemporal dementia with Parkinsonism linked to chromosome 17
The discovery of causal tau gene mutations in Frontotemporal dementia with
Parkinsonism linked to chromosome 17 (FTDP-17) in 1998 (Hutton et al., 1998) lead to an
unequivocal link between tau protein metabolism dysregulation induced toxicity and
neurodegenerative disease. Clinical manifestations are variable but include dementia, speech or
language impairments, behavioural changes, and Parkinsinism (Neary et al., 1998).
To date there have been 53 mutations in tau protein linked to FTDP-17 reviewed in
(Ghetti et al., 2015). These mutations can be separated into two main categories: First, mutations
reducing microtubule interactions microtubule (R5H, R5L, K257T, G272V, S320F, V337M,
K369I, G398R, R406W, P301L and P301S) many of which have a reduced ability to report
microtubule polymerization (Hasegawa et al., 1998). Second are mutations affecting exon 10
splicing (Intronic +3, +11, +12, +13, +14, +16, as well as exonic N279K, L284L, N296N, S305N
and S305S) which typically display altered ratio of 4R:3R tau protein with a higher proportion of
4R tau protein (Liu and Gong, 2008). Additionally there are three mutations that appear to affect
both exon splicing and microtubule binding (N296H, E342V, and ∆K280) (Ingram and
Spillantini, 2002).
The tau protein pathology associated with mutations in FTDP-17 is extremely variable
and a detailed summery can be found in (Ghetti et al., 2015). Regions frequently affected include
frontal and temporal cortices, hippocampus, amygdala, caudate nucleus and putamen (Ghetti et
al., 2015). Both neurons and glia can be affected though this appears to be related to the mutation
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in question, and glial pathology in the absence of neuronal pathology is not a feature of these
disorders (Ghetti et al., 2015). Furthermore, the isoform composition of inclusions and inclusion
morphological phenotype varies according to tau protein mutations in these disorders (Ghetti et
al., 2015; Ingram and Spillantini, 2002).
1.5.3 Parkinson’s related diseases
Parkinson’s disease (PD) is not generally associated with tau protein deposition as a
major distinguishing neuropathological factor. However, tau protein interaction with αsynuclein, including its presence in Lewy Bodies which consist mainly of α-synuclein
(Spillantini et al., 1997b) has shown a strong link between tau protein and Parkinson’s disease,
particularly when extramotor symptoms are involved, as in the case of Lewy body dementia
(Arima et al., 1999; Moussaud et al., 2014). The tau pathology associated with PD is similar to
that observed in Lewy body dementia, but less pronounced (Jellinger and Attems, 2006). To this
point, dementias associated with PD are generally tau protein positive (Dickson, 2012). In
addition to Parkinson’s disease and Lewy body dementia, multiple system atrophy (MSA) is
another α-synuclein positive neurodegenerative disease characterized by autonomic dysfunction,
ataxia and Parkinsonism in which tau protein pathology is a pathological component (Nagaishi et
al., 2011).
1.5.4 Primary age-related tauopathy
Primary age related tauopathy (PART) is a recently described neurodegenerative disease
associated with cognitive impairment driven by predominantly Alzheimer’s- like tau protein
pathology in the absence of amyloid-beta pathology (Crary et al., 2014; Jefferson-George et al.,
2017). It is notable, however that PART as a disease entity is contentious with some authors
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suggesting that it may simply be an early manifestation of preclinical Alzheimer’s disease with
low levels of amyloid beta pathology (Duyckaerts et al., 2015).
1.5.5 Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by
progressive upper and lower motor neuron death causing paralysis (Ludolph et al., 2015). While
ALS is not typically associated with tau protein pathology there are notable exceptions from
several Pacific Island populations and sporadic case reports. The most well-known population of
ALS with tau pathology is the Guamanian ALS-Parkinsonism complex (ALS-PDC) also known
as Lytico-Bodig. This disease was up to 100 fold higher than the worldwide rate of ALS in the
1950s, but has decreased to similar rates to worldwide of approximately 3/100, 000 presently
(Plato et al., 2003). While this was strongly indicative of an environmental factor shifted by
cultural changes, leading to several hypotheses of disease origin, the cause remains speculative
(Plato et al., 2003). ALS-PDC was characterized by tau protein pathology throughout the central
nervous system in the form of neurofibrillary tangles in the temporal lobe especially prominent
in the hippocampus and entorhinal cortex (Guiroy et al., 1987; Hirano et al., 1961; Ito et al.,
1991; Wakayama et al., 1993). A very unique aspect of this disease was the tau protein
deposition in the motor neurons of the anterior horn of the spinal cord (Ito et al., 1991; Schmidt
et al., 2001b; Umahara et al., 1994). Tau in ALS-PDC has been shown to be phosphorylated at
Thr181, Thr231, Ser262, Ser396, Ser404, and Ser422 (Mawal-Dewan et al., 1996).
Similar to the Guamanian ALS-PDC, a set of two separate populations on the Kii
peninsula of Japan (Muro disease) (Kuzuhara and Kokubo, 2005) and another population in New
Guinea showed a similar disease with an elevated rate of occurrence (Okumiya et al., 2014).
Finally, sporadic case reports consistently appear with tau protein deposition throughout the
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brain and even in motor neurons (Dobson-Stone et al., 2013; Nakamura et al., 2014; Orrell et al.,
1995; Soma et al., 2012). Recently, studies have reported elevated phosphorylated and truncated
tau protein in both hippocampus and spinal cord in different ALS populations (Gomez-Pinedo et
al., 2016; Vintilescu et al., 2016).
Beyond the aforementioned exceptions, the most consistent observation of tau protein
pathology in a Western ALS population have been those observed in the frontal and temporal
lobes of patients with ALS with cognitive impairment (ALSci). ALSci is associated with
neuronal degeneration in both the frontal and temporal cortex, and is pronounced in the anterior
cingulate cortex (Wilson et al., 2001). ALSci is defined as a variant of ALS in which patients
perform at or below the 5th percentile on at least 2 cognitive tasks, but not meeting the full
criteria for frontotemporal dementia (Strong et al., 2009; Strong et al., 2017). In ALS, cognitive
impairment occurs in upwards of 50% of ALS cases (Ringholz et al., 2005).
Tau protein pathology in ALSci was first observed as Gallyas silver staining (Yang et al.,
2003). Tau protein was then observed to be phosphorylated at a series of epitopes that had been
previously observed in other tauopathies. However tau protein deposits in ALS consisted of all 6
isoforms, suggesting that it is distinct from the Alzheimer’s disease associated PHF motif
(Strong et al., 2006). Tau protein deposition in ALSci is not simply a function of aging (Yang et
al., 2005). It was subsequently demonstrated that the tauopathy of ALSci was associated with an
upregulation of active GSK3β activation (Yang et al., 2008). Due to the relatively uninvestigated
nature of phosphorylated Thr175, an epitope that had been previously identified in
phosphopeptide mapping studies of AD tissue (Hanger et al., 1998; Reynolds et al., 2000), our
lab conducted in vitro studies that demonstrated that tau protein pseudophosphorylated at Thr175
was prone to form fibrils in both HEK293T cells and Neuro2A cells (Gohar et al., 2009). It was
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further shown that phosphorylation of Thr175 was associated with cell toxicity and apoptotic cell
death (Gohar et al., 2009).
Following this a more detailed characterization of tau protein pathology in ALSci was
conducted in which tau protein pathology in the anterior cingulate and superior frontal cortices
along with entorhinal cortex, hippocampus, amygdala, basal ganglia and substantia nigra was
observed (Yang and Strong, 2012). The major distinguishing feature from ALS was tau protein
pathology in the frontal cortex and anterior cingulate cortex of ALSci. Pathology was observed
in neurons and astrocytes as NFTs, neuropil threads and diffuse neuronal cytoplasmic
immunoreactivity. The observations of tau pathology, phosphorylated at Thr175 in ALS and
ALSci were more recently demonstrated in 50% of cases studied in a separate cohort (Behrouzi
et al., 2016). One genetic study of a family in which ALS and FTD were both present, and the
only case in which cognitive impairment was present was that driven by a MAPT mutation
driving tau protein pathology in which the authors suggested that a critical driver of the cognitive
elements was tau dysfunction (King et al., 2013).
1.5.6 Chronic traumatic encephalopathy
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with
of repeated head trauma (McKee et al., 2009). CTE is associated with rapid cognitive decline and
neurobehavioral disturbances. In about 10% of cases, motor neuron dysfunction develops in a
manner consistent with ALS. In this case, it is, termed chronic traumatic encephalomyelopathy
with amyotrophic lateral sclerosis (CTE-ALS) (McKee et al., 2010; Meyers et al., 1974).
It is thought that dementia pugilistica (DP), a clinically diagnosed disease associated with
neurodegeneration after repeated head trauma (Martland, 1928) is the same disease. However, no
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neuropathological assessment under the CTE diagnostic criteria has been conducted on cases
prior to 2013 (McKee et al., 2013). As such, this means that much of the literature of dementia
pugilistica may or may not represent CTE, as dementia pugilistica may involve different
neurodegenerative diseases without the hallmarks of CTE, such as AD, PD, ALS or
combinations of these diseases without meeting the criteria for CTE. Notably, one account of
dementia pugilistica (Schmidt et al., 2001a) makes the case for AD type tau pathology, but this
was undertaken before the detailed classification of CTE was described.
CTE is defined by phosphorylated tau protein pathology located at the depths of the sulci,
periventricular and perivascular regions preferentially. In late stages, this pathology is observed
in a more widespread manner. CTEM differs from CTE by the additional presence of tau protein
pathology in both motor neurons and astrocytes in the ventral and lateral horn of the spinal cord
(McKee et al., 2009; McKee et al., 2010; McKee et al., 2013). The isoform composition of
insoluble tau protein is in the form of 3R and 4R tau but has not been described in detail (McKee
et al., 2013). No known mutations are currently associated with CTE.
1.6 Experimental paradigms used in the study of tauopathy
1.6.1 Human tissue and tau antibodies
The study of tissue from human tauopathy cases has been the gold standard in the
understanding and characterization of tau protein abnormalities in neurodegenerative disease.
Immunohistochemical and biochemical analysis of human brain tissue have been critical in
determining isoform composition, tau protein pathological distinctions, cell type and regional
specificity, as well as posttranslational modifications associated with the disease processes
themselves. Additionally, any discovery made in vivo or in vitro must be validated in human
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disease to be meaningful for future disease understanding or therapeutic potential. A host of tau
protein conformation and phosphorylation specific antibodies have been developed which enable
the assessment of human tissue without requiring full sequencing and phosphopeptide mapping
by mass spectrometry (Table 1.4). Double labeling experiments are particularly useful for
determining more specific information such as dual protein contribution to inclusions, or
isoform, truncation product, and phosphoepitpe co-occurrence which can be insightful to
validation of disease mechanisms.
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Table 1.4: Commonly used tau antibodies and their epitopes
Antibody name
AT270
AT8
AT180
PHF1
AT100
CP13
CP9
T22
TG3
PG5
T14
Tau46
HT7

Epitopes
pThr181
pSer202/pThr205
pThr231/pSer235
pSer396/pThr205
pSr212/pThr214
pSer202
pThr231
Soluble tau protein oligomer
pThr231
pSer404
aas 141-149
aas 404-441
aas 159-163
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1.6.2 Tau protein polymerization assays
Tau protein is frequently studied for its propensity to form fibrillar aggregates in vitro.
Pseudophosphorylation studies have shown that in the absence of external modifiers, tau protein
phosphorylated or mutated at various sites, especially within the C-terminal can form fibrillar
aggregates much more effectively than unmodified tau protein, and in some studies, differential
sites of pseudophosphorylation have shown different effects on aggregate propensity in different
tau protein isoforms (Abraha et al., 2000; Combs et al., 2011; Sun and Gamblin, 2009). Tau
protein pseudophosphorylated at Thr175 did not show increased aggregation propensity, but
Thr231 tau protein did (Haase et al., 2004). Additionally, tau protein phosphorylated at Thr231
showed reduced ability to promote microtubule polymerization by this assay (Kiris et al., 2011).
1.6.3 Cell culture
Tau protein has been studied in cell culture models using a variety of immortalized cell
lines and primary neuronal cultures. These studies have used human tau protein isolated from
disease cases (Santa-Maria et al., 2012), expression of tau protein constructs displaying genetic
mutations associated with neurodegenerative disease (Alonso et al., 2010), and tau protein
constructs displaying pseudophosphorylation at residues or sets of residues identified in human
disease states including Thr175 and Thr231 (Alonso et al., 2010; Cho and Johnson, 2004; Fath et
al., 2002; Lin et al., 2007). In most cases tau protein is observed to be toxic to cells and display
reduced microtubule interaction when modified in any way associated with disease, or when
expressed at sufficient levels. The primary benefit of cell culture studies is their utility in
studying cause and effect of individual protein modifications rapidly and at low cost. They do
not, however provide insight into organ-level changes where multiple cell types are present.
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1.6.4 Rodent models of tauopathy
Mutant mouse models expressing G272V, P301L, P301S, V337M, K369I and R406W
mutatiuons causing FTDP-17 have been studied (Ittner et al., 2008; Santacruz et al., 2005;
Schindowski et al., 2006; Tanemura et al., 2001; Zhang et al., 2004). A rat model using
adenoviral (AAV9) expression of P301L mutant human tau protein showed that expression of
mutant tau protein in adult brain could induce tau protein pathology and behavioural changes
(Mustroph et al., 2012). Depending on location, cell type, and the specific mutation or
pseudophosphorylated variant expressed, differing behavioural and pathological phenotypes are
observed and mimicry of all elements of the disease is never accomplished (Pankevich et al.,
2013; Richardson and Burns, 2002). In particular, driving tauopathy appears to be challenging in
the absence of tau mutation expression. The cause of this may be in the difference in human and
rodent tau protein expression, whereby rodent tau protein is more difficult to drive to
pathological processes. Mice only express 3 tau protein isoforms, while rats do express 6
isoforms, however 4R isoforms are expressed at much higher levels (Hanes et al., 2009). In fact,
Thr175 in the rodent brain is neighboured by a second Thr residue rather than a Pro residue,
making phosphorylation by proline directed kinase much more difficult, making Thr175 less
likely to be phosphorylated and unable to exert toxicity. However, studies have shown that tau
protein isolated from neural tissue of neurodegenerative disease cases and injected into rodent
brain is able to induce propagating tau protein pathology in the brain which is capable of
spreading (Lasagna-Reeves et al., 2012).
1.7 Abnormal tau protein metabolism is a source of neuronal toxicity
Tau protein has been associated with neurodegenerative disease and pathology in many
different states and forms, and has been implicated as both a primary cause and a secondary
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contributor to these states (Iqbal et al., 2016). The hypothesis of tau protein being causative to
disease etiology was confirmed with the discovery of FTDP-17 causing mutations (Hutton et al.,
1998). Existing evidence supports both toxic gain of function changes along with loss of function
associated toxicity (Trojanowski and Lee, 2005). It is likely however that tau protein loss of
function is not sufficient to induce neurodegenerative disease as MAPT knockout mice are viable
(Dawson et al., 2001; Harada et al., 1994). It is possible that at least in the total absence of tau
protein, other microtubule associated proteins are capable of maintaining microtubule function. It
is notable, however that when the ability of tau protein to bind to the microtubule is inhibited, it
may become toxic to the cell (Patrick et al., 1999). Moreover, microtubule binding may be
essential to reduce a pool of unbound tau protein which may contribute to other toxic activities in
the cell (Ballatore et al., 2007; Kuret et al., 2005).
The hypothesis that tau protein itself gains toxic function is supported by the
observation that expression of FTDP-17-associated MAPT mutations or pseudophosphorylation
at epitopes observed in tauopathies induces neuronal dysfunction and cell death (Alonso et al.,
2010; Combs et al., 2011; Fath et al., 2002; Gohar et al., 2009; Mustroph et al., 2012).
Additionally, tau protein isolated from neurodegenerative disease tissue can induce tau protein
pathology, neuronal dysfunction, and neuronal death in both cultured cells and rodent brains
(Lasagna-Reeves et al., 2012; Santa-Maria et al., 2012). This has lead to hypotheses surrounding
the uptake of tau protein by neurons from the interstitium, and tau protein seeding to promote
spread of pathology. This is not, however consistent with prion biology in which a pathological
prion protein is capable of autocatalyzing a conformational shift from a healthy isoform to
pathological prion in another protein of the same type (Baskakov and Breydo, 2007). It is more
likely that pathological tau protein exerts toxicity to the cell via cell-wide molecular signaling
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changes induced by uncontrolled N-terminal interactions with other proteins including the kinase
GSK3β, which then result in cell stress-induced tau protein pathology, introducing a cycle of
aberrant stress response ultimately resulting in cellular apoptosis. If tau protein can induce
increased activation of tau-phosphorylating kinases, however, it is possible that it could induce a
positive feedback loop whereby tau protein becomes increasingly toxic to cells, ultimately
inducing neuronal death. This would be consistent with the slowly developing nature of many
tauopathies lacking mutations or other external stressors.
The question of what the toxic species may be in tauopathies has also been asked, and
whether the fibrillar aggregates themselves are toxic or if some other form of tau protein is toxic.
While fibrillar tau protein has been shown be associated with toxicity, this may be a result of the
toxic process itself (Cowan and Mudher, 2013). It has been suggested that it is likely the soluble
tau protein oligomer that constitutes the toxic species (Lasagna-Reeves et al., 2012) which goes
along with the concept that tau protein may exert toxicity through aberrant signaling, which it
can do while still soluble rather than in an aggregate sink. Importantly, tau protein oligomerizes
on its way to forming aggregates (Cisek et al., 2014), and as such the fibrils themselves are an
indicator of toxicity (Bandyopadhyay et al., 2007).
Regardless of the toxic species, aberrant, uncontrolled tau protein phosphorylation
is a common factor in many neurodegenerative diseases, leading to tau-mediated toxicity, tau
protein fibril formation and neuronal death. That Thr175 phosphorylation is unique to
pathological disease states, present in 2 tauopathies (uninvestigated in others), and demonstrates
toxicity when expressed in cell culture, warrants further investigation. That pThr175 tau protein
does not form aggregates alone suggests that further modification to tau protein is required for
this to occur. Thr231 phosphorylation alone has been shown to regulate tau protein structure, and
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if driven further than normal may be able to drive tauopathy. Given that this site has been shown
to be phosphorylated by GSK3β and that tau protein has been shown to be capable of activating
GSK3β-dependent pathways, it is conceivable that these two phospho-epitopes and kinase are
closely related to one another as mediators of phospho-tau toxicity.
1.8 Hypothesis
pThr175 tau protein is implicated in the neurodegenerative process through a toxic
pathway dependent on downstream activation of GSK3β and further phosphorylation at pThr231
which is critical for fibril formation and cell death.
1.9 Thesis overview
The focus of the studies presented in this manuscript is the pathogenesis of tau protein
phosphorylated at amino acid Thr175.
In Chapter 2, I show that pThr175 tau protein when unmodified by further
phosphorylation does not have an increased propensity to self-aggregate, but that when further
phosphorylated at Thr231 in a sequence of events dependent on pThr175-mediated enhancement of
GSK3β activation, pThr175 tau protein induces fibril formation and cell death. Inhibition of
GSK3β reduces tau protein fibril formation and cell death associated with pThr175 tau protein
expression.
In Chapter 3, I show that pThr175 tau protein pathology is not unique to ALSci or
Alzheimer’s disease but that it can be observed in 8 other tauopathies, and that it is associated
with Thr231 phosphorylation and tau protein oligomerization in pathological inclusions. I also
show that pThr175 tau protein is not observed in non-pathological human brain tissue.
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In Chapter 4, I show that pThr175 tau protein pathology is present in chronic traumatic
encephalopathy and in chronic traumatic encephalomyelopthy in both hippocampal and spinal
cord neuronal pathology. This was associated with pThr231 and activated GSK3β in human
tissue. In a rat model of moderate traumatic brain injury I show that after a single head trauma
pThr175 tau protein can be induced along with tau protein pathology.
In Chapter 5, I show that pThr175 tau protein induces tau pathology in adult rat
hippocampus when expressed by an adenoviral vector.
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Chapter 2: Thr175 phosphorylated tau induces pathological fibril formation via GSK3β
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2.1 Abstract:
We have previously shown that amyotrophic lateral sclerosis with cognitive impairment (ALSci)
can be characterized by pathological inclusions of microtubule associated protein tau (tau
protein) phosphorylated at Thr175 (pThr175) in association with GSK3β activation. We have now
examined whether pThr175 induces GSK3β activation and whether this leads to pathological fibril
formation through Thr231 phosphorylation. 72 hours after transfection of Neuro2A cells with
pseudophosphorylated GFP-tagged 2N4R tau protein (Thr175Asp), pGSK3β (active GSK3β)
levels were significantly increased as was pathological fibril formation and cell death. Treatment
with each of 4 GSK3β inhibitors or shRNA knockdown of GSK3β abolished fibril formation and
prevented cell death. Inhibition of Thr231 phosphorylation (Thr231Ala) prevented pathological tau
protein fibril formation, regardless of Thr175 state while Thr231Asp (pseudophosphorylated at
Thr231) developed pathological tau protein fibrils. Ser235 mutations did not affect fibril formation,
indicating an unprimed mechanism of Thr231 phosphorylation. These findings suggest a
mechanism of tau protein pathology by which pThr175 induces GSK3β phosphorylation of Thr231
leading to fibril formation, indicating a potential therapeutic avenue for ALSci.
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2.2 Introduction:
Amyotrophic lateral sclerosis (ALS) is the most common adult onset neurodegenerative disorder
of the motor system with a lifetime risk of 1:300 and a survival of 2-5 years after diagnosis
(Factor-Litvak et al., 2013). Over 50% of patients with ALS develop a cognitive (ALSci),
behavioural (ALSbi) or dysexecutive syndrome consistent with that of frontotemporal
dysfunction, including a frontotemporal dementia (FTD) (Ringholz et al., 2005; Strong et al.,
2009). The frequent co-existence of ALS and FTD has led to the postulate that both are two
states along one disease continuum (Robberecht and Philips, 2013). Importantly, patients with
frontotemporal dysfunction have a reduced survival compared to other ALS cases (Elamin et al.,
2011; Elamin et al., 2013; Hu et al., 2013; Olney et al., 2005). We have previously shown that
ALSci is typically associated with frontotemporal atrophy with superficial linear spongiosis
affecting the frontal cortex (Wilson et al., 2001), accompanied by both neuronal and glial
inclusions of microtubule associated protein tau (tau protein) (Yang et al., 2003; Yang and
Strong, 2012). This finding is significantly greater than observed as a function of age (Yang et
al., 2005).
Tau protein is a cytoskeletal stabilizing protein, which binds to microtubules in the
axonal processes, helping to prevent microtubule breakdown and providing structural support by
maintaining space between microtubules and other cytoskeletal elements or the cell wall (Chen
et al., 1992; Weingarten et al., 1975). In the diseased states known as tauopathies, tau protein
relocates from its normal localization in the axon to the cell body where it forms aggregates
(Kowall and Kosik, 1987). In ALSci cases, tau protein is found in the form of fibrillar inclusions
and is phosphorylated at Thr175 ; a phenomenon not observed in Alzheimer’s tau protein
inclusions (Strong et al., 2006) and to a much greater extent than that observed in ALS with no
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cognitive impairment (Yang and Strong, 2012). In solution, tau protein isolated from ALSci
patients has a greater propensity to aggregate, while in both HEK293T and Neuro2A cells, tau
protein pseudophosphorylated at Thr175 was found to form fibrillar aggregates to a much larger
extent than wild type (WT) tau protein, regardless of the isoform (Gohar et al., 2009). In these
latter experiments, pathological fibril formation was associated with increased cell death. We
also observed that pathological tau protein inclusions in ALSci co-localize with phosphorylated
kinase glycogen synthase kinase 3 beta (pGSK3β- the active isoform of GSK3β) (Yang et al.,
2008). Because GSK3β is a proline-directed kinase capable of exhibiting primed and unprimed
phosphorylation of tau protein (Cho and Johnson, 2003) (Cho and Johnson, 2003)and because
GSK3β has been strongly implicated as a major contributor to tau protein pathology (Cho and
Johnson, 2003; Cho and Johnson, 2004a; Cho and Johnson, 2004b; Hernandez et al., 2013;
Lucas et al., 2001; Pei et al., 1997; Sahara et al., 2008; Sato et al., 2002), we postulated that
GSK3β activation would also be key to pathological tau protein fibril formation in ALSci. We
have also postulated that phosphorylation of Thr231 will be key to pathological tau protein fibril
formation.
Thr231 is a tau protein phosphorylation site which, when phosphorylated, causes a
conformational change in which tau protein’s ability to bind to microtubules is reduced (Lin et
al., 2007). Thr231 is a known substrate of GSK3β (Alonso et al., 2010; Cho and Johnson, 2004b;
Sahara et al., 2008; Sengupta et al., 1998). It is neighbored by a proline, and also fits the Ser/ThrXXX-pSer/pThr motif required by GSK3β for primed phosphorylation if the site at Ser235 is
phosphorylated first. It is therefore a likely site of synergistic modification to tau protein in its
pathology along with phosphorylation of Thr175.
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In this study, we demonstrate that phosphorylation of tau protein at Thr175 leads to the
activation of GSK3β, which then phosphorylates tau protein at Thr231 and which in turn leads to
pathological fibril formation. Inhibition of GSK3β, pharmacologically and by small hairpin RNA
(shRNA) knockdown prevents toxic pathological tau protein fibril formation, and prevents cell
death. Phosphorylation at Thr231 is critical to this process, although independent of Ser235
phosphorylation status.

2.3. Methods:
2.3.1. Cell culture and transfection:
Because we had previously shown that Thr175Asp induces pathological tau protein fibril
formation in Neuro2A and HEK293T cells, we performed all studies using the 2N4R tau protein
isoform in Neuro2A cells (Gohar et al., 2009). Neuro2A cells were grown on 10 cm plates in
Dulbecco’s Modified Eagle medium (DMEM; Gibco, Burlington ON, Canada) enriched with
10% fetal bovine serum (Gibco, Burlington On. Canada) and 50 µg/mL Penicillin/Streptomycin
(Gibco, Burlington, On. Canada). Cells were maintained at 37˚C and 5% CO2. Transfections for
all survival and aggregation studies were performed using Lipofectamine 2000 (Invitrogen,
Burlington On. Canada) with appropriate amounts of DNA for the plate size at a 3:1 ratio (µL
Lipofectamine: µg DNA). Liposome-DNA complex was added to cells in serum free medium
and transfected for 3 hours at 37˚C. Due to the increased number of cells required to yield
sufficient amounts of protein for lysate analysis, the calcium phosphate method of transfection
(Jordan et al., 1996) was used for western blot studies. Cells were incubated for 18 hours at 37˚C
and 5% CO2 in the presence of 10 µg DNA and a mixture of CaCl2 and HEPES buffered serum.
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Medium was changed to end all transfections. All analyses were conducted 72 hours after
transfections were ended.

2.3.2. Thioflavin S assay for Tau aggregation:
GST fusion variants of WT and Thr175Asp 2N4R tau protein were generated and expressed in
Escherichia Coli (E. coli) BL21 cells via pGEX vector using the GST spintrap purification
module (General Electric Healthcare NJ, USA). E. coli was grown in YTA medium for 3-5 hours
at 37 ˚C with vigorous agitation. E. coli was then pelleted by centrifugation, resuspended in PBS
and then lysed by sonication. Tau protein was purified from the resulting homogenate as
previously described (Gohar et al., 2009), and the ability to form pathological fibrils assayed by
in vitro thioflavin S assay (Friedhoff et al., 1998; Taniguchi et al., 2005). 100 µL purified protein
sample containing 0.35 to 10.0 µg/µL was brought to a total volume of 300 µL with a final
concentration of 3 µM thioflavin S (Sigma-Aldrich, Oakville, ON, Canada) in 20 mM 3-(Nmorpholino) propanesulfonic acid (MOPS; Sigma-Aldrich, Oakville, ON, Canada), pH 6.8.
Samples were analyzed with or without 5 µM heparin (Sigma-Aldrich, Oakville, ON, Canada).
The assembly of tau protein into fibrils is enhanced by heparin, a polyanion, which acts as a
positive control for this assay (Pickhardt et al., 2005; von Bergen M. et al., 2000). Thioflavin S
fluorescence was read at 22˚C with a SPECTRmax M5 ROM (Fischer Scientific, Pittsburgh, PA,
USA) set at 440 nM excitation and 521 nM emission. Background fluorescence and light
scattering of a negative control sample containing only thioflavin S was subtracted from the
values obtained. All experiments were performed in triplicate.
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2.3.3. Fibril quantification:
Cells were transfected with GFP-tagged mutant tau protein and visualized live by fluorescence
microscopy on a Zeiss LSM 510 Meta NLO multiphoton confocal microscope in confocal
microscopy dishes at 63x magnification. Plates were divided into 4 quadrants and a minimum of
25 transfected cells from random fields in each quadrant were counted and categorized into a)
cells containing fibrillar aggregates or b) cells containing no fibrillar aggregates. Consistent with
our previous studies, fibrillar aggregates were defined as discrete, dense, thickened, curvilinear
cytosolic structures in contrast to the fine filamentous threads observed in WT tau protein
transfected cells (Supplemental figure 2.1) (Gohar et al., 2009). The percentage of cells
containing aggregates was defined as the number of GFP- tau protein expressing cells counted
containing fibrils. All experiments were performed in triplicate after plates were blinded to the
observer (AJM) by a separate party.
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Supplemental figure 2.1: Phenotype of Thr175Asp tau fibrils in Neuro2A cells.
GFP-tagged tau protein was imaged by live cell confocal microscopy 72 hours after transfection.
A) Both wild-type and Thr175Ala transfected cells demonstrated fine, filamentous fibril formation
typical of that expected for cytosolic tau protein. B) Fibrillar tau protein pathology in Thr175Asp
tau protein transfected cells. In contrast to the wild-type and Thr175Ala transfected cells, cells
transfected with Thr175Asp formed thick, curvilinear tau protein inclusions. Additional bundling
along the periphery of the cell was also commonly observed. Images taken at 63x magnification.
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2.3.4. GSK3β Inhibitors:
Four GSK3β inhibitors that act through different mechanisms were used at their respective IC50
values in fibril and survival experiments. These included: lithium chloride (LiCl; SigmaAldrich, St. Louis MO, USA), IC50 5 mM, which acts through a Mg2+ competitive mechanism;
AR-A014418 (Sigma-Aldrich, St. Louis MO, USA), IC50 104 nM (Bhat et al., 2003), which acts
through an ATP competitive mechanism; Tideglusib (Sigma-Aldrich, St. Louis MO, USA), IC50
60 nM (Dominguez et al., 2012), which acts through a non-ATP competitive mechanism; and,
TWS-119 (BioVision, Milpitas CA, USA), IC50 30 nM (Ding et al., 2003), which acts through a
non-ATP competitive mechanism. Toxicity was assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay prior to use in fibril studies to demonstrate that the
inhibitors would not be lethal to Neuro2A cells at their IC50. Inhibitors were administered in
fresh medium at their IC50 concentration at the end of transfection when medium was changed.

2.3.5. Site-directed mutagenesis and mutant constructs used:
Site-directed mutagenesis was used to create mutant GFP-tagged tau protein from plasmid
constructs in pEGFP-C1 vector as previously described (Gohar et al., 2009). Based on our
previous observations, all studies performed here utilized the 2N4R tau protein isoform (with a
green fluorescent protein (GFP) tag on the N terminus) as the template for all double mutants. To
assess the effect of phosphorylation of Thr175, the following constructs were used: wild type
2N4R tau protein, a Thr175Ala mutant (cannot be phosphorylated at Thr175), and a Thr175Asp
mutant (mimics phosphorylation at Thr175). Agilent technologies QuickChange lightening sitedirected mutagenesis kit (Agilent Technologies, Mississauge On, Canada) was used to generate 6
double mutant GFP-tagged tau protein constructs containing Thr231 mutants (1: WT Thr175
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/Thr231Ala, 2: WT Thr175 /Thr231Asp, 3: Thr175Ala /Thr231Ala, 4: Thr175Ala /Thr231Asp, 5:
Thr175Asp /Thr231Ala, 6: Thr175Asp /Thr231Asp). Full length primers for Thr231Ala mutants were:
forward (5’-GCA GTG GTC CGT GCT CCA CCC AAG TCG-3’) and reverse (5’-CGA CTT
GGG TGG AGC ACG GAC CAC TGC-3’). Full length primers for Thr231Asp mutations were:
Forward (5’-GCA GTG GTC CGT GAT CCA CCC AAG TCG-3’) and reverse (5’-CGA CTT
GGG TGG ATC ACG GAC CAC TGC-3’).
An additional series of 6 GFP-tau protein mutants containing Ser235 mutations was
created to test the requirement of a primed phosphorylation mechanism at Thr231. These mutants
were (1: WT Thr175 /Ser235Ala, 2: WT Thr175 /Ser235Asp, 3: Thr175Ala /Ser235Ala, 4: Thr175Ala
/Ser235Asp, 5: Thr175Asp /Ser235Ala, 6: Thr175Ala /Ser235Asp). Full length primers for Ser235Ala
mutants were: Forward (5’-CCC AAG GCG CCG TCT TCC GCC-3’) and reverse (5’-GGC
GGA AGA CGG CGC CTT GGG-3’). Full length primers for Ser235Asp mutants were: Forward
(5’-CCC AAG GAC CCG TCT TCC GCC-3’) and reverse (5’-GGC GGA AGA CGG GTC
CTT GGG-3’).
All mutants were sequenced to confirm presence of mutations of interest.

2.3.6. MTT survival assay:
Cells were grown and transfected in 96 well plates. 72 hours post transfection, 20µL 5mg/mL 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich, St. Louis
MO, USA) was added to each well and then incubated for 1 hour at 37˚C and 5% CO2. After
incubation, cells from one well per treatment group were resuspended in 100 µL fresh DMEM,
and transferred to a 1.5 mL microcentrifuge tube. 10 µL was then loaded onto a hemocytometer
(improved Neubauer, Hausser scientific, Horsham PA) and purple (live) and white (dead) cells
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were counted. Cell death was expressed as dead cells/total cells counted. All experiments were
performed in triplicate.

2.3.7. Trypan blue assay:
Cells were grown and transfected in 96 well plates. 72 hours post transfection, cells from one
well per treatment group were resuspended in 100 µL fresh DMEM and transferred to a 1.5 mL
microcentrifuge tube. 100 µL 0.4% trypan blue stain (Gibco, Burlington, On. Canada) was then
added and cells were incubated at room temperature for 1 min. 10µL was then loaded onto a
hemocytometer and white (live) and blue (dead) cells were counted. Cell death was expressed as
dead cells/total cells counted. All experiments were performed in triplicate.

2.3.8. Western blot:
Cells were lysed on ice 72 hours after transfection in NP40 lysis buffer (50 mM Tris, 100 mM
NaCl, 1 mM EDTA, 1% NP40, 10% glycerol) containing protease (cOmplete, Roche
Diagnostics, Indiapolis, IN, USA) and phosphatase inhibitors (Phosstop, Roche Diagnostics,
Indiapolis, IN, USA). Lysate protein content was quantified using a DC protein assay kit (BioRad, Hercules, CA, USA). Samples were suspended in sample buffer (100 mM Tris-HCl, 4%
SDS, 0.02% bromophenol blue, 20% glycerol, 200 mM DTT) and denatured for 5 minutes in a
hot water bath at 95˚C. 20 µg protein was run on a 10% sodium dodecyl sulfate polyacrylamide
gel and transferred to a nitrocellulose membrane. To assess transfection efficiency, gels were
probed for GFP using a rabbit anti-GFP antibody (1:5000 titer; Life Technologies Eugene, OR,
USA). GSK3β activation was assessed using a mouse anti-pTyr216 GSK3β (1:10 000 titer; BD
Biosciences, Mississauga, On. Canada). To fully investigate activation status relative to overall
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levels of kinase, total GSK3β was examined by stripping blots (2%SDS, 62.5 mM Tris-HCl, 100
mM β- mercaptoethanol, pH 6.8) and re-probing with mouse anti-total GSK3β (1:10 000 titer;
BD Biosciences, Mississauga, On. Canada). Nitrocellulose membranes were probed with
primary antibody overnight at 4˚C. Blots were then washed in Tris-buffered saline with 0.2%
Tween (TBS-T) before probing with horseradish peroxidase tagged secondary antibody (Goat
anti-Mouse IgG (1:5000 titer; Bio-Rad, Hercules, CA, USA) or Swine anti-rabbit (1:1000 titer;
Dako, Burlington, On. Canada) for 1 hour at room temperature. Densitometry was conducted
using open source ImageJ software (NIH). GSK3β activation was normalized for overall
expression and transfection efficiency by the equation (pTyr216/Total GSK3β)/(GSK3β/GFP). All
experiments were performed in triplicate.
For shRNA knockdown efficacy studies, total GSK3β was normalized to α-tubulin by
densitometry using mouse anti-α-tubulin (1:2500 titer, Abcam, Toronto, On. Canada). GSK3α
was assessed using mouse anti-GSK3α (1:1000 titer, Abcam, Toronto, On. Canada), and
normalized to α-tubulin by densitometry.

2.3.9. shRNA:
A small hairpin RNA (shRNA) specific to GSK3β was designed according to a previously
reported sequence (Yu et al., 2003) shown to specifically knock down GSK3β in Neuro2A cells
while leaving GSK3α unaffected (Garrido et al., 2007). The shRNA sequence was modified to
have a hairpin sequence specific to the pSuper plasmid vector into which it was inserted via
BglII and HindIII restriction digest and ligation with T4 DNA ligase. Sequence primers were, as
described by Yu et al 2013: Forward (5’-GAT CCC CGA TCT GGA GCT CTC GGT TCT TTC
AAG AGA AGA ACC GAG AGC TCC AGA TCT TTT TA-3’) and Reverse (5’-AGC TTA
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AAA AGA TCT GGA GCT CTC GGT TCT TCT CTT GAA AGA ACC GAG AGC TCC AGA
TCG GG-3’).
shRNA plasmid was transfected into Neuro2A cells with lipofectamine 2000 and GSK3β
expression analysed at 24 and 96 hours post transfection to investigate the efficacy and
sustainability of GSK3β knockdown.
For knockdown studies, 24 hours before transfection with GFP-tau plasmid, shRNA or
pSuper vector was transfected into cells so that expression of GSK3β would be reduced at the
time of tau plasmid transfection. Fibril quantification was then conducted as above.

2.3.10. Nocodazole experiments:
Cells were transfected with GFP-tagged wild type tau or Thr175Asp tau with Lipofectamine as
above in confocal dishes. 72 hours after transfection cells were exposed to 500 nM nocodazole
(Sigma-Aldrich, Oakville, ON, Canada) for 1 hour which has previously been reported to
effectively reduce microtubule dynamics (Vasquez et al., 1997). Cells were imaged live by
confocal imaging after 1 hour incubation at 37˚C.

2.3.11. In vitro β-tubulin co-localization:
N terminal mCherry-tagged β-tubulin constructs were created by inserting β-tubulin (isolated
from human muscle tissue) into a pmCherry-N1 vector (Clontech, Mountain View, CA, USA)
using HindIII and SalI cleavage sites incorporated into forward and reverse primers respectively:
Forward (5’-CGA AGC TTA TGA GGG AAA TC-3’) and Reverse (5’-AAG TCG ACC CGG
CCT CCT CTT CGG C-3’).
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Neuro2A cells were co-transfected with both GFP-tagged Thr175Asp tau protein and
pmCherry-tagged β-tubulin. Live cell confocal imaging was conducted at 72 hours post
transfection. To compare the differential effects on tau protein and tubulin formations, half of the
plates were exposed to 500 nM nocodazole for 1 hour before live cell confocal imaging.

2.3.12 Statistical analysis:
Statistics were conducted using Sigmaplot 10.0 software. Following a Shapiro-Wilk test for
normality, a one-way analysis of variance (ANOVA) was conducted (or Kruskal-Wallis
ANOVA on ranks for z non-normal data) and Tukey’s post-hoc test was conducted. Results were
considered to be significant when p<0.05.
2.4. Results:

2.4.1. Thr175 phosphorylation alone is insufficient to induce fibril formation:
WT, Thr175Asp, and Thr175Ala 2N4R tau protein was isolated from E. coli and the extent to
which each would form fibrils, in the presence or absence of heparin, determined using the
Thioflavin S assay (Figure 2.1). No difference was detected between the individual constructs.
This suggested that phosphorylation at Thr175 is not sufficient to induce pathological fibril
formation by itself.
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Figure 2.1: Phosphorylation at Thr175 alone is not sufficient to induce aggregation. GST
fusion variants of WT and Thr175Asp 2N4R tau protein was isolated from E. coli BL21 cells.
Extent of fibril formation was then assayed by in vitro Thioflavin S assay with and without
heparin. No difference was detected between Thr175Asp GST-fusion tau protein compared to WT
GST-fusion tau protein with or without heparin. Values are representative of three independent
experiments.
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2.4.2. GSK3β activation is increased in cells transfected with Thr175Asp tau:
Given our previous observation of co-localization between tau protein aggregates and activated
GSK3β in ALSci, we characterized GSK3β activation status in Neuro2A cells transfected with
each tau protein construct. In cells transfected with Thr175Asp tau protein, the level of pTyr216
was elevated relative to all other transfection groups (Figure 2.2). Relative to the GFP control,
WT tau protein transfected cells had 1.13±0.16 times as much pGSK3β (mean±SEM), and
Thr175Ala tau protein had 1.12±0.13 times as much pGSK3β. Neither were significantly different
relative to each other, or to the GFP control. Only Thr175Asp tau protein transfected cells had a
significant increase in pGSK3β (1.81±0.14) relative to GFP transfected cells after KruskalWallis one-way ANOVA on ranks (p=0.002, F=8.684). This indicates that pThr175 tau protein
induces increased expression of the active form of GSK3β. This in turn may further modify tau
protein, giving rise to pathological changes necessary for tau protein fibril formation.

77

Figure 2.2: GSK3β activation increases in Neuro2A cells transfected with Thr175
phosphomimic tau protein. A) Representative western blot for active GSK3β (pTyr216) in
untransfected (Ctrl), wild type tau protein (WT), unphosphorylated (Thr175Ala) and
phosphomimic (Thr175Asp) transfected Neuro2A cells 72 hours after transfection. B)
Densitometric analysis of western blots probed for pTyr216 GSK3β and then normalized against
total GSK3β, and transfection efficiency by the equation (pTyr216/Total GSK3β)/(GSK3β/GFP).
Values are representative of three independent experiments.
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2.4.3. Fibril formation is abolished by pharmacologic inhibition of GSK3β:
In keeping with previous studies (Gohar et al., 2009), GFP-tau protein fibril formation occurred
to some extent in all tau construct transfection groups but to a much greater extent in Thr175Asp
tau transfected cells (Figure 2.3).
Prior to pharmacological studies, all four inhibitors were tested on untransfected
Neuro2A cells over a range of concentrations focused around their respective IC50. Survival was
assessed by MTT assay (described below) after 72 hours of exposure. None of the inhibitors was
toxic to the cells at their reported IC50.
Upon analysis of fibril formation, Thr175Asp tau transfected cells exhibited increased
levels of fibril formation relative to all other groups (p<0.001 Tukey’s post-hoc test after one
way ANOVA with p<0.001, and F=7.905) (Figure 2.3, Supplemental table 2.1).
All four inhibitors administered at their respective IC50 concentrations were able to
reduce fibril formation in Thr175Asp tau transfected cells to baseline levels (Supplemental table
2.1, Figure 2.3). This indicates that the increased GSK3β activity observed in Thr175Asp mutant
tau protein is necessary for the increased fibril formation observed.
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Figure 2.3: Fibril formation is reduced to baseline when GSK3β is pharmacologically
inhibited. A) 5 mM LiCl. B) 104 nM AR-A014418. C) 60 nM Tideglusib. D) 30 nM TWS-119.
GFP= GFP transfected group, WT= wild type tau, Thr175Ala= unphosphorylated mutant,
Thr175Asp= phosphomimic. TWS= TWS119 treated group, Tide= Tideglusib treated group,
LiCl= LiCl treated group, ARA= AR-A014418 treated group. * denotes p<0.05 compared to all
other groups by post hoc test after one way ANOVA. Values are representative of three
independent experiments.

80
Supplemental Table 2.1: Thr175Asp tau fibril formation is increased compared to all treatment
groups and constructs. Untreated= no GSK3β inhibitor used, WT= wild type tau, Thr175Ala=
unphosphorylated mutant, Thr175Asp= phosphomimic. TWS= TWS119 treated group, Tide=
Tideglusib treated group, LiCl= LiCl treated group, ARA= AR-A014418 treated group. Values
represent mean±SEM % of GFP-tau protein expressing cells exhibiting fibrils. * denotes
increased fibril formation in comparison to all groups (treated and untreated) p<0.001 Tukey’s
post-hoc test after one way ANOVA (p<0.001, F=7.905).

Group

Untreated

5 mM LiCl

WT
Thr175Ala
Thr175Asp

22±2
23±2
52±2 *

26±1
24±3
24±3

104 nM ARA014418
25±3
26±2
24±1

60 nM
Tideglusib
25±6
24±1
25±2

30 nM TWS119
22±2
24±2
25±2
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2.4.4. shRNA knockdown of GSK3β abolishes fibril formation:
Although the evidence thus far suggests GSK3β is the downstream kinase responsible for further
tau protein phosphorylation and toxicity leading to fibril formation, a separate isoform (GSK3α)
shares 95% similarity in its catalytic domain and 85% similarity overall (Woodgett, 1990).
Although there are shared substrates, GSK3α and GSK3β are encoded by 2 separate genes; they
are differentially expressed in different tissues (Lau et al., 1999; Uzbekova et al., 2009); they are
differentially regulated in the brain (Takahashi et al., 1994) with GSK3β having a higher overall
expression in the brain (Lau et al., 1999; Yao et al., 2002); and, they show different substrate
affinity (Wang et al., 1994). Therefore, a shRNA was developed to selectively knock down
GSK3β. Western blots for GSK3β and GSK3α were quantified by densitometry, and
standardized relative to that of an untransfected control. At 24 hours, levels of GSK3β expression
(standardized against untransfected control) were: pSuper vector 76.9±8.8% and shRNA
50.8±3.0% (p<0.05 after significant ANOVA with p=0.002 and F=21.177). At 96 hours, relative
levels of GSK3β expression were: pSuper vector 123.5±3.3% and shRNA 67.7±6.7% (p<0.05
after significant ANOVA on ranks with p=0.004). GSK3α levels were unaffected by shRNA
transfections.
Using this shRNA, tau construct transfected cells were assessed for fibril formation as in
previous experiments (Figure 2.4). As previously noted, Thr175Asp tau transfected cells showed a
significant increase in fibril formation when contrasted to WT-tau transfected cells (52±2% vs.
26±2%, Thr175 vs. WT-tau respectively). Cotransfection with pSuper vector had no effect on
fibril formation (54±4% vs. 25±2%, Thr175 vs. WT-tau respectively). In contrast, cells
cotransfected with GSK3β specific shRNA showed a complete inhibition of fibril formation
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(24±0% vs. 27±1, Thr175 vs. WT-tau respectively) (p<0.001 after significant ANOVA with
p<0.001 and F=50.339).
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Figure 2.4: shRNA knockdown of GSK3β abolishes pathological fibril formation. A)
Representative western blots for GSK3β and GSK3α at 24 and 96 hours post-transfection. B)
Densitometric quantification of GSK3β and GSK3α expression relative to untransfetced control
cells. Values were expressed as the ratio of GSK:α-tubulin before comparison. C) Fibril
formation in shRNA expressing cells was abolished relative to empty vector (pSuper) and cells
only transfected with tau protein. WT= wild type tau, Thr175Asp= phosphomimic * denotes
p<0.001 compared to all other groups by post hoc test after significant one way ANOVA. All
values are representative of three independent experiments.
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2.4.5. Thr175Asp tau induced cell death is prevented by GSK3β inhibition:
After 72 hours, Thr175Asp transfected cells showed increased death relative to GFP, WT tau, or
Thr175Ala tau transfected cells, consistent with previous studies (Figure 2.5, Supplemental table
2.2) (Gohar et al., 2009). This was also increased relative to all GSK3β inhibitor treatment
groups (p<0.05 Tukey’s post-hoc test after one way ANOVA). The same observations were
made using the Trypan blue experiments across all inhibitors (Supplemental figure 2.2). These
data suggest that fibril formation is accompanied by cell death, and inhibiting fibril formation
prevents cell death.
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Figure 2.5: Thr175Asp induced tau cell death is alleviated by GSK3β inhibition. A) 5 mM
LiCl. B) 104 nM AR-A014418. C) 60 nM Tideglusib. D) 30 nM TWS-119. GFP= GFP
transfected group, WT= wild type tau, Thr175Ala= unphosphorylated mutant, Thr175Asp=
phosphomimic. TWS= TWS119 treated group, Tide= Tideglusib treated group, LiCl= LiCl
treated group, ARA= AR-A014418 treated group. * denotes p<0.05 compared to all other groups
by post hoc test after one way ANOVA. Values are representative of three independent
experiments.
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Supplemental figure 2.2: Thr175Asp induced tau cell death is prevented by GSK3β inhibition as
determined by trypan blue assay. A) 5 mM LiCl. B) 104 nM AR-A014418. C) 60 nM Tideglusib.
D) 30 nM TWS-119. GFP= GFP transfected group, WT= wild type tau, Thr175Ala=
unphosphorylated mutant, Thr175Asp= phosphomimic. TWS= TWS119 treated group, Tide=
Tideglusib treated group, LiCl= LiCl treated group, ARA= AR-A014418 treated group. *
denotes p<0.05 compared to all other groups by post hoc test after one way ANOVA. Values are
representative of three independent experiments.
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Supplemental Table 2.2: pThr175 induced cell death is prevented by GSK3β inhibition.
Untreated= no GSK3β inhibitor used, Treated= GSK3β inhibitor administered. GFP= GFP
transfected group, WT= wild type tau, Thr175Ala= unphosphorylated mutant, Thr175Asp=
phosphomimic. TWS= TWS119 treated group, Tide= Tideglusib treated group, LiCl= LiCl
treated group, ARA= AR-A014418 treated group. Values represent mean±SEM % cell death. *
indicates p=0.002, ** indicates p<0.001 compared to all other groups in each treatment row after
significant ANOVA.

GFP

Treatment
5 mM LiCl
104 nM ARA014418
60 nM
Tideglusib
30 nM TWS119

Thr175Ala

WT

Thr175Asp

Untreated

Treated

Untreated

Treated

Untreated

Treated

Untreated

Treated

10±2
4±3

10±1
8±0

10±0
10±1

9±1
6±1

9±0
7±2

8±1
5±1

20±2**
22±4**

8±1
7±1

9±1

9±1

10±0

9±0

8±1

8±1

15±2**

10±1

10±1

10±1

8±1

8±1

7±0

8±2

18±3*

8±2
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2.4.6. Thr231 phosphorylation is necessary for Thr175 mediated fibril formation:
To test if Thr231 is a downstream mediator of Thr175Asp induced pathological fibril formation, we
constructed GFP-tagged double mutant tau protein with either a Thr231Ala or Thr231Asp
mutation, with or without Thr175Asp. A total of 6 constructs were tested. All constructs formed
fibrils to a baseline extent as previously observed in other constructs (Supplemental table 2.3,
Figure 2.6). However, those containing the Thr231Ala mutation did not form increased fibrils,
regardless of Thr175 phosphorylation state, while all Thr231Asp mutants formed increased fibrils
relative to baseline regardless of Thr175 phosphorylation status (increased relative to others with
p<0.001 tukey’s post-hoc test after one way ANOVA with p<0.001, and F=60.087). This
suggests that phosphorylation at Thr231 is key to pathological fibril formation.
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Figure 2.6: Thr231 phosphorylation is required for pathological fibril formation in Thr175
mutant tau. WT= wild type tau; Thr175Ala= unphosphorylated mutant; Thr175Asp=
phosphomimic; Thr175 /Thr231Ala= phosphorylation inhibited only at Thr231; Thr175 /Thr231Asp=
phosphomimic only at Thr231; Thr175Ala /Thr231Ala= phosphorylation prevented at Thr175 and
Thr231; Thr175Ala /Thr231Asp= phosphorylation prevented at Thr175 but phosphomimic at Thr231;
Thr175Asp /Thr231Ala= phosphomimic at Thr175 but phosphorylation prevented at Thr231;
Thr175Asp /Thr231Asp= phosphomimic at both Thr175 and Thr231. * denotes p<0.001 post hoc
after one way ANOVA. Values are representative of three independent experiments.
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Supplemental Table 2.3: Tau fibril formation in Thr231 mutant containing constructs. WT
Thr175= wild type tau at Thr175; Thr175Ala= unphosphorylated mutant at Thr175; Thr175Asp=
phosphomimic at Thr175. WT Thr231= wild type tau at Thr231; Thr231Ala= unphosphorylated
mutant at Thr231; Thr231Asp= phosphomimic at Thr231.Values represent mean±SEM % of GFPtau expressing cells exhibiting fibrils. * denotes p<0.05 tukey’s post-hoc test after one way
ANOVA (p<0.001, F=60.087).

Group
WT Thr175
Thr175Ala
Thr175Asp

WT Thr231
28±1
24±2
53±3 *

Thr231Ala
28±1
28±1
29±0

Thr231Asp
52±2 *
59±2 *
53±2 *
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2.4.7. Thr175Asp mediated phosphorylation of Thr231 is not dependent on primed
phosphorylation at Ser235:
To test if Ser235 phosphorylation is necessary to prime phosphorylation of Thr231 in response to
Thr175Asp, site directed mutagenesis was used to create GFP-tagged tau protein with Ser235Ala
and Ser235Asp mutations. A total of 6 mutants were made, each having a combination of Thr175
mutations as discussed previously. Ser235Ala mutations did not prevent fibril formation in
Thr175Asp mutant transfected cells (increased relative to all others with p<0.001 Tukey’s posthoc test after one way ANOVA with p<0.001, and F=70.537), indicating that the mechanism of
primed Thr231 phosphorylation is not necessary for the downstream pathology after Thr175
phosphorylation (Figure 2.7, Supplemental table 2.4). Ser235Asp mutations did not increase fibril
formation in the absence of Thr175 phosphomimic, indicating that its presence is not permissive
to fibril formation either.
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Figure 2.7: Ser235 phosphorylation is not required for Thr175 mediated fibril formation. .
WT= wild type tau; Thr175Ala= unphosphorylated mutant; Thr175Asp= phosphomimic; Thr175
/Ser235Ala= phosphorylation inhibited only at Ser235; Thr175 Ser235/Asp= phosphomimic only at
Ser235; Thr175Ala /Ser235Ala= phosphorylation prevented at Thr175 and Ser235; Thr175Ala
/Ser235Asp= phosphorylation prevented at Thr175 but phosphomimic at Ser235; Thr175Asp
/Ser235Ala= phosphomimic at Thr175 but phosphorylation prevented at Ser235; Thr175Asp
/Ser235Asp= phosphomimic at both Thr175 and Ser235. * denotes p<0.001 post hoc after one way
ANOVA. Values are representative of three independent experiments.
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Supplemental Table 2.4: Tau fibril formation in Ser235 mutant containing constructs. WT
Thr175= wild type tau at Thr175; Thr175Ala= unphosphorylated mutant at Thr175; Thr175Asp=
phosphomimic at Thr175. WT Ser235= wild type tau at Ser235; Ser235Ala= unphosphorylated
mutant at Ser235; Ser235Asp= phosphomimic at Ser235.Values represent mean±SEM % of GFP-tau
expressing cells exhibiting fibrils. * denotes p<0.001 tukey’s post-hoc test after one way
ANOVA (p<0.001, F=70.537).
Group
WT Thr175
Thr175Ala
Thr175Asp

WT Ser235
26±1
28±2
54±2 *

Ser235Ala
31±1
30±1
53±1 *

Ser235Asp
27±1
28±2
54±2 *
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2.4.8. Tau fibrils persist after nocodazole exposure
After 1 hour exposure to nocodazole, live cell confocal imaging showed that GFP-tau protein
fibril structures were still present in cells transfected with both wild type GFP-tau protein and
Thr175Asp tau protein (Supplemental figure 2.3). This effect was observed in co-transfected cells
even when β-tubulin structures were lost and there was a lack of co-localization with tau protein
fibrils (Supplemental figure 2.4).
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Supplemental figure 2.3: Thr175Asp induced tau fibrils persist after 1 hour nocodazole
treatment. Cells were treated with 500 nM nocodazole for 1 hour prior to live cell confocal
imaging. WT= wild type tau, Thr175Asp= phosphomimic. Images shown are live cells transfected
with tau constructs. This experiment was performed once as a proof of concept. Images taken at
63x magnification.
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Supplemental figure 2.4: β-tubulin co-localization with tau protein is lost in nocodazole treated
cells. Untreated= double-transfected cells without nocodazole. 500 nM nocodazole= cells treated
with 500 nM nocodazole for 1 hr. GFP-Thr175Asp= Tau protein phosphomimic. pmCherry βtubulin= β-tubulin. Overlay= both tau and tubulin channels. Images shown are live cells
transfected with both tau and β-tubulin constructs. This experiment was performed once as a
proof of concept. Images taken at 63x magnification.
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2.4.9. Tau fibrils are not composed of β-tubulin
Co-localization of β-tubulin and tau protein was observed in cellular processes extending from
cell bodies. This was in stark contrast to the fibrils within the soma of the cell, which were
visibly composed of tau protein, but lacked β-tubulin in their composition (Figure 2.8). This
effect was especially clear when nocodazole treated cells showed the persistence of tau fibrils,
but not the extending processes consisting of both proteins (Supplemental figure 2.4).
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Figure 2.8: β-tubulin does not co-localize with tau protein in fibrils. Representative confocal
micrograph depicting tau protein fibril in cell body (arrowhead) lacking tubulin co-localization.
Co-localization occurs in the processes extending out from the cell (arrow). GFP-Thr175Asp=
Tau protein phosphomimic. pmCherry β-tubulin= β-tubulin. Overlay= both tau protein and
tubulin channels. Images shown are live cells transfected with both tau protein and β-tubulin
constructs. This experiment was performed once as a proof of concept. Images taken at 63x
magnification.
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2.5. Discussion:
We have demonstrated that phosphorylation of Thr175 induces pathological fibril formation by
inducing GSK3β activation, which in turn leads to unprimed Thr231 phosphorylation. The latter
step is both necessary and sufficient for the formation of pathological fibrils. Inhibition of this
event using any of a panel of GSK3β inhibitors resulted in reduced fibril formation, and reduced
cell death. To address the inability of these inhibitors to differentiate between GSK3α and
GSK3β, we used shRNA studies to confirm that GSK3β knockdown was able to prevent fibril
formation.
The role of Thr231 in mediating a conformational change in tau protein has been
previously described (Lin et al., 2007) and shown to have functional implications on tau
protein’s microtubule binding ability. Of note is its proximity to a bend in what has been
proposed as tau protein’s soluble global hairpin structure (Jeganathan et al., 2006). In this
structure, the N-terminus of tau protein folds over the C-terminus, effectively sheltering it from
further modification and interaction with other proteins. It is possible that phosphorylation at this
site opens up the hairpin, exposing normally sheltered sections of tau protein, conferring the
ability to self-interact, effectively seeding insoluble aggregates with itself beginning with
dimerization through cross linking of β pleated sheets located within the microtubule binding
domains which are normally sheltered by the C- and N-termini (von Bergen M. et al., 2000).
Because GSK3β activity is enhanced by tau protein priming where an amino acid at the
n+4 site has already been phosphorylated and because Ser235 is commonly found to be
phosphorylated in conjunction with Thr231 (Cho and Johnson, 2004b), it was expected that Ser235
phosphorylation would enhance the observed pathology. However, we observed no impact of
Ser235 phosphorylation on the extent of tau protein fibril formation, suggesting that GSK3β acts
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on Thr231 in the absence of priming in response to pThr175. This is not completely unexpected as
GSK3β is known to phosphorylate tau protein through unprimed mechanisms as well (Cho and
Johnson, 2003) and activated GSK3β is known to be capable of phosphorylating substrates
through both primed as well as unprimed mechanisms (Doble and Woodgett, 2003). That GSK3β
does not depend on any other kinases to phosphorylate Thr231 is consistent with the finding that
other kinases known to phosphorylate tau protein do not show increased activity in the ALSci
brain (Yang et al., 2008).
The increased GSK3β activation induced tau protein pathology is consistent with
previous reports of GSK3β overexpression-induced neurodegeneration in transgenic mice (Lucas
et al., 2001). Of specific importance to this study, GSK3β activity is also associated with
phosphorylation at Thr231 (Cho and Johnson, 2004b; Sato et al., 2002; Sun and Gamblin, 2009)
in cell culture models. It has also been suggested that early, but not late administration of GSK3β
inhibitors such as LiCl may be able to prevent tauopathy (Hernandez et al., 2013), as done in this
study. Further investigations using this model can be used to assess the efficacy to abolish fibrils
after they have formed.
GSK3β has been heavily implicated as a kinase responsible for tau protein
phosphorylation, and its expression profile in the central nervous system through development
has been shown to closely follow that of tau protein phosphorylation status (Takahashi et al.,
1994). Although closely related, GSK3β and GSK3α have differences in substrate specificity
(Wang et al., 1994). Although there is evidence for tau protein phosphorylation by GSK3α
(Maurin et al., 2013), we have established that in our model there is no role for GSK3α in the
pathological phosphorylation of tau protein downstream of Thr175 phosphorylation. This is in
keeping with previous reports of the modulation of GSK3α and GSK3β activity. While GSK3β
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can be highly upregulated, with increases in expression and activity, GSK3α is relatively
consistently expressed across the lifespan (Takahashi et al., 1994) and therefore may not be tied
as closely to the disease state. In fact, GSK3β has been shown to follow a level of expression
proportional to the level of tau protein phosphorylation in normal development, as well as
increased expression in the diseased state when tau protein phosphorylation is increased (Pei et
al., 1997; Yang et al., 2008).
In this study, only the 2N4R isoform of tau protein was assessed. Of note, it has been
shown that differential phosphorylation patterns have can have different, or even opposite effects
on different tau protein isoforms with regards to aggregation propensity. This phenomenon has
been suggested to explain differential isoform expression in insoluble aggregates in different
tauopathies (Combs et al., 2011). One example of this differential isoform expression is that the
triplet isoform motif (1N4R, 1N3R, and 0N3R) in the western blot of the sarkosyl insoluble
fraction in brain tissue from Alzheimer’s disease (Buee et al., 2000; Strong et al., 2006). This is
in stark contrast with the inclusion of all 6 tau protein isoforms in the insoluble fraction from
ALSci brains (Strong et al., 2006). The expression of all 6 isoforms in ALSci insoluble tau
protein is consistent with the observation that Thr175Asp tau protein induced aggregation in cells
transfected with all 6 tau protein isoforms equally (Gohar et al., 2009). Therefore, the analysis of
only the longest tau protein isoform in this study may be justified, and these results extended to
the other 5 isoforms found in the human brain, although further studies would have to confirm
this.
The finding that Thr231 phosphorylation is necessary and sufficient for the induction of
fibril formation after Thr175 phosphorylation does not rule out the possibility that other sites are
also being phosphorylated downstream, or that this may be part of a series of sites that may all be
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critically phosphorylated and work synergistically for this process to occur, as suggested by
others (Alonso et al., 2010; Sengupta et al., 1998; Sun and Gamblin, 2009). However, it does
imply that without this site, the others are not capable of inducing fibril formation in this model.
In order to further characterize the fibrils observed in these studies, β-tubulin colocalization studies and nocodazole studies were conducted to determine if these observations
were a result of tubulin bundling, a commonly described artifact of tau protein overexpression
(Liu et al., 2012). The persistence of fibrils in the presence of nocodazole (a tubulin polymer
destabilizing agent), paired with the lack of co-localization of tubulin with tau protein in these
structures suggests that this is an independent phenomenon from tubulin bundling, and that it is
in fact a result of pathological tau protein modification in these experiments.

2.6. Conclusions:
These findings represent the first time a cascade-like sequence of phosphorylation events
underpinning the induction of pathological tau protein aggregates in ALSci has been described.
The focus of these studies was on the downstream effects of Thr175 phosphorylation. How this
site is phosphorylated will be the subject of future investigations, and sequence analysis searches
using the kinase phosphorylation prediction tool KinasePhos has suggested that likely candidates
are MAPK and cdc2. Our studies also suggest a potential therapeutic avenue through the
inhibition of GSK3β activation. Further studies using in vivo models of Thr175Asp expression are
currently in progress.
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3.1 Abstract:
Microtubule associated protein tau (tau protein) deposition is associated with a spectrum of
neurodegenerative diseases collectively termed tauopathies. We have previously shown that
amyotrophic lateral sclerosis (ALS) with cognitive impairment (ALSci) is associated with tau
protein phosphorylation at Thr175 and that this leads to activation of GSK3β which then induces
phosphorylation of tau protein at Thr231. This latter step leads to dissociation of tau protein from
microtubules and pathological tau protein fibril formation. To determine the extent to which this
pathway is unique to ALS, we have investigated the expression of pThr175 tau protein and
pThr231 tau protein across a range of frontotemporal degenerations. Representative sections from
the superior frontal cortex, anterior cingulate cortex (ACC), amygdala, hippocampal formation,
basal ganglia, and substantia nigra were selected from neuropathologically confirmed cases of
Alzheimer’s disease (AD; n=3), vascular dementia (n=2), frontotemporal lobar degeneration
(FTLD; n=4), ALS (n=5), ALSci (n=6), Parkinson’s disease (PD; n=5), corticobasal
degeneration (CBD; n=2), diffuse Lewy body dementia (DLBD; n=2), mixed DLBD (n=3),
multisystem atrophy (MSA; n=6) and Pick’s disease (n=1) and three neuropathologically-normal
control groups aged 50-60 (n=6), 60-70 (n=6) and 70-80 (n=8). Sections were examined using a
panel of phospho-tau protein antibodies (pSer208,210, pThr217, pThr175, pThr231, pSer202 and T22
(oligomeric tau)). Across diseases, phospho-tau load was most prominent in layers II/III of the
entorhinal cortex, amygdala and hippocampus. This is in contrast to the preferential deposition of
phospho-tau protein in the ACC and frontal cortex in ALSci. Controls showed pThr175 tau
protein expression only in the 7th decade of life and only in the presence of tau protein pathology
and tau protein oligomers. With the exception of DLBD, we observed pThr175 co-localizing with
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pThr231 in the same cell populations as T22 positivity. This suggests that this pathway may be a
common mechanism of toxicity across the tauopathies.
3.2 Introduction:
Microtubule associated protein tau (tau protein) is a cytoskeletal stabilizing protein involved in
microtubule maintenance, fast axonal transport, and other physiological functions in neurons.
Tau protein deposition is a characteristic of many neurodegenerative diseases that are
collectively referred to as tauopathies. It has been shown that pathological species of tau protein
are abnormally phosphorylated at multiple residues (Goedert et al., 1994) and that this is linked
to a decrease in tau protein’s ability to bind to and stabilize microtubules (Bramblett et al., 1993;
Lin et al., 2007) with accompanying cytotoxicity (Bandyopadhyay et al., 2007). While the
isoform composition of insoluble tau protein deposits and the structural formation of the protein
aggregates differs, there are several phosphorylation sites that are thought to be universally
important in induction of a tauopathy.
One potentially important phosphorylation site that has gone relatively unstudied is
threonine175 (Thr175). First identified in Alzheimer’s disease as a phosphoepitope (Hanger et al.,
1998), it was then determined that this site could be phosphorylated by multiple kinases linked to
tau protein pathology including GSK3β, JNK, ERK2, and p38 (Reynolds et al., 2000). pThr175
tau protein was then identified in amyotrophic lateral sclerosis with cognitive impairment
(ALSci) (Strong et al., 2009) and characterized in further detail in the context of this disease
(Behrouzi et al., 2016; Strong et al., 2006; Yang et al., 2003; Yang et al., 2008; Yang and Strong,
2012). Importantly, pThr175 tau protein has been shown to induce tau protein fibril formation and
cell death in vitro (Gohar et al., 2009). Unlike other widely accepted pathological
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phosphorylation sites on tau protein, such as pThr231 and pSer202, pThr175 has not been observed
in the fetal brain where tau protein is hyperphosphorylated (Brion et al., 1993; Kenessey and
Yen, 1993; Watanabe et al., 1993), suggesting that this site may be uniquely associated with
pathological processes. pThr175 tau protein has been shown to induce GSK3β activation in cell
culture, and may therefore act as a destabilizing event resulting in enhanced phosphorylation of
tau protein at other residues, resulting in dissociation from microtubules and neuronal toxicity
(Moszczynski et al., 2015). In order to understand the extent to which this pathway of pThr175
mediated tau protein aggregate formation underlies a broad range of tauopathies, we have used a
panel of phospho-specific antibodies to characterize tau protein pathology with specific interest
in the expression of pThr175 tau protein across a broad range of tauopathies.
3.3 Methods:
Diseases studied included Alzheimer’s (AD; 3 cases), vascular dementia (VD; 2 cases), ALS (5
cases), ALSci (6 cases), dementia with Lewy Bodies (DLBD; 2 cases), DLBD with mixed
pathology (mDLBD; 3 cases including 2 with DLBD/VD and 1 with DLBD/AD)),
frontotemporal lobar dementia (FTLD-TDP; 3 cases including one with a pathological C9orf72
hexanucleotide expansion with Type B pathology; a single case with Type A pathology and a
single case with Type B pathology, FTLD-Tau; 1 case with familial history and no known
mutations) (Mackenzie et al., 2011), multiple system atrophy (MSA; 6 cases), Parkinson’s
disease (PD; 5 cases), Pick’s disease (1 case), and corticobasal degeneration (CBD; 2 cases)
(Table 3.1). The institutional research ethics board approved the protocol and consent was given
for use of all tissue used in this study. All neuropathological diagnosis were performed by a
neuropathologist (RH, LCA). For all comparisons, we grouped the staining according to ALS
(n=5), ALSci (n=6), or other tauopathy (n=22).
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To assess the extent of pThr175 tau protein, pThr231 tau protein and tau protein oligomer
pathological inclusions as a function of ageing, three groups of controls were studied,
encompassing the 6th (n=6), 7th (n=6), and 8th (n=8) decades of life (Table 3.1). Hippocampal
sections from each group were stained for pThr175 tau protein, pThr231 tau protein and oligomeric
tau protein (T22). These cases have been previously characterized in a study examining agedependant tau protein deposition in the frontal and entorhinal cortices and were shown to be free
of neurodegenerative disease (Yang et al., 2005).
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Table 3.1: Case demographics
Neuropathological
diagnosis
AD
VD
ALS
ALSci
DLBD
mDLDB
FTLD
MSA
PD
Pick’s
CBD
Control 1
Control 2
Control 3

Age
72±8
78±11
56±16
64±11
68±1
83±6
64±9
69±12
77±2
70±2
71±1
55±2
64±2
75±3

n
(n Male)
3 (2)
2 (1)
5 (4)
6 (5)
2 (2)
3 (3)
4 (1)
6 (3)
5 (4)
2 (2)
2 (1)
4 (3)
4 (3)
4 (2)

AD: Alzheimer’s disease, VD: Vascular dementia, ALS: amyotrophic lateral sclerosis, ALSci:
ALS with cognitive impairment, DLBD: diffuse Lewy body dementia, mDLBD: Lewy body
dementia with mixed pathology, FTLD: frontotemporal lobar dementia, MSA: multiple system
atrophy, PD: Parkinson’s disease, Pick’s: Pick’s disease, CBD: corticobasal degeneration.
Control 1: 6th decade control group, Control 2: 7th decade control group, Control 3: 8th decade
control group.
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Five to six micrometer paraffin-embedded sections from the superior frontal gyrus,

anterior cingulate (ACC), hippocampus, entorhinal cortex, dentate gyrus, amygdala, basal
ganglia and substantia nigra were used for all immunohistochemical analyses.
Cases were stained by haematoxylin and eosin (H&E) and Gallyas silver stain for routine
histological analysis and overall pathology characterization. Immunohistochemistry was
conducted using a series of antibodies (Table 3.2) previously characterized in ALSci (Yang and
Strong, 2012), consisting of PHF tau protein (AT8; Thermo Fischer IL, Canada), pThr175 tau
protein, pSer208,210 tau protein, pThr217 tau protein (antibodies generated and designed in house
(Yang and Strong, 2012), pThr175 commercially available through 21st Century, MA, USA).
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Table 3.2: Antibodies used
Antibody
Tau pThr175
Tau pThr217
Tau pSer208, 210
PHF (AT8)
Tau pThr231
T22
Alexa Fluor
488

Clone
Rabbit,
polyclonal
Rabbit,
polyclonal
Rabbit,
polyclonal
Mouse,
monoclonal
Rabbit,
polyclonal
Rabbit,
polyclonal
Goat antirabbit

Titer
1:1000

Antigen retrieval Epitope
1
pThr175

Company
21st Century

1:1000

1

pThr217

21st Century

1:1000

1

pSer208, 210

21st Century

2.5 ug/ml

No

pSer202

1:1000

2

pThr231

1:500

2

1:200

2

Tau
oligomer
Secondary

Thermo
Fischer
Thermo
Fischer
EMD
Millipore
Life
Technologies

1) Boil in 10mM sodium citrate, 0.05% Tween 20 pH 6.0 for 2 min.
2) Pressure cooker (2100 Retriever; Aptum Biologics, UK) 10mM sodium citrate, 0.05% Tween
20 pH 6.0 for 15 min.
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Antigen retrieval was conducted as necessary (Table 3.2). Endogenous peroxidase was
quenched with 3% hydrogen peroxide (BDH Chemicals, VWR, On, Canada). Primary antibody
incubation was performed at 4˚C overnight in blocking buffer (5% BSA, 0.3% Triton-X 100 in 1
X PBS). After washing, secondary antibody (1:200 biotinylated IgG) incubation was performed
for 1 hour at room temperature in blocking buffer. Antigen:antibody complex was visualized
with either horseradish peroxidase or alkaline phosphatase according to the manufacturer’s
instructions (Vectastain ABC kit, Vector Laboratories CA, USA), followed by substrate
development with either DAB plus NiCl2 or AP substrate kit III (Vector Laboratories).
Counterstaining was performed using haematoxylin or nuclear fast red. The extent of pathology
was described topographically and semi-quantitatively as previously reported (Yang and Strong,
2012). Representative images were captured with a 20x lens under light microscopy (Olympus
BX45) and subsequently used for semi-quantitative analysis. The semi-quantitative scale was
manually applied for each type of pathology by an evaluator blinded to the underlying diagnosis
(WY) (neuronal, neuritic, or glial) separately as follows: ‘-’ = none; ‘±’ = less than 5 inclusions;
‘+’ = less than 10 inclusions; ‘++’ = more than 20 inclusions with scattered distribution; ‘+++’ =
more than 20 inclusions but with locally dense distribution; ‘++++’ = more than 20 inclusions
with a diffuse distribution. Additionally, the case positive ratio was defined for each antibody
used and brain region investigated as the number of cases showing any pathology (± or more)
compared to the total number of cases stained.
3.3.1 Oligomeric tau and pThr231 staining:
Rabbit anti T22 (EMD Millipore CA, USA) and rabbit anti tau pThr231 (Thermo Fischer) were
used to probe tau protein inclusions for the presence of oligomeric tau protein (T22) and for
phosphorylation at Thr231. Tau protein oligomeric species are currently hypothesized to be more
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toxic to neurons than the fibrillar inclusions themselves (Ward et al., 2012), and pThr231 is
thought to be a key site in the regulation of tau protein folding and ability to interact with
microtubules (Lin et al., 2007; Schwalbe et al., 2015). Double labeling was performed on
hippocampus from one case each from AD, ALSci, FTD, MSA, DLDB, and mDLDB. Tau
protein was probed for pThr175 using rabbit primary antibody (1:1000) overnight at 4˚C and
Alexa Fluor goat anti-rabbit 488nm secondary (1:200, Thermo Fischer) for 1 hour at room
temperature. Rabbit anti tau pThr231 antibody was then labeled using a Zenon primary antibody
labeling kit with Alexa Fluor 555nm dye (Thermo Fisher) and probed for 1 hour at room
temperature. Slides were stored overnight at 4˚C and visualized within 24 hours of labeling by
confocal imaging on a Zeiss LSM 510 Meta NLO multiphoton confocal microscope.
3.4 Results:
3.4.1 Tau antibody staining:
3.4.1.1 Neuronal tau:
ALS: Consistent with our earlier reports, we observed tau protein pathology in multiple brain
regions in ALS, although to a lesser degree than either ALSci or the remaining tauopathies.
Neuronal tau protein inclusions were most consistently observed in the entorhinal cortex,
hippocampus, and amygdala. All antibodies were immunoreactive with neuronal tau protein
inclusions in multiple brain regions (Table 3.3). Frontal and anterior cingulate pathology was
limited in both load and case-positive incidence. In all regions studied, inclusions took the form
of punctate cytosolic inclusions or tangles (Figure 3.1). Deposition was mainly restricted to the
superficial cortical layers in the entorhinal cortex but restricted to deeper layers in the ACC and
superior frontal cortex when present.
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Table 3.3: ALS pathology
Stain
Frontal
Neuronal
pThr175
± (1/5)

Cingulate Hippocampus Dentate

Entorhinal Amygdala BG

SN

± (1/4)

± (1/5)

± (1/5)

± (2/4)

++ (1/2)

-(0/5)

PHF

± (1/5)

± (1/4)

± (3/5)

± (2/5)

±-++ (5/5)

+++ (1/1)

pSer208,210

- (0/5)

++ (1/4)

± (1/5)

- (0/4)

± (1/2)

++ (1/2)

pThr217

+ (1/5)

± (1/4)

± (1/5)

- (0/4)

±-++ (3/4)

++ (1/2)

±
(1/4)
(0/5)
±
(1/4)

(0/5)
±
(3/4)
(0/5)
±
(2/5)

Glial
pThr175

++ (1/5) - (0/5)

- (0/4)

- (0/5)

- (0/2)

± (1/2)

PHF

± (1/5)

± (1/4)

± (1/5)

- (0/5)

+ (1/5)

++ (1/1)

pSer208,210

- (0/5)

- (0/4)

- (0/5)

- (0/4)

± (1/2)

++ (1/2)

pThr217

+++
(1/5)

+++ (1/4)

+ (1/5)

- (0/4)

+++ (1/4)

++ (1/2)

+
(1/5)
(0/4)
++
(2/5)
++
(2/4)

(0/5)
(0/4)
(0/5)
(0/5)

Neuritic
pThr175

- (0/5)

- (0/5)

± (1/4)

- (0/4)

± (2/5)

++ (1/2)

PHF

± (2/5)

± (1/4)

± (3/5)

- (0/5)

+-++ (5/5)

++ (1/1)

pSer208,210

- (0/5)

± (1/4)

- (0/5)

- (0/4)

± (1/2)

- (0/2)

pThr217

± (1/5)

- (0/4)

± (1/5)

- (0/4)

±-++ (3/4)

± (1/2)

(0/5)
±
(1/4)
+
(1/5)
+-++
(2/4)

±
(1/5)
±
(3/4)
+
(2/5)
+-++
(3/5)
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Figure 3.1: Representative pThr175 tau pathology in each neurodegenerative disease. A) AD
Frontal cortex, B) ALS amygdala, C) ALSci amygdala, D) ALSci hippocampus neuritic plaque,
E) CBD entorhinal cortex, F) DLBD amygdala, G) mDLBD entorhinal cortex, H) FTLD
putamen, I) MSA amygdala, J) PD amygdala, K) Pick’s entorhinal cortex, L) VD anterior
cingulate cortex. Nuclear fast red or hematoxylin counterstain used. Original images taken at
100x. Scale bar= 20 µm.

119
ALSci: Tau protein pathology (Figure 3.1, supplemental figures 3.1, 3.2, 3.3) in the form of
tangles, skein-like inclusions, and punctate staining was observed to a greater extent in ALSci
than ALS, especially in the ACC and superior frontal cortex. The load of pathology was
increased in amount and distribution and the case positive ratio was higher than ALS in all brain
regions studied (Table 3.4). As observed in ALS, pathological tau protein neuronal inclusions
were observed predominantly in the superficial layers of the entorhinal cortex and within deeper
cortical layers in the ACC and superior frontal cortex. However superficial layer involvement
was noted in both the ACC and superior frontal cortex in ALSci, indicating a greater distribution
across cortical layers in ACC and frontal cortex, further differentiating ALSci from ALS. Of
note, Thr175 tau and PHF tau identified pathology to different extents in different brain regions.
Notably, pThr175 tau and pThr217 tau identified a higher case positive ratio than PHF in the
superior frontal cortex.
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Supplemental Figure 3.1: Representative PHF tau pathology in each neurodegenerative disease.
A) AD hippocampus, B) ALS amygdala, C) ALSci superior frontal cortex, D) ALSci superior
frontal cortex astrocytic tau E) CBD entorhinal cortex, F) DLBD amygdala, G) mDLBD
entorhinal cortex, H) FTLD entorhinal cortex, I) MSA amygdala, J) PD entorhinal cortex, K)
Pick’s amygdala, L) VD anterior cingulate cortex. Nuclear fast red or hematoxylin counterstain
used. Original images taken at 100x. Scale bar= 20 µm.

121

Supplemental Figure 3.2: Representative pSer208,210 tau pathology in each neurodegenerative
disease. A) AD substantia nigra, B) ALS amygdala, C) ALSci entorhinal cortax, D) ALSci ACC
neuritic plaque, E) CBD entorhinal cortex, F) DLBD entorhinal cortex, G) mDLBD amygdala,
H) FTLD superior frontal cortex, I) MSA amygdala, J) PD entorhinal cortex, K) Pick’s
entorhinal cortex, L) VD superior frontal cortex. Nuclear fast red or hematoxylin counterstain
used. Original images taken at 100x. Scale bar= 20 µm.
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Supplemental Figure 3.3: Representative pThr217 tau pathology in each neurodegenerative
disease. A) AD anterior cingulate cortex, B) ALS entorhinal cortex, C) ALSci hippocampus, D)
ALSci superior frontal cortex astrocytic plaque, E) CBD entorhinal cortex, F) DLBD
hippocampus, G) mDLBD amygdala, H) FTLD amygdala, I) MSA amygdala, J) PD entorhinal
cortex, K) Pick’s entorhinal cortex, L) VD entorhinal cortex. Nuclear fast red or hematoxylin
counterstain used. Original images taken at 100x. Scale bar= 20 µm.
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Table 3.4: ALSci pathology
Stain
Neuronal
pThr175
PHF
pSer208,210
pThr217
Glial
pThr175
PHF
pSer208,210
pThr

217

Neuritic
pThr175
PHF
pSer208,210
pThr217

Frontal

Cingulate Hippocampus Dentate

Entorhinal Amygdala BG

±
(4/5)
+
(2/4)
±
(2/5)
±
(5/5)

±
(2/5)
±
(3/3)
±
(3/5)
±-+
(3/5)

±
(5/5)
±-+
(4/4)
±-++
(4/5)
±-++
(5/5)

+
( 1/5)
±-+
(2/4)
±
(1/5)
±-++
(3/5)

+
(4/4)
±-++
(4/4)
±-++
(3/4)
±-++
(5/5)

+
(1/1)
±-++ (2/2)

±-++
(2/5)
±-++
(4/4)
++
(4/5)
++-+++
(5/5)

±-++
(2/5)
±-++
(2/3)
++
(2/5)
+++
(2/5)

(0/5)
(0/4)
(0/5)
++
(2/5)

(0/5)
(0/4)
(0/5)
(0/5)

±
(1/4)
(0/4)
±
(1/4)
±
(1/5)

(0/1)
+
(1/2)

±-+
(3/5)
±-+
(2/4)
±-+
(2/5)
±-++
(5/5)

±-+
(2/5)
±-+
(3/3)
±
(3/5)
±-++
(2/5)

±-+
(3/5)
±-+
(3/4)
±
(4/5)
±-+
(4/5)

±-++
(4/5)
±
(3/4)
±
(2/5)
++
(2/5)

±-++
(4/4)
±-++
(4/4)
±-++
(4/5)
+-+++
(5/5)

+
(1/1)
+
(1/1)

- (0/1)
(0/1)
(0/1)
±-++ (2/2)
+
(1/1)
+
(1/1)

SN

(0/5)
(0/5)
(0/5)
(0/5)

(0/3)
±
(2/2)
(0/3)
±-+
(2/2)

±-+
(2/5)
±
(3/5)
±-+
(4/5)
+-++
(5/5)

(0/3)
(0/2)
±
(1/3)
(0/2)

±
(4/5)
±
(2/5)
±
(1/5)
±
(3/5)

±
(1/3)
±
(2/2)
±
(1/3)
±-++
(2/2)

124
Tauopathies: Within the tauopathies and consistent with the literature, we observed tau protein
neuronal pathology across multiple regions (Table 3.5). pThr175 tau protein was present in all
disease states where tau protein pathology was prominent. In Alzheimer’s disease (AD), all tau
antibodies showed robust neuronal pathology as neurofibrillary tangles and punctate cytoplasmic
deposition in all brain regions studied. Across all cortical regions studied, neuronal pathology
was present across all cortical layers but was most prominent in deeper layers (IV-VI). Amongst
the tauopathies, the most prominent pThr175 tau protein immunostaining was observed in AD.
This included more prominent expression of pThr175 tau protein than observed in ALSci.
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Table 3.5: Tauopathies pathology
Stain
Frontal
Neuronal
pThr175
±-++
(10/27)
PHF
±-++++
(13/27)
pSer208,210
±-+++
(12/27)
pThr217
±-+++
(15/27)
Glial
pThr175
±-+++
(6/27)
PHF
±-++++
(8/27)
pSer208,210
+-++
(2/28)
pThr217
±-+++
(7/26)
Neuritic
pThr175
±-++
(10/27)
PHF
±-++++
(14/27)

Cingulate

Hippocampus

Dentate

Entorhinal

Amygdala

±-++
(10/25)
±-+++
(16/24)
±-+++
(12/25)
±-+++
(14/24)

±-+++
(20/26)
±-++++
(28/29)
±-+++
(25/29)
±-+++
(23/29)

±-++
(8/28)
±-++++
(18/29)
±-++
(10/28)
±-++
(12/29)

±-+++
(21/28)
±-++++
(28/29)
±-+++
(23/28)
±-+++
(24/29)

±-+++
(19/23)
±-++++
(21/21)
±-+++
(23/28)
±-+++
(19/21)

±-+
(10/29)
±-++
(13/28)
±-++
(9/28)
±-+
(6/27)

±
(3/23)
±-++
(7/23)
±-+
(5/23)
±
(7/23)

±-++
(6/25)
±-+++
(7/24)
±-+++
(3/25)
±-+++
(7/24)

±-+
(4/29)
±-+
(5/29)
++
(3/29)
±-+++
(3/29)

± (1/28)

± (2/28)

±-++ (3/24)

(0/29)
++
(1/28)
(0/29)

±-+++
(8/29)
±-++
(3/27)
++-+++
(2/29)

±-+++
(12/21)
±-+++
(3/22)
±-+++
(4/21)

±-++
(16/29)
±-++++
(11/28)
±-++
(10/28)
±-+++
(15/27)

±
(3/23)
(0/23)
(0/23)
(0/23)

±-++
(9/25)
±-++++
(15/24)

±-+++
(20/28)
±-++++
(24/29)

±-++
(6/28)
±-+
(11/29)

±-+++
(21/28)
±-++++
(28/29)

±-+++
(16/24)
±-++++
(17/21)

±-+
(12/28)
±-+++
(16/28)

pSer208,210

±-+++
(9/25)
±-++++
(14/25)

±-+
(6/28)
±-+
(11/29)

±-+++
(22/28)
±-+++
(24/29)

±-+++
(18/23)
±-++++
(18/23)

±-++
(11/28)
±-+++
(11/27)

±-++
(10/23)
±++++
(13/23)
±-++
(11/23)
±-++
(11/23)

pThr217

±-++++
(18/27)
±-++++
(15/27)

±-++
(18/29)
±-++ (21/29)

BG

SN
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As in AD, VD exhibited tau protein deposition as tangles and punctate cytoplasmic
inclusions in all brain regions studied. This followed the same trend as AD with pathology being
most prominent in deep cortical layers. In CBD, balloon neurons were observed and tau
pathology was prominent in all brain regions as punctate inclusions and neurofibrillary tangles.
Notably, PHF tau staining was more intense than pThr175 tau in all regions, both in case positive
ratio and in semiquantitative pathological load. In both DLBD and mDLBD, a similar degree of
tau pathology was observed in the form of cytoplasmic punctate deposition and neurofibrillary
tangles. Pathology within the dentate gyrus, basal ganglia and substantia nigra was present to a
much greater extent in mDLBD than DLBD. In FTLD, tau pathology was observed as punctate
inclusions and tangles in all brain regions investigated. In general, pThr175 tau protein was less
prominent than PHF tau protein, except in the frontal and cingulate cortex where it was more
prominent on a case positive basis and the pathological load observed. In MSA, tau protein
pathology in the form of tangles and punctate inclusions was present in all brain regions studied
although frontal and ACC pathology was sparse. In Parkinson’s disease, tau protein pathology
was observed in all brain regions except the substantia nigra. Pathological tau protein expression
was equivalent across all antibodies. In Pick’s disease, all brain regions investigated exhibited
tau protein pathology in the form of tangles, punctate inclusions and Pick bodies. Notably, PHF
tau protein pathology was greater than the other antibodies including pThr175 tau.
3.4.1.2 Neuritic tau
ALS: No neuritic plaques were observed in ALS. Neuritic pathology in the form of dystrophic
neurites was observed to a limited extent in all brain regions studied and with a pattern of
distribution mimicking that described above for neuronal pathology. Basal ganglia neuritic
pathology was observed to a larger extent in the putamen than the globus pallidus by all tau
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protein antibodies but pThr175 tau. Neuritic tau protein pathology within the substantia nigra was
immunoreactive against all antibodies employed in the analysis.
ALSci: Neuritic tau protein pathology was observed predominantly as dystrophic neurites
assuming a short curvilinear morphology. This was consistently observed in both cortical and
subcortical tissues. Contrary to the superficial localization of frontal and ACC neuronal
pathology, frontal neuritic pathology was observed mainly in deep layers as short curved
neurites. Entorhinal neuritic pathology was observed mainly in the superficial layers in proximity
to tau protein inclusion bearing neurons. Neuritic plaques were observed in the entorhinal cortex
by all antibodies with the exception of the pThr175 tau antibody. Neuritic plaques within the
amygdala were observed by PHF tau antibody labeling only. Neuritic plaques and tau protein
positive neurites were observed in the hippocampus and were immunoreactive to all antibodies.
Coiled bodies were observed throughout the basal ganglia.
Tauopathies: Neuritic pathology was prominent across all the tauopathies and typically mirrored
the presence of tau protein immunoreactive neuronal pathology. Neuritic plaques were observed
in AD as small atypical plaques and typical plaques in deeper layers (IV/V) more frequently than
in superficial layers (II/III). No antibody identified neuritic plaques in basal ganglia or substantia
nigra. Like neuronal tau ptotein, all cortical neuritic pathology was most prominent in deeper
layers (IV-VI). All antibodies recognized neuritic pathology, most commonly in deeper cortical
layers near tau protein positive neurons as short and curved, or long, straight neurites. Neuritic
pathology was also observed to a lesser extent in white matter in frontal, ACC, and entorhinal
cortices.
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Similar to AD, neuritic pathology in VD was present as tau protein positive neurites and
neuritic plaques in all brain regions studied except the substantia nigra. Also similar to AD,
neuritic pathology followed a tendency to be most prominent in regions of prominent neuronal
tau protein pathology and in particular in the deeper cortical layers. In CBD, neuritic plaques
were only observed in the ACC and substantia nigra, and then, only using the PHF tau antibody.
Neuritic pathology, as dystrophic neurites, was present in all brain regions investigated and
mirrored the distribution of neuronal pathology. This was most evident in the entorhinal cortices
where dystrophic neurites were most evident in superficial cortical layers. In contrast, dystophic
neurites were most prominent in deep subcortical regions of the superior frontal cortex and ACC.
In DLBD, no frontal, ACC, dentate gyrus or basal ganglia neuritic pathology was
observed. All other regions studied were positive for neuritic tau protein pathology, but no
plaques were observed. Entorhinal neuritic pathology was most prominent in DLDB in layers
II/III. In mDLBD, neuritic plaques were observed in all regions except for the substantia nigra.
All regions studied exhibited neuritic pathology. In both FTLD and MSA, neuritic plaque
pathology was not frequent and usually observed by PHF tau only. pThr175 tau protein neuritic
pathology was not as prominent as that observed using other tau protein antibodies. However,
neuritic tau protein pathology was observed in all brain regions studied as with neuronal
pathology. In PD, neuritic plaques were not observed, but tau protein positive neurites were
observed in a similar distribution to neuronal pathology in all brain regions studied. In Pick’s
disease, neuritic pathology was identified mainly by PHF tau in all but the dentate gyrus.
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3.4.1.3 Glial tau
ALS: Glial tau protein pathology was observed in all brain regions except the dentate gyrus, and
substantia nigra (Table 3.3). Where present, glial pathology presented as astrocytic tangles and
astrocytic plaques as previously described(Yang and Strong, 2012). The distribution was rare and
followed that of neuronal and neuritic tau protein as described above and was similar in case
positive ratio, although higher in semiquantitative load than neuronal and neuritic pathology in a
single case.
ALSci: Glial pathology was present in ALSci (Figure 3.1, Supplemental Figures 3.1-3.3) to a
similar degree as in ALS, but was more frequent in terms of regional distribution, case positive
rate, and pathological load (Table 3.4). Frontal and ACC glial pathology was increased in both
case positive incidence and pathological load.
Tauopathies: In the tauopathies, the extent of glial pathology was highly dependant on the
underlying disease (Table 3.5). In AD, glial pathology was rare, and when present was usually
observed only in the amygdala and basal ganglia. No glial pathology was observed in VD.
Consistent with the literature, CBD contained astrocytic plaques throughout the grey and white
matter across multiple brain regions. Additional astrocytic staining and tau protein positive
microglia were observed. Glial pathology in CBD was identified to a far greater extent by PHF
than the pThr175 tau antibody. In DLBD, minimal glial pathology was observed in frontal cortex
and basal ganglia, and when present, only as punctate astrocytic inclusions. In contrast to the
limited glial pathology observed in DLBD, mDLBD showed much more frequent glial pathology
across multiple brain regions, pathology that was less evident with the pThr175 tau antibody. In
FTLD, glial pathology was observed in all brain regions except the dentate gyrus and substantia

130
nigra. Notable in this disease, pThr175 tau identified glial pathology to a greater extent than PHF
tau by both case positive incidence and increased load. In MSA, glial pathology was largely
absent, being present only in the entorhinal cortex, amygdala and basal ganglia by multiple
antibodies. Interestingly, the basal ganglia contained astrocytic inclusions in the putamen
identified by all antibodies whereas in the globus pallidus they were only identified by pThr175
tau. In Parkinson’s disease, glial pathology was present in all regions except the dentate gyrus
and substantia nigra. Notably, the PHF tau antibody identified astrocytic plaques in the frontal
cortex while tufted astrocytes were observed in the amygdala. In Pick’s disease, glial pathology
was observed in multiple brain regions using the PHF antibody mainly, although in the
entorhinal cortex pThr175 tau was also positive for glial pathology.
3.4.2 pThr231 tau and T22 staining:
We examined the presence of oligomeric tau protein (recognized by the T22 antibody) and
pathological tau protein phosphorylation at Thr231 using sections from the hippocampus of a
single case each of AD, ALSci, FTD, MSA, DLBD, and mDLB. Cases were selected on the
basis of the pathology described earlier. In each case, tau protein neuronal inclusions were
recognized by both antibodies (Figure 3.2, Figure 3.3). Only DLBD showed notably reduced T22
pathology which, when present, was in the dystrophic neurites (Figure 3.3). Glial pathology was
not observed with either antibody, regardless of diagnosis.
AD neuronal pathology was observed as fibrillar and punctate inclusions by pThr231 tau
antibody but only as fibrillar/ tangles with T22. Neuritic pathology in the form of short and long
torsional and dystrophic neurites was observed. pThr231 tau, but not T22, recognized plaques
consisting of dystrophic neurites.
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Similar to AD, ALSci neuronal pathology was observed by pThr231 tau and T22 as
fibrillar and punctate staining. However additional solitary cytoplasmic inclusions were observed
in neurons with the T22 antibody. Neuritic pathology was observed using both the pThr231 tau
and T22 antibodies. Neuritic plaques were identified by both the pThr231 tau and T22 antibodies.
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Figure 3.2: Representative hippocampal pThr231 tau pathology. A) AD, B) ALSci, C) DLBD, D)
mDLBD, E) FTLD, F) MSA. Counterstained with hematoxylin. Original images taken at 100x.
Scale bar= 20 µm.
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Figure 3.3: Representative hippocampal tau oligomer (T22) pathology. A) AD, B) ALSci, C)
DLBD, D) mDLBD E) FTLD F) MSA. Counterstained with hematoxylin. Original images taken
at 100x. Scale bar= 20 µm.
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FTLD pathology was distinct from AD and ALSci in that pThr231 tau protein neuronal
pathology was observed as a dense nuclear ring staining around abnormally folded nuclei, and
solitary cytosolic inclusions on homogenously stained cytosol. While T22 neuronal cytoplasmic
pathology was observed, neuritic pathology was observed as frequent short dystrophic neurites
by both antibodies. No neuritic plaques were observed.
MSA pathology resembled AD and ALSci. Neuronal pathology was observed as tangles
and punctate inclusions by both the pThr231 tau and T22 antibodies. In addition, pThr231 tau
antibody diffuse cytoplasmic immunostaining was observed. Neuritic pathology was observed by
both antibodies, although T22 immunoreactive neurites demonstrated a punctate staining pattern.
DLBD tau protein pathology was observed only faintly by pThr231 tau as punctate
cytosolic deposition. While neuritic pathology was observed using the pThr231 tau antibody, no
pathology was observed by T22 other than a few sporadic neurites. Conversely, mDLBD
pathology was observed by both pThr231 tau and T22. pThr231 tau protein pathology was
observed as tangles and punctate staining accompanied by dystrophic neurites and other neuritic
pathology. No neuritic plaques were observed. T22 pathology however was observed as punctate
cytosolic staining and dystrophic neurites.
Having confirmed that both T22 and pThr231 tau protein immunoreactive pathology was
present, although as described to varying degrees, we next sought to confirm whether pThr175 tau
protein and pThr231 tau protein co-localized using confocal imaging (Figure 3.4). Co-localization
within neuronal tau protein inclusions was observed between pThr175 tau protein and pThr231 tau
protein in each disease state except for DLBD. Co-localization was also observed in neuritic
plaques in AD. No pThr175 tau protein immunoreactivity was observed in the absence of pThr231.
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Figure 3.4: Co-localization of pThr175 and pThr231 tau in hippocampal neuronal inclusions. AD:
Alzheimer’s disease. ALSci: amyotrophic lateral sclerosis with cognitive impairment. FTLD:
frontotemporal lobar dementia. mDLBD: mixed diffuse dementia with Lewy bodies. MSA:
Multiple system atrophy. Co-localization stains were performed in one case per disease. Scale
bar represents 5 µm.
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3.4.3 Hippocampal pThr175, pThr231 and oligomeric tau deposition as a function of aging:
Consistent with our previous report, we observed an increase in tau protein immunoreactive
pathology beginning in the 7th decade of life (Yang et al., 2005). In contrast, no immunoreactive
inclusions were observed to either the pThr175 tau protein or oligomeric tau protein (T22
immunoreactivity) in the 6th decade (Figure 3.5). pThr231 tau protein immunoreactivity was
observed in each of the 6th, 7th and 8th decades within the hippocampus. In distinction to the
pathological tau protein deposition observed in both ALSci and the tauopathies, neuronal Thr231
tau protein immunoreactivity was diffuse and localized to otherwise healthy appearing neurons
and axonal processes. In the 7th decade, T22 immunoreactive neuronal cytoplasmic inclusions
were observed minimally and when present were within the same regions in which we observed
punctate pThr175 immunoreactivity. All but one case demonstrated pThr231 tau protein
immunoreactivity, and importantly this case was negative for all three tau epitopes. In all cases,
neuritic pathology was minimal or nonexistent, while neuronal positivity was mainly punctate
tau protein expression.
In the 8th decade, we observed a marked increase in pThr175 tau, pThr231 tau and T22
immunoreactivity. In this decade, each antibody revealed tau protein immunoreactive punctate
staining of neurons, neurofibrillary tangles, dystrophic neurites, and neuritic plaques. Across all
three decades, T22 pathology was present in all cases and in regions where pThr231 tau protein
and pThr175 tau protein was present, and was only positive in cases with prominent pThr175 tau
protein positive cells and pathology.
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Figure 3.5: Age dependent tau pathology increases in the hippocampus of controls and is
associated with pThr175 tau pathology in the 8th decade of life. Large images taken in the CA2
region of the hippocampus at 10x magnification, inset is same region at 40x magnification.
Images are representative of 4 cases per age group. Scale bar large image= 100 µm, inset= 50
µm.
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3.5 Discussion:
In undertaking these studies, we were specifically interested in determining whether the
pathogenic phospho-tau protein species recognized by antibodies against pThr175 tau protein and
pThr231 tau protein as well as oligomeric tau ptotein (T22) were expressed across a broad range
of tauopathies. We were also interested in determining whether these pathological tau
proteinspecies were co-localized in ALS and ALSci. It is known that the phosphorylation of tau
protein at Thr231 is of both physiological and pathological significance in mediating the
dissociation of tau protein from microtubules (Lin et al., 2007; Schwalbe et al., 2015; Sengupta
et al., 1998). Thr231 is phosphorylated by activated GSK3β physiologically and in pathological
states (Alonso et al., 2010; Cho and Johnson, 2004; Luna-Munoz et al., 2005; Sahara et al., 2008;
Sengupta et al., 1998). We have previously shown that pThr175 tau protein induces GSK3β
phosphorylation and that this in turn leads to Thr231 tau protein phosphorylation resulting in tau
protein fibril formation, and cell death in vitro (Moszczynski et al., 2015).
Although the number of cases studied here is limited, the intent was not to undertake a
detailed topographic analysis of tau protein deposition across all tauopathies, but rather to
determine whether the proposed pathway of pThr175 tau protein mediated induction of pThr231
tau protein with its attendant pathological tau fibril formation (as recognized by T22) was
evident. It is noteworthy therefore that we observed that in each tauopathy studied, pThr175 tau,
pThr231 tau and T22 immunoreactivity co-localized to the same inclusion-containing neuronal
populations. In each case, neuronal pThr175 tau protein co-localized with pThr231 tau protein.
This, paired with prior identification of pThr175 tau protein in AD brain tissue but not controls
(Hanger et al., 2007) and the lack of identified pThr175 in fetal tau protein (Kenessey and Yen,
1993; Watanabe et al., 1993) suggests that pThr175 is a key point in pathological tau protein
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metabolism, as it is not a physiologically utilized site involved in the regulation of tau protein
function during development or microtubule reorganization. This suggests that the downstream
events triggered by pThr175 tau protein, including toxic oligomer formation, are common to each
of these diseases.
To further assess the pathogenicity of pThr175 and pThr231, we investigated each epitope
in the hippocampus of control cases across three decades of life where tau protein pathology has
been shown to increase with age (Yang et al., 2005). We observed no pThr175 tau protein
pathology in the 6th decade with minimal immunoreactive neuronal inclusions in the 7th decade.
pThr175 tau immunoreactivity was most prominent in the 8th decade. In each case in which we
observed pThr175 tau immunostaining, we also observed T22 immunoreactivity. Similarly, we
never observed T22 immunoreactivity in the absence of either pThr175 tau protein or pThr231 tau
protein immunoreactivity. In contrast, pThr231 tau protein immunoreactivity was frequently
observed in the absence of either pThr175 tau protein or T22 staining in younger individuals and
when present, was within healthy appearing neurons and axonal processes. pThr175 and T22 did
not show pathology in hippocampal regions spared from pThr231 pathology, and T22 was only
positive in cases showing prominent pThr175 pathology.
Glial pathology was recognized to a greater degree by pThr217 tau and PHF tau than by
the pThr175 tau antibody, suggesting that different pathological processes are at play in these
cells. This is supported by the lack of identifiable glial pathology by pThr231 tau and T22. This
paired with the low frequency of pThr175 tau protein glial pathology further strengthens the
correlation between pThr175 and pThr231 in the induction of neuronal pathology and provides
evidence that this pair of phosphorylation sites may be exerting specific neuronal toxicity in the
disease process across multiple tauopathies.
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Although limbic regions universally presented tau protein pathology, frontal and ACC tau
protein pathology was present mainly in AD, VD, ALSci, FTLD, mDLBD and MSA. This paired
with the deeper layer pathology in this region may indicate that tau protein pathology did not
originate here but instead propagated from other regions. If tau originates in limbic structures,
propagating along the Papez circuit, it is possible that it would arrive in ACC through thalamic
projections to layer IV and V which could act as a hub for propagation to other brain regions
such as frontal cortex through this well connected region. Regardless of the induction cause or
place, tau protein toxicity is undeniable once initiated (Gomez-Ramos et al., 2006; Ward et al.,
2012), and must be considered when attempting to understand the underlying biology of many
neurodegenerative diseases. This hypothesis also implies that disease entities such as primary
age-related tauopathies (PART) (Crary et al., 2014) may be in fact not age-related, but neuronal
stress related, as increasing age would indicate longer time periods for normal mechanical stress
on neurons to become pathological through stochastic processes (Kagias et al., 2012). Therefore,
tau protein deposition should not be considered a simple function of normal ageing, but ageing
should be considered a risk factor for tauopathy among a plethora of neuronal stresses. Of note
as well is the frontal involvement in ALSci, which can be concluded is not likely a result of
PART, which spares the neocortex by definition (Crary et al., 2014; Yang et al., 2005). We
cannot conclude, however if the layer distribution of tau pathology resembles PART, as this was
not described in the consensus report.
3.6 Conclusions:
These findings implicate a toxic axis of phosphorylation events beginning with Thr175
phosphorylation, dependent on further phosphorylation at Thr231, which appears to be neuron
specific and which may be common to the tauopathies. It may therefore be a contributor to
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neuronal death in these diseases, and may be a point of intervention capable of slowing disease
progression resulting from tau protein toxicity.
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Chapter 4: Chronic traumatic encephalopathy (CTE) and CTE with amyotrophic lateral
sclerosis (CTE-ALS): evidence for trauma-induced pathological tau phosphorylation at
Threonine175
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4.1 Abstract:
Chronic traumatic encephalopathy (CTE) and chronic traumatic encephalopathy with
amyotrophic lateral sclerosis (CTE-ALS) are neurodegenerative diseases associated with
traumatic brain injury (TBI) characterized by pathological microtubule associated protein tau
(tau protein) deposition. Common features of many tauopathies include: the pathological
phosphorylation of tau protein at Thr175 (pThr175 tau protein), GSK3β activation, the induction of
tau protein phosphorylation at Thr231 (pThr231 tau protein) and pathological tau protein
oligomerization. To investigate whether CTE and CTE-ALS share these features, we
characterized pGSK3β, pThr175 tau protein and pThr231 tau protein expression in human cases of
CTE and CTE-ALS. To determine if GSK3β activation and pathological tau protein
phosphorylation were a consequence of traumatic brain injury we analyzed these markers in a rat
model of TBI. Tau protein isoform expression was assayed by western blot in 6 stage III CTE
cases. We also used immunohistochemistry to analyze 5 cases each of CTE, CTE-ALS, and 5
controls for the expression of pGSK3β, pThr175 tau protein, pThr231 tau protein and oligomerized
tau protein (T22) within spinal cord tissues and hippocampus. Using a rat model of moderate
TBI, we assessed tau neuronal pathology and pGSK3β expression at 3 months post-injury. Both
CTE and CTE-ALS are characterized by the presence of all 6 tau protein isoforms in both
soluble and insoluble tau protein isolates. pGSK3β, pThr175 tau protein, pThr231 tau protein and
oligomerized tau protein expression was observed in hippocampal neurons and in spinal cord.
We also observed tau neuronal pathology (fibrillar inclusions and axonal damage) and increased
levels of pThr175 tau and activated GSK3β in moderate TBI rats. Pathological phosphorylation
of tau at Thr175 and Thr231, and activation of GSK3β are characteristic features of the tauopathy
of CTE and CTE-ALS, a feature that can be replicated in an animal model of moderate TBI.
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4.2 Introduction:
Chronic traumatic encephalopathy (CTE) and chronic traumatic encephalomyelopathy
(CTE-ALS) are fatal neurodegenerative diseases that are closely associated with traumatic brain
injury (TBI) (McKee et al., 2009). While typically associated with elite athletes, participants in
recreational sport are experiencing increased rates of traumatic brain injury and the majority of
TBI occurs as a result of non-sport related accidents, meaning the impact of traumatic brain
injury are more widespread than just accidents and elite athletes (Coronado et al., 2015; Langlois
et al., 2006) . Additionally, there is an increasingly evident relationship between TBI and
neurodegenerative disease processes such as Alzheimer’s disease (AD) Parkinson’s disease (PD)
and amyotrophic lateral sclerosis (ALS) (Bazarian et al., 2009; Chen et al., 2007). Therefore, an
understanding of the molecular changes and biochemistry associated with the neuropathology of
protein aggregation and neuronal death in CTE and CTE-ALS may lead to a better understanding
of pathophysiology of these disorders.
Both CTE and CTE-ALS share the pathological hallmark of neuronal and glial
intracellular aggregates of microtubule associated protein tau (tau protein), placing these
disorders amongst the tauopathies and thus potentially sharing a pathophysiology with AD, PD
and ALS with cognitive impairment (ALSci) (McKee et al., 2009; Moszczynski et al., 2017;
Tartaglia et al., 2014). Pathological tau protein phosphorylation at threonine 231 (pThr231 tau
protein) is considered to be a critical event leading to reduced interaction between microtubules
and tau protein. The increased level of unbound tau protein promotes the formation of soluble
pathogenic tau protein oligomers that further aggregate into insoluble pathological tau protein
fibrils (Lasagna-Reeves et al., 2012; Lin et al., 2007; Nakamura et al., 2013; Ward et al., 2012).
To date, there have been no detailed studies of the phosphorylation state of tau protein in either
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CTE or CTE-ALS and thus it is unknown if the tauopathy of these disorders is homologous to
that of related tauopathies.
We have recently described a sequence of phosphorylation events leading to tau protein
toxicity in ALSci whereby tau protein phosphorylation at Thr175 (pThr175 tau protein), that alone
is insufficient to induce fibril formation, promotes further phosphorylation of tau protein at
Thr231 by activated GSK3β (Moszczynski et al., 2015). We subsequently extended this
observation to a broad range of tauopathies (Moszczynski et al., 2017). In this sequence, pThr231
tau protein is the critical mediator of toxicity downstream of pThr175 tau. Importantly, pThr175
has only been observed in pathological states thus far while phosphorylation of tau protein at
Thr231 appears to be a crucial physiological regulator of tau protein function (Lin et al., 2007;
Schwalbe et al., 2015). Given the widespread applicability of this sequence in tauopathies, we
have examined post mortem archival tissues from CTE and CTE-ALS patients to determine
whether tau protein is pathologically phosphorylated at Thr175 and Thr 231 and whether this is
associated with increased levels of the active isoform of GSK3β (pGSK3β) and tau protein
oligomerization. We have also examined whether this process is also triggered by moderate TBI
in a rodent.
4.3 Methods:
4.3.1 CTE and CTE-ALS studies:
All studies were conducted in accordance with the institutional ethics board standards at
University Hospital (London, ON, Canada) and Boston University (Boston MA, USA).
Microscope slides with 6 µm thick hippocampal and spinal cord sections from fifteen cases (5
CTE, 5 CTE-ALS, and 5 Control; cases MSL1-MSL15) were used for immunohistochemical

148
studies. An additional 6 cases (cases 1-6) were obtained as frozen tissue from anterior cingulate
and temporal pole. All tissue and slides were obtained from the Boston University CTE brain
bank and were diagnosed as stage III CTE (McKee et al., 2013). Demographic data is
summarized in supplemental table 4.1.
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Supplemental Table 4.1: Case demographics
Case
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
17
18
19
20
21
22

Slide/
Tissue
Tissue
Tissue
Tissue
Tissue
Tissue
Tissue
Slides
Slides
Slides
Slides
Slides
Slides
Slides
Slides
Slides
Slides
Slides
Slides
Slides
Slides
Slides

CTE/CTE-ALS/Ctrl

Sex

Decade

CTE
CTE
CTE
CTE
CTE
CTE
CTE-ALS
CTE-ALS
CTE-ALS
CTE-ALS
CTE-ALS
CTE
CTE
CTE
CTE
CTE
Ctrl
Ctrl
Ctrl
Ctrl
Ctrl

M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M

25
58
46
71
84
69
49
31
41
67
62
82
73
56
75
50
83
61
61
55
81
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4.3.1.1 Tau fractionation and Western blot:
Tau protein was isolated from the anterior cingulate gyrus and the temporal pole of 6
stage III CTE cases and a single Alzheimer’s case as a control for the tau fractionation. Tau
protein isolation, fractionation, and dephosphorylation was conducted as previously reported
(Hanger et al., 1998; Strong et al., 2006). Tissue was homogenized in 1 ml of MES buffer (pH
6.5) and centrifuged at 27,000 x g for 60 minutes at 4˚C. The supernatant was then removed and
centrifuged at 95,000 x g for 60 minutes at 4˚C. The supernatant containing the soluble tau
protein fraction was saved and stored at -80˚C. The pellet containing the insoluble tau protein
fraction was solubilized in 150 µl 4 M guanidine HCl for 1 hour at room temperature with a brief
sonication and then dialyzed against 50 mM Tris-HCl, (pH 7.5, 1 mg/ml PMSF) overnight at
4oC. The following day the dialysate was centrifuged at 15,000 x g for 60 minutes at 4oC. The
supernatant containing the insoluble tau protein was boiled at 100oC for 10 minutes and then
centrifuged at 15,000 x g for 30 minutes at 4oC. Supernatant volume was then brought to
approximately 3.0 ml in 50 mM Tris-HCl, 1.35 g ammonium sulphate added, and then cooled on
ice for 15 minutes. Precipitated proteins were collected after centrifugation at 15,000 x g for 30
minutes at 4˚C and resuspended in 150 µl 50 mM Tris-HCl (pH 7.5). The suspension was
dialyzed against 50 mM Tris-HCl (pH 7.5, 1 mg/ml PMSF) overnight at 4oC and the dialysate
clarified by centrifugation at 15,000 x g for 30 minutes at 4oC.
Dephosphorylation of tau protein was conducted on aliquots of the soluble or insoluble
tau protein in 50 mM Tris-HCl (pH 7.5) were incubated with lambda alkaline phosphatase (20
U/µl, Sigma, Oakville ON, Canada) for 6 hours at 30oC (Strong et al., 2006). Reactions were
stopped by the addition of 2x electrophoresis buffer (100 mM Tris-HCl, 4% SDS, 0.02%
bromophenol blue, 20% glycerol, 200 mM DTT).
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After fractionation and dephosphorylation with lambda alkaline phosphatase, equal
aliquots of supernatant from dephosphorylated and non-dephosphorylated samples were run on
7.5% SDS-PAGE gels and electrophoretically transferred to a nitrocellulose membrane. Gels
were probed for total tau protein with rabbit anti tau T14/T46 antibodies (1:1000 and 1:3000
titers, respectively; Thermo-Fischer, Burlington, Canada). After blocking with 10% bovine
serum albumin (BSA) in tris-buffered saline with 0.2% tween (TBS-T) for 1 hour at room
temperature, nitrocellulose membranes were probed with primary antibody overnight at 4˚C.
Blots were then washed in TBS-T before probing with horseradish peroxidase tagged secondary
antibody (Goat anti-Mouse IgG (1:5000 titer; Bio-Rad, Herculese, USA). Blots were visualized
using enhanced chemiluminescence (Perkin Elmer, Waltham, USA).

4.3.1.2 Immunohistochemistry (IHC):
Six µm paraffin-embedded sections from the hippocampus and spinal cord were analyzed
for all cases. Immunohistochemistry was conducted using a series of antibodies that recognized
pThr175 tau protein (1:1000 titer, antibody generated and designed in house, now commercially
available through 21st Century, MA, USA), pThr231 tau (1:1000 titer, Thermo Fischer) and
oligomeric tau protein (1:500 titer, T22; EMD Millipore CA, USA) and activated GSK3β (1:50
titer, pTyr216; BD Biosciences, Mississauga, Canada). Antigen retrieval (10 mM sodium citrate,
0.05% Tween 20 pH 6.0) was conducted for all antibodies using a pressure cooker (2100
Retriever; Aptum Biologics, UK, Supplemental table 4.2). Endogenous peroxidase was quenched
with 3% hydrogen peroxide (VWR, Mississauga, Canada). Primary antibody incubation was
performed at 4˚C overnight in blocking buffer (5% BSA, 0.3% Triton-X 100 in 1 X PBS). After
washing, secondary antibody (1:200 biotinylated IgG) incubation was performed for 1 hour at
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room temperature in blocking buffer. Antigen:antibody complex was visualized with horseradish
peroxidase according to the manufacturer’s instructions (Vectastain ABC kit, Vector
Laboratories CA, USA), followed by substrate development with DAB. Counterstaining was
performed using Harris haematoxylin.
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Supplemental Table 4.2: Antibodies used
Antibody
Tau pThr175
Tau pThr231
T22

Clone
Rabbit, polyclonal
Rabbit, polyclonal
Rabbit, polyclonal

Titer
1:1000
1:1000
1:500

T14

Mouse, monoclonal 1:3000

T46

Mouse, monoclonal 1:1000

Total tau

Rabbit polyclonal

GSK3β

Mouse, monoclonal 1:10,000

GSK3β pTyr216
Alexafluor 488

Mouse, monoclonal 1:50 (IHC)
1:10,000 (WB)
Goat anti-rabbit
1:200
Secondary

Alexafluor 633

Goat anti-mouse

IHC

1:5000

1:200

Epitope
pThr175
pThr231
Tau
oligomer
Tau aa’s
141-178
Tau aa’s
404-431
Tau aa’s
384-397
GSK3β
aa’s 1-160
pTyr216

Secondary

Utility
WB, IHC
IHC
IHC

Company
21st Century
Thermo- Fischer
EMD Millipore

WB, IP

Thermo-Fisher

WB

Thermo-Fisher

WB

Abcam

WB

BD Biosciences

WB, IHC

BD Biosciences

IHC

Life
Technologies
Life
Technologies

WB: western blot, IHC: immunohistochemistry, IP: immunoprecipitation
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The extent of pathology was described semi-quantitatively as previously reported using
visualization with a 20x objective under light microscopy (Olympus BX45) (Moszczynski et al.,
2017; Yang and Strong, 2012). The semi-quantitative scale was applied as follows: ‘-’ = none;
‘±’ = less than 5; ‘+’ = less than 10; ‘++’ = more than 20 with scattered distribution; ‘+++’ =
more than 20 but with locally dense distribution; ‘++++’ = more than 20 with a diffuse
distribution. Additionally, the case positive ratio was defined for each antibody used as the
number of cases showing any pathology (± or more) compared to the total number of cases
stained. Spinal cord pathology was assessed by a binary scale due to the sparse nature of
pathology where ‘+’ = pathology present and ‘-’ = pathology absent.
4.3.1.3 Co-localizations and fluorescence staining:
Double labeling was performed on sections from the hippocampus from one case per
double label experiment. Tau protein was probed with pThr175 or oligomeric tau (T22) rabbit
primary antibody overnight at 4˚C and Alexafluor goat anti-rabbit 488 nm secondary (1:200,
Thermo Fischer) for 1 hour at room temperature. Rabbit anti-tau pThr231 antibody was then
labeled using a Zenon primary antibody labeling kit with Alexafluor 555 nm dye (Thermo
Fisher) and probed for 1 hour at room temperature. Slides were visualized within 24 hours of
labeling by confocal imaging on a Zeiss LSM 510 Meta NLO multiphoton confocal microscope.
For co-localizations with phospho-GSK3β (pGSK3β), staining was performed with mouse antipTyr216 GSK3β antibody (1:50 titer, BD Biosciences) followed by secondary labeling with goat
anti-mouse Alexafluor 633nm (Invitrogen).
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4.3.2 In vivo studies
All protocols for these experiments were approved by the University of Western Ontario
Animal Care Committee in accordance with the policies established in the guide to Care and Use
of Experimental Animals prepared by the Canadian Council on Animal Care. Twelve (12) adult
female Sprague-Dawley rats were subjected to a left-sided 5 mm diameter craniotomy followed
by a single moderate head trauma (3.5 m/s, 2 mm deep, with dwell time of 500 ms) using a
cortical impactor (Precision systems model TBI 0310) (moderate TBI). After 3 months, all rats
were euthanized by trans-cardiac perfusion with ice cold saline after intraperitoneal injection
with a lethal dose of Euthanyl. Six (6) brains were drop-fixed in ice cold Bouin’s fixative
(Thermo-Fisher) for IHC analysis while 6 were frozen on dry ice for neurochemical analysis.
Bouin’s fixative was used to reduce artefactual tau pathology (Planel et al., 2004; Trojanowski et
al., 1989). After 24 hours of fixation, tissue was embedded in paraffin.
4.3.2.1 Western blots:
Immunoblots were also performed using isolates from 6 moderate TBI rats and 4 age
matched controls. Brain tissue was homogenized in RIPA buffer (1% NP40, 10% glycerol, 137
mM NaCl, 2mM EDTA) containing protease inhibitors (cOmplete; Roche Diagnostics,
Indianapolis, USA) and phosphatase inhibitors (Phosstop, Roche Diagnostics) using a
Brinkmann Polytron PT 3000 (Kinetamica, Bohemia, NY, USA). Protein concentration was
determined by modified Bradford assay (BioRad).
Immunoprecipitations (IP) were performed on 1 mg of brain lysate protein using mouse
anti-total tau (T46) in order to isolate all tau protein isoforms from the rat brain homogenates.
The entire IP yield was then run on a 10% SDS-PAGE gel and probed with rabbit anti pThr175
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tau (1:1000). Gels were stripped (2% SDS, 1M Tris, 7 µl/ml β-mercaproethanol) for 30 min at
50˚C and reprobed with rabbit anti-total tau (1:5000, Abcam ab24230). pGSK3β studies were
performed on total brain lysate with mouse anti GSK3β pTyr216 (1:10,000) followed by
reprobing with mouse anti total GSK3β (1:10,000, BD Biosciences). Blots were visualized by
enhanced chemiluminescence (Perkin Elmer) (BioRad Chemidoc MP imaging system and
acquired with ImageLab 5.2.1 software). Densitometry was conducted in imageJ.
4.3.2.2 Immunohistochemistry:
6 moderate TBI and 3 age-matched control rat brains were cut to 5-6 µm thickness and
stained for pThr175 tau, pThr231 tau protein and pTyr216 GSK3β using the same antibodies and
protocol used in human cases. GFAP staining was also conducted.
4.3.2.3 Statistical analysis:
Statistical analyses were conducted using SigmaPlot 10.0 software. A one way analysis
of variance (ANOVA) was conducted following a Shapiro-Wilk test for normality. Post-hoc
Tukey’s test was conducted and a p value of 0.05 or lower was considered significant.
4.4 Results:
4.4.1 Western blot of human CTE:
Insoluble tau protein isolated from CTE cases contained all 6 isoforms. This was evident
in both phosphorylated and dephosphorylated samples. This was in contrast a control
Alzheimer’s disease case in which the insoluble fraction consisted of mainly three isoforms
constituting the paired helical filament motif as previously reported (Figure 4.1) (Strong et al.,
2006).
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Figure 4.1: Representative Western blot of CTE-derived fractionated tau protein showing all 6
tau protein isoforms in the insoluble fraction in distinction to the 3 isoform motif which was
observed in Alzheimer’s disease. Images representative of 6 CTE cases and 1 Alzheimer’s case.
(Probed with mouse anti-T14/T46 total tau antibody; blots shown are from the same case on 2
separate blots).
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4.4.2 Immunohistochemistry in CTE cases:
We observed immunoreactivity to pThr175, pThr231 and T22 within the hippocampal
formation in all cases of CTE and CTE-ALS (Table 4.1, Figure 4.2a). This included tau protein
immunoreactive tangles and dystrophic neurites throughout the CA1-4 regions and extending
into the entorhinal cortex in all cases. Consistent with the limited pThr175 tau protein nonneuronal pathology observed previously (Moszczynski et al., 2017), oligodendroglial tau protein
immunoreactivity was observed to a limited extent in 5 cases only (Moszczynski et al., 2017).
When present in control cases (3/5), tau protein immunoreactivity was observed only as faint
immunoreactive punctate neuronal staining in the absence of tangles (Figure 4.2b). No neuritic
pathology was observed in controls.
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Table 4.1: Hippocampal and spinal cord pathology summary
Antibody

CTE
CTE-ALS
Ctrl
Hippocampus semi quantitation (case positive ratios)
175
pThr
++++ (5/5)
+++-++++ (5/5)
+-++ (3/5)
231
pThr
++++ (5/5)
+++-++++ (5/5)
±-+ (3/5)
T22
++++ (5/5)
±-+++ (5/5)
±-+ (3/5)
Spinal cord pathology case positive ratios
175
pThr
3/5
3/5
0/5
231
pThr
4/5
4/5
2/5
T22
4/5
1/5
0/5
Semi-quantitative scale was applied under 20x objective for neuronal pathology as follows: ‘-’ =
none; ‘±’ = less than 5 inclusions; ‘+’ = less than 10 inclusions; ‘++’ = more than 20 inclusions
with scattered distribution; ‘+++’ = more than 20 inclusions but with locally dense distribution;
‘++++’ = more than 20 inclusions with a diffuse distribution.
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Figure 4.2 A
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Figure 4.2 B

Figure 4.2: Tau pathology in hippocampus and ventral horn in CTE and CTE-ALS. A) Low
magnification (4 x objective) composites of whole hippocampus stained for pThr175 tau protein
in CTE and control (inlay is CA2 region taken with 40 x objective, scale bar = 50 µm). DG =
Dentate gyrus, CA1 = CA1 region, CA3 = CA3 region, sub = subiculum (composite image based
on images taken with a 4x objective). Note the presence of prominent tau protein
immunoreactivity in CA1 through CA4, extending into the entorhinal cortex. B) Representative
tau protein pathology observed in both the hippocampus (CTE case) and ventral horn of the
spinal cord (CTE-ALS) when probed by rabbit anti-pThr175 tau, rabbit anti-pThr231 tau, or rabbit
anti-T22 (tau oligomer) antibodies. Images taken with 100x objective (scale bar= 20 µm).
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We also observed pathological tau protein deposition within the spinal cord regardless of
the tau protein phosphoepitope studied (Figure 4.2b). The presence of tau protein pathology was
independent of whether the underlying pathological diagnosis was CTE or CTE-ALS (Table 4.1)
and consisted of sparsely distributed neurofibrillary tangles in motor neurons and dystrophic
neurites. In all cases, pathological inclusions were minimal in number relative to a more diffuse
immunoreactivity to pThr231 tau and pThr175 tau. No pThr175 tau staining was observed in control
motor neurons. pThr231 tau protein was observed but only as diffuse perikaryal staining of motor
neurons when present. Lipofuscin staining was also observed in some controls.
We also noted a significant alteration in the immunoreactivity towards pGSK3β from a
primarily nuclear to a diffusely cytosolic pattern of immunoreactivity (Supplemental Figure 4.1).
This pattern was observed in both hippocampal CA2 and spinal cord motor neurons in all CTE
cases while only being present in occasional isolated cells in controls.
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Supplemental Figure 4.1: Activated GSK3β (pGSK3β) localization in hippocampus of CTE
and control. A redistribution of pGSK3β is observed in CTE and CTE-ALS cases in which
immunoreactivity is prominent in both the nuclear and cytosolic compartments whereas in
control cases, immunoreactivity is restricted to the nuclear compartment. Tissue stained with
mouse anti-GSK3β pTyr216. Images taken from hippocampal CA4 region with 100x objective.
Scale bar= 20 µm.
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Double-immunolabeling of the hippocampus demonstrated that pThr175 tau and pThr231
tau co-localize consistently such that pThr175 always co-occurred with pThr231 immunoreactivity.
However, as observed previously (Moszczynski et al., 2017), pThr231 tau immunoreactivity could
occur independently of pThr175 tau suggesting that a subset of pThr231 tau pathology is pThr175
positive (Moszczynski et al., 2017). Additionally, we observed co-localization of pThr231 tau and
T22, suggesting that oligomeric tau was a component of pThr231 tau pathology. Due to the nature
of the antibodies, it was not possible to test for co-localization of pThr175 with T22 (oligomerized
tau protein) as they were raised in the same species, not purified and not compatible with the
primary antibody labeling system available to us. We can therefore only infer that pThr175 tau
protein co-localizes with oligomeric tau protein as well. We did however observe pThr175 colocalization with active GSK3β (Figure 4.3).
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Figure 4.3: Co-localization of pThr175 tau and pThr231 tau was observed in hippocampal neurons
of CTE (upper panels). The presence of pathological tau protein oligomers (T22
immunoreactivity) was co-localized to pThr231 tau protein immunoreactive neurons in CTE
(middle panels). Consistent with a role in activation of GSK3β in inducing pathological tau
protein deposition, we observed the co-localization of pThr175tau protein with the active pGSK3β
immunoreactivity (lower panel). Tissues were immunolabelled with rabbit anti-pThr175 tau
protein, rabbit anti-pThr231 tau, rabbit anti-T22 antibody and mouse anti GSK3β pTyr216
antibody. For double-labeled tissue, red channel antibodies were labeled directly with Alexafluor
555. Co-localization stains were performed in one case per antibody combination. Scale bar = 5
µm.
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4.4.3 pThr175 and pThr231 expression in moderate TBI:
Both pThr175 and pThr231 tau neuronal immunoreactivity was observed in moderate TBI
rat brains (Figure 4.4). Of note, pThr175 positive neuronal staining was observed in regions
distant to the injury site mainly as axonal staining; however, no fibrillar inclusion type pathology
was observed in regions distant from the injury site. While pThr175 tau protein was significantly
elevated within the hemisphere ipsilateral to the injury, the contralateral hemisphere also showed
a trend to increased pThr175 tau protein expression when normalized against total tau protein
(p=0.05 and 0.065 respectively after one way ANOVA with p=0.008 and F= 5.757). Diffuse
pThr231 staining was observed in healthy neurons. Pathology-bearing pThr231 tau protein was
only observed near the site of injury. GFAP staining did not show inclusions at site of injury
indicating that pathology was a protein specific phenomenon. Additionally previous studies in
our lab have shown the specificity of the pThr175 antibody to tau protein using peptide blockers
(Yang et al 2012).
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Figure 4.4 A
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Figure 4.4: pThr175 tau pathology is recapitulated in an in vivo model of moderate TBI at 3
months post injury. A) Composite images of whole brain sections stained for pThr175 tau protein.
Images were taken with a 4 x objective. Inlay image taken with 40 x objective. Arrow denotes
site of injury. DG= Dentate gyrus, CA1= CA1 region, CA3= CA3 region. Scale bar= 50 µm. B)
High magnification images with moderate TBI showing neuronal and neuritic pathology. Images
were taken with 100 x objective. Scale bar = 20 µm. C) Western blots of pThr175 tau protein and
total tau protein in ipsilateral and contralateral brain injuries. D) densitometry of western blots
probed for pThr175 tau protein and total tau protein (pThr175/total tau). E) pTyr216 GSK3β and
total GSK3β (pTyr216/ total GSK3β) in ipsilateral and contralateral brain injuries. F)
densitometry of western blots probed for pTyr216 GSK3β and total GSK3β. * represents p < 0.05.
Ipsi: ipsilateral injury hemisphere, contra: contralateral injury hemisphere. Data are
representative of 6 rats (TBI; IHC and western blot), or 4 rats (control; western blot), or 3 rats
(control; IHC).
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We investigated tau protein phosphorylation and GSK3β activation by western blot
(Figure 4.4c). pTyr216 GSK3β was also significantly elevated in ipsilateral and contralateral
hemispheres relative to uninjured controls (p=0.005 and 0.001 respectively after one way
ANOVA with p<0.001 and F=13.928) when normalized against total GSK3β (Figure 4.4).
Finally, we observed the same change in localization of pGSK3β in moderate TBI rat brains as in
CTE cases. This was quantified by blinded counts in which we observed a significant increase in
diffuse expression of pTyr216 GSK3β in the injured hemisphere compared to uninjured control
rats (p= 0.01 by Tukey post hoc test after one way ANOVA p= 0.004 and F= 7.559 ;
Supplemental figure 4.2).
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Supplemental Figure 4.2: Quantification of cytosolic active GSK3β in both injured and
uninjured rats. Bar graph showing ratio of cells with widespread pTyr216 GSK3β compared to
cells showing predominantly nuclear pTyr216 GSK3β. Values represent counts from 3 rats
(control) or 6 rats (TBI). * represents p < 0.05.
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4.5 Discussion:
We have observed that both CTE and CTE-ALS are tauopathies in which pathological
tau protein aggregates contain aberrantly phosphorylated tau protein with immunoreactivity to
both pThr175 tau and pThr231 tau. The presence of T22 immunoreactivity (recognizing
oligomeric tau protein) is consistent with a pivotal role for phosphorylation at Thr175 in the
pathogenesis of CTE and CTE-ALS. The inference can be made on the basis of our previous
study which showed that pThr175 tau protein pathology only occurs in pathological conditions
and that the expression of pThr175 tau protein coincides with oligomerized tau protein in the same
neuronal populations (Moszczynski et al., 2017). This was observed at the same time as pThr231
tau protein was observed in pathological inclusions. This continues therefore to be consistent
with the postulated role of pathological tau protein phosphorylation across a broad range of
tauopathies (Moszczynski et al., 2017). Uniquely, we have also observed that this pathological
process of tau protein phosphorylation can be triggered experimentally in an in vivo model of
moderate TBI. The finding that the tauopathy of CTE, CTE-ALS consists of the expression of all
6 tau protein isoforms in both the soluble and insoluble tau protein isolates further suggests that
this process is biochemically distinct from the tauopathy of AD.
Consistent with our previous reports, pThr175 tau staining was only observed when other
pathological tau protein markers were also present (Moszczynski et al., 2017) and as such,
pThr175 tau positive staining in controls was restricted to mainly those individuals with advanced
age where some tau protein pathology is expected in the hippocampal formation (Yang et al.,
2005). Therefore beyond its role in toxicity itself, pThr175 also appears to also be an indicator of
toxicity and neuronal damage. Because of this, pThr175 tau protein may be useful as a biomarker
of tauopathy, being more specific than other tau protein phosphoepitopes that have been
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investigated previously as CSF biomarkers of disease (Mattsson et al., 2009). If this proves true
for general tauopathies, it may be useful to investigate the ratios of pThr175 tau protein and other
proteins that have previously been investigated such as14-3-3 (Foote and Zhou, 2012), and
neurofilament proteins (Li et al., 2016) in CSF or blood of CTE and CTE-ALS patients.
The tau protein isoform composition profile observed in CTE in this study and previously
in ALSci (Strong et al., 2006) in which all 6 tau protein isoforms are observed in the soluble and
insoluble tau protein isolates is in distinction to that observed in a number of tauopathies,
including AD (in which the pathogenic tau protein marker is the PHF triplet), CBD and PSP (4R
tauopathies) and Pick’s disease (3R tauopathy) (Buee, V et al., 1996; Delacourte et al., 1996;
Delacourte et al., 1998). This could be interpreted as indicative that the tauopathy of CTE, CTEALS and ALSci is a “secondary event” which is triggered in response to a primary neuronal
injury. In both CTE and CTE-ALS, this can be postulated to be directly due to the traumatic
brain injury itself, a hypothesis that is strongly supported by the in vivo moderate TBI
experimental paradigm. While it is less clear what the ‘trigger’ for the tauopathy of ALS may be,
it is clear that once initiated, the induction of phosphorylation at Thr175 leads to a cascade of
events that culminates in neuronal death in vitro (Gohar et al., 2009; Moszczynski et al., 2015).
At this time, it is unknown whether or not pThr175 tau protein pathology is capable of
transneuronal propagation as has been posited with regards to other neurodenegeration related
proteins. It may be that a longer time than the three months in this study is required for this to
occur from a state of no disease to sufficient changes and pathological load necessary for
propagation.
In relationship to our understanding of the pathophysiology of ALS, upwards of 10% of
CTE cases also develop motor symptoms consistent with ALS (CTE-ALS), a rate much higher

174
than the incidence of ALS (2-3 per 100,000) observed in the general population (McKee et al.,
2010). Unique to the motor neuron degeneration associated with CTE-ALS is tau protein
pathology in the spinal cord. The only other instance of a disseminated tauopathy in association
with motor neuron degeneration is that which was observed in the previously hyper-endemic
Western Pacific variant of ALS; a variant of ALS increasingly recognized to be at the
intersection of an environmental insult in an at risk population (Garruto, 1991; Hirano et al.,
1961). While we have observed pathological tau protein phosphorylation in the spinal cords of
both CTE and CTE-ALS patients in this study, the variability observed warrants investigation on
a larger cohort of cases with regional stratification. The resources available to us in this study did
not allow for regional stratification due to the random nature of tissue selection (cervical,
thoracic, or lumbar for different cases, but not all) and thus we were not able to discern whether
there was a correlation between motor symptom progression and regional tau protein deposition.
However, the failure to observe tau protein deposition in the spinal cords of individuals afflicted
with sporadic ALS suggests that the spinal motor neuron tauopathy of CTE-ALS is not an
incidental finding or secondary to the primary neuronal injury of ALS. It is possible that tau
protein phosphorylation and pathology begins early in the neurodegenerative process in CTE or
CTE-ALS, in which case spinal cord pathology would be expected to precede symptom onset in
patients that would otherwise develop motor impairment.
To conclude, we report the presence of all 6 tau protein isoforms in the insoluble fraction
of tau protein isolated from CTE and CTE-ALS, and have observed pThr175 tau, in conjunction
with pThr231 tau, oligomerized tau, and changes in active GSK3β localization are consistent with
a pathological tauopathy driven by the aberrant phosphorylation of Thr175 tau protein. The
observation that this pathway can be triggered following a single moderate TBI suggests that

175
brain trauma itself can drive this process directly. Understanding how moderate TBI drives
phosphorylation at Thr175 is the topic of current studies. However, given our previous findings
that this pathological cascade of tau protein phosphorylation can be fully inhibited, and that this
inhibition abolishes pThr175 tau protein induced neuronal death suggests that both CTE and CTEALS may be amenable to pharmacological inhibition of GSK3β activation.
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5.1 Abstract
Aberrant phosphorylation of the microtubule associated protein tau (tau protein) is associated
with multiple neurodegenerative diseases (collectively known as tauopathies) where it is a critical
contributor to toxicity in neurons. An individual phosphorylation site at Thr175 (pThr175) has been
observed in multiple tauopathies and has been shown to exert toxicity when expressed as a
pseudophosphorylated tau construct (Thr175Asp) in vitro. This toxicity is exerted through activation
of GSK3β and further phosphorylation of tau protein at Thr231. In this study, we used a recombinant
adenoviral expression vector (rAAV9) to express a GFP-tagged Thr175Asp tau protein construct in
adult female Sprague-Dawley rat hippocampus to assess the ability of pThr175 tau protein to exert
toxicity in vivo. 10 rats per group were injected with rAAV9 vectors encoding either GFP, wild type
GFP-tagged tau protein, Thr175Ala tau protein or Thr175Asp tau protein. 12 months post-injection all
rats were euthanized and investigated by immunohistochemistry for GFP (extent of vector
expression), pThr231 tau protein, activated GSK3β, and caspase-3 cleavage. Thr175Asp tau protein
inoculated neurons showed tau protein pathology in the form of axonal beading, fibrils, and
neurofibrillary tangles. Caspase-3 cleavage was observed in the Thr175Asp tau protein group but not
others. These results indicate that pThr175 tau protein is capable of exerting toxicity in vivo and that
this may be a therapeutic intervention in neurodegenerative diseases exhibiting this pathological
phosphoepitope.
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5.2 Introduction

Over 50% of ALS cases present with, or develop, cognitive impairment in the form of a
frontotemporal dysfunction (Strong et al., 2009; Strong et al., 2017). These neuropsychological
deficits are also associated with shorter patient survival and an increased caregiver burden (Chio
et al., 2010; Govaarts et al., 2016). Previous studies have demonstrated the presence of
pathological intracellular inclusions of the microtubule associated protein tau (tau protein) in the
subgroup of cognitively impaired ALS patients known as ALS with cognitive impairment
(ALSci). Tau protein in ALSci is associated with neuronal and glial tau protein inclusions and is
phosphorylated at Thr175 (pThr175 tau) (Strong et al., 2006; Yang et al., 2003; Yang and Strong,
2012). Further study revealed that the presence of neuronal cytoplasmic inclusions of tau protein
in ALSci is associated with activated GSK3β, a kinase that has been clearly demonstrated to
phosphorylate tau protein in other tauopathies (Yang et al., 2008). In vitro studies using
pseudophosphorylated tau protein constructs to mimic pThr175 (Thr175Asp) showed that this
phosphoepitope induces tau protein aggregate formation and increased cell death in vitro (Gohar
et al., 2009). This was then shown to be reliant on increased GSK3β activity and further
phosphorylation of tau protein at Thr231 (Moszczynski et al., 2015). In order to determine
whether this pathway leading to pathological tau phosphorylation could be applied to the
tauopathies, we evaluated a larger cohort of ALS cases (in collaboration with the Mann group)
(Behrouzi et al., 2016) and a broad range of neuropathologically confirmed tauopathies
(Moszczynski et al., 2017b). Critically, in the latter study, we observed that the presence of
pThr175 tau protein inclusions was also associated with GSK3β activation and the induction of
pThr231 tau protein with associated pathological tau protein oligomerization (recognized by the
antibody T22) (Lasagna-Reeves et al., 2012). In our most recent studies, we have shown that this
pThr175 tau protein is present within tau neuronal cytoplasmic inclusions in both hippocampal
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neurons and motor neurons in chronic traumatic encephalopathy (CTE) with or without an
associated motor neuron degeneration (CTE-ALS) (Moszczynski et al., 2017a). Of importance to
future mechanistic studies, a remarkably similar pathology inclusive of both pThr175 tau protein
and pThr231 tau protein can be induced by traumatic brain injury (TBI) in a rodent model of
moderate TBI (Moszczynski et al., 2017a).
The role of pThr175 tau protein in the induction of a tauopathy seems therefore to have
wide applicability to a range of neurodegenerative processes, including ALSci, CTE and CTEALS. However, the effects of pThr175 tau protein have not been investigated in vivo. The purpose
of this study was to investigate the effects of expressing pseudophosphorylated tau protein
(Thr175Asp tau protein) in a rat model to characterize its capacity to induce tau protein
fibrillization and toxicity as it does in vitro.
5.3 Methods:
All experimental protocols were approved by the University of Western Ontario Animal
Care Committee (AUP #2013-008) in accordance with the policies established in the guide to
Care and Use of Experimental Animals prepared by the Canadian Council on Animal Care.
5.3.1 Somatic gene transfer:
A previously described (Mustroph et al., 2012) somatic gene transfer technique was used
to express recombinant adeno-associated virus (rAAV9) vectors: rAAV9 tau (wt-human tau),
rAAV9 Thr175Alanine-tau (phosphorylation inhibition), rAAV9 Thr175Asp tau protein
(phosphorylation mimic), rAAV9 EGFP (control) into both hippocampus of adult, wild-type
female Sprague Dawley rats.
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5.3.2 Surgical procedures:
Two-month old wild type female Sprague-Dawley rats (Charles River Canada) were
housed in pairs prior to surgery and randomly assigned to an experimental or control group. Food
and water were provided ad libitum. Ten rats were used per inoculum; thus a total of 40 rats
underwent surgery. Each rat weighed approximately 250 g at the time of surgery.
All surgical procedures were conducted at level 2+, in a biosafety cabinet. Rats were
weighed, anesthetized under an induction dose of 5% isofluorane and 2 L/min oxygen, and
shaved at the top of their head. With a stereotaxic apparatus, each skull was immobilized using
ear bars and a mouth-piece. A plastic mask covered the nose and delivered a maintenance dose
of 2-3% isoflurane anesthetic with 1% oxygen. Eye lubricant was applied to the eyes to prevent
eye damage during the procedure. The shaved area of the head was disinfected using a threestage preparation: rub with soap, then isopropyl alcohol, and finally iodine. Body temperature
was maintained by placing a 37˚C isothermal pad beneath the rat for the duration of the
procedure. A rostrocaudal incision was made along the midline of the scalp, and the
subcutaneous tissue and periosteum were elevated to expose the underlying bone. The head was
leveled using Bregma and Lambda as reference points. Four small holes (1mm) were bored into
the skull using an electric drill. Injections of the rAAV9 vectors were conducted using
stereotactic coordinates, with Bregma as the reference point. Four inoculations per animal were
conducted at two sites per side (3 µL per site), all within the hippocampus at the following
coordinates: A/P: -5.5 mm, M/L: ±4.6 mm with D/V: -3.2 mm, and M/L: ±6.0 with D/V: -6.0
mm. Using a Hamilton syringe, a total volume of 12 µL (3 µL per site) was injected over the
course of 20 minutes (5 minutes per site) for a total of 1.32 x 1010 vector genomes (2 injections
each hippocampus). After injection, the syringe tip remained in place for 2 minutes, before
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withdrawal. The vector volume was adopted from previously reported studies utilizing
adenoviral vectors to express tau protein in hippocampus (Mustroph et al., 2012).
Rats were then sutured and administered 0.1 mL/100 g Baytril, and 0.1 mL/100 g
Meloxicam subcutaneously. After surgery, rats were placed in a recovery cage under a heat lamp
until fully recovered from the anesthesia. Rats were then singly housed for 1 week to allow for
the incision to close, and then were housed in pairs.
5.3.3 Behavioural and imaging analysis:
All rats underwent Morris water maze testing, startle box testing, as well as open field
testing as part of a behavioural battery, and neuroimaging on a 9.4 T magnetic resonance
imaging (MRI) scanner for structural and diffusion tensor imaging analysis. These were
conducted as the focus of separate graduate theses. Hence, the details of these methods and
results will not be considered in detail for this chapter, given that my thesis focused on the
pathological analysis.
5.3.4 Immunohistochemistry:
At 12 months post injection, 4 rats per group were sacrificed by trans-cardiac perfusion
with heparinized saline (10 units heparin/ mL, 9% NaCl) followed by perfusion fixation with 4%
formaldehyde (pH 7.4) after intraperitoneal injection with a lethal dose of Euthanyl. Brains were
removed and stored in 4% formaldehyde for 24 hours before tissue processing and embedding in
paraffin wax. Tissue was then serially sectioned at 4-6 µm thick sections and mounted to
microscope slides.
Immunohistochemistry was conducted using a series of antibodies that included rabbit
anti-GFP (1:750 titer, Life Technologies, OR, USA) and rabbit anti-pThr231 tau (1:7500 titer,

184
Thermo Fischer). Antigen retrieval (10 mM sodium citrate, 0.05% Tween 20 pH 6.0) was
conducted for all antibodies using a pressure cooker (2100 Retriever; Aptum Biologics, UK).
Endogenous peroxidase was quenched with 3% hydrogen peroxide (VWR, Mississauga,
Canada). Primary antibody incubation was performed at 4˚C overnight in blocking buffer (5%
BSA, 0.3% Triton-X 100 in 1 X PBS). After washing, secondary antibody (1:200 biotinylated
IgG) incubation was performed for 1 hour at room temperature in blocking buffer.
Antigen:antibody complex was visualized with horseradish peroxidase according to the
manufacturer’s instructions (Vectastain ABC kit, Vector Laboratories CA, USA), followed by
substrate development with DAB. Counterstaining was performed using Harris haematoxylin.
5.3.5 GFP expression and pathology mapping:
Every tenth slide from the serially sectioned brain was stained with rabbit anti-GFP and
analyzed for expression. For analysis, the hippocampus was divided into dentate gyrus, CA4,
CA3, CA2, CA1, subiculum and fimbria. Expression in each region was graded as present
(positive) or absent (negative) for each animal, regardless of how many positive cells were
present or expressing pathology. The percentage of animals expressing the GFP construct or
pathological tau inclusions was documented. Thalamus, cerebellum and brainstem were used as
negative controls.
For each GFP expressing region, the extent of tau protein deposition and pathology was
mapped by probing for GFP and pThr231 tau protein separately, and then expressed according to
the same hippocampal breakdown and positive or negative criteria in each animal for all GFPexpressing regions. One slide per animal was selected for a detailed analysis based on presence
of GFP construct expression in the region of interest. The evaluator (AM) remained blinded to
the grouping of the rodents until all aspects of the analysis had been completed.
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5.3.5 Co-localization and fluorescence staining:
Tau protein was probed with chicken anti-GFP (1:500, Abcam, MA, USA) in conjunction
with rabbit anti-pThr231 tau protein (1:1000, Thermo Fischer), rabbit anti-cleaved (Asp175)
caspase-3 (1:200 titer, Cell signaling, MA, USA) or mouse anti-pTyr216 GSK3β (1:50 titer,
pTyr216; BD Biosciences, Mississauga, Canada) primary antibodies overnight at 4˚C and
Alexafluor goat anti-chicken 488 nm and goat anti-rabbit 555nm or donkey anti-mouse 565 nm
secondary (all used at 1:200, Thermo Fischer) for 1 hour at room temperature. Rabbit anti-tau
protein pThr231 antibody was then labeled using a Zenon primary antibody labeling kit with
Alexafluor 555 nm dye (Thermo Fisher) and probed for 1 hour at room temperature. Slides were
visualized within 24 hours of labeling by confocal imaging on a Zeiss LSM 510 Meta
multiphoton confocal microscope. For co-localizations with phospho-GSK3β (pGSK3β),
staining was performed with mouse anti-pTyr216 GSK3β antibody (1:50 titer, BD Biosciences)
followed by secondary labeling with goat anti-mouse Alexafluor 633nm (Invitrogen).
5.3.6 Quantification and Statistical analysis:
Randomly selected fields within the GFP-expressing CA2 hippocampal pyramidal layer
were photographed by confocal microscopy with a 25x objective in GFP-expressing CA2 regions
for each animal. The total number of GFP-expressing cells, and the number of cleaved Caspase-3
positive, GFP-expressing cells were counted and expressed as Caspase-3/total cells. Statistical
analyses were conducted using SigmaPlot 10.0 software. A one way analysis of variance
(ANOVA) was conducted following a Shapiro-Wilk test for normality. Post-hoc Tukey’s test
was conducted and a p value of 0.05 or lower was considered significant.
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5.4 Results:
5.4.1 Behavioural and imaging:
Although the results of the behavioural and neuroimaging studies are the topic of
independent thesis projects, it was noteworthy that no overt differences were observed between
groups by any method of behavioural analysis or imaging at any time in this study. Fifteen rats
developed mammary (Wild type human tau protein n= 2 rats, Thr175Asp tau protein n= 4 rats,
Thr175Ala tau protein n= 3 rats, GFP n= 2 rats) or pituitary tumours (Thr175Asp tau protein n= 2
rats, Thr175Ala n= 2 rats) and were sacrificed or died prior to the 12 month timepoint. This extent
of benign tumour development was unexpected but upon literature review, it has been
documented that the development of tumours can occur spontaneously in up to 50% of rats in the
Sprague-Dawley line after the age of 6 months (Giknis and Clifford, 2013).To increase the
number of rats for statistical power for imaging and behavioural studies, fifteen additional
surgeries were performed to replace the missing rats from each group. None of these rats were
used in histological analyses given that I was specifically interested in pathology at the 12 month
time interval.
5.4.2 GFP construct expression in the hippocampus:
Hippocampal GFP expression was observed in all groups throughout the anterioposterior
axis of the hippocampus (Figure 5.1). The CA2 subregion revealed GFP positive staining in
pyramidal neurons as well as in projections within the radiatum layer and cell bodies within the
oriens layer in all animals regardless of group, suggesting consistent long term expression of the
adenoviral vector across all inoculums. In regions outside of the CA2, we observed variability in
the extent of GFP expression within each construct-expressing group. Staining in non-CA2
regions was never as intense as the positive staining in the CA2 region. Cortical GFP neuronal
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expression was also observed in the subcortical white matter just superficial to the hippocampus.
Extrahippocampal staining was observed in the cortex superficial to the hippocampus only, and
was not observed in control regions studied including the thalamus, cerebellum and brainstem.
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Figure 5.1 A
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Figure 5.1 B

Figure 5.1: AAV9-mediated GFP construct expression. A) We observed adenoviral construct
expression (GFP immunoreactivity) throughout the rostrocaudal axis of the hippocampus. B) The
most consistent expression was observed within the CA2 region (red) of all animals regardless of
the rAAV9 construct with varying degrees of expression throughout the remaining aspects of the
hippocampus. % score represents percentage of animals with GFP-positive immunoreactivity in
each region. DG=dentate gyrus, SUB= subiculum. Images are composites of photographs taken
with a 10 x objective. Data are representative of 3-4 rats per group.
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5.4.3 Activated GSK3β expression:
In the CA2 pyramidal neurons of all animals, activated GSK3β was observed in both the nucleus
and cytosol. No difference in the GSK3β localization or apparent expression could be detected
between groups, although we were unable to reduce the degree of nonspecific background
immunoreactivity (Figure 5.2).
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Figure 5.2: Activated GSK3β is expressed in all groups. Nuclear and cytosolic GSK3β
expression was observed in GFP-expressing hippocampal neurons in all construct-bearing
groups. No inter-group differences were observed. Scale bar = 20 µm. Data are representative of
3 rats per group.
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5.4.4 Tau protein pathology expression in vivo:
Tau immunoreactive neuronal cytoplasmic inclusions were observed exclusively in the
Thr175 Asp tau protein expressing rats in all hippocampal regions expressing GFP constructs.
This was evident using either the rabbit anti-GFP (recognizing tau constructs, Figure 5.3) or the
pThr231 tau antibody (Figure 5.4) and could be characterized as axonal beading, fibrils, and
tangles (see Figure 5.3 for examples as observed using anti-GFP immunohistochemistry). In
addition to this, pThr231 staining revealed fibrillar neuronal inclusions and glial positive cells in a
phenotype resembling coiled bodies (Figure 5.4).
We observed some degree of axonal beading in all groups within GFP-immunoreactive
processes, suggesting that this was a nonspecific feature of the inoculation itself. However, no
other pathology was observed outside of that found in Thr175 Asp tau protein expressing rats.
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Figure 5.3 A
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Figure 5.3 B

Figure 5.3: Thr175 Asp tau protein pathology. A) GFP probing by immunohistochemistry
reveals GFP-tau protein pathology expression in the form of axonal beading (white arrow),
fibrils (black arrow) and tangles (black arrowhead). B) Pathology was expressed in Thr175 Asp
tau protein expressing rats to a greater extent than all other groups. % score represents
percentage of pathology-positive animals in each region. DG=dentate gyrus, SUB= subiculum,
Fimb= fimbria. Images taken with a 100x oil immersion objective. Data are representative of 3-4
rats per group. Scale bar= 20 µm.
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Figure 5.4 A
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Figure 5.4 B

Figure 5.4: pThr231 tau protein pathology. A) pThr231 tau protein probing by
immunohistochemistry reveals GFP-tau protein pathology expression in the form of neuronal
fibrils (white arrow) and glial coiled body-like inclusions (black arrow). B) Pathology was
expressed in Thr175 Asp expressing rats to a greater extent than all other groups. % score
represents percentage of pathoplogy-positive animals in each region. DG=dentate gyrus, SUB=
subiculum, Fimb= fimbria. Image taken with a 100x oil immersion objective. Data are
representative of 3-4 rats per group. Scale bar= 20 µm.

197
5.4.5 pThr231 tau protein co-localizes with tau protein fibrils in vivo:
Consistent with the known physiological role of pThr231 in modulating microtubule/tau
protein interactions, I observed similar degrees of pThr231 immunoreactivity across all animal
groups, regardless of construct expressed. Uniquely within Thr175 Asp tau protein expressing
neurons in which tau protein fibrils were observed, pThr231 tau protein immunoreactivity colocalized in fibrils (Figure 5.5). In Thr175 Asp tau protein expressing neurons where GFP-positive
fibrils were present, pThr231 positive staining was always present. Conversely, no pThr231
positive fibrils occurred in the absence of GFP suggesting that the presence of pThr231
immunoreactive fibrils was dependant on the expression of the pathological human tau construct.
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Figure 5.5: pThr231 tau protein is expressed in hippocampal neurons and co-localizes with
GFP-tau protein pathology. No difference in pThr231 tau protein immunoreactivity was
detected between groups. pThr231 tau protein co-localized to pathological inclusions Thr175 Asp
tau protein expressing neurons (white arrows). Scale bar = 100 µm for low magnification images
and 10 µm high magnification images. Images are representative of 4 rats per group.
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5.4.6 Thr175Asp tau protein expressing cells are positive for cleaved caspase-3:
The number of GFP-positive cells expressing cleaved caspase-3 was calculated as a proportion
of the total number of GFP-positive cells in the field of randomly photographed GFP-expressing
CA2 region taken by confocal microscopy with a 25x objective. Representative high
magnification GFP-expressing neurons are shown in Figure 5.6A. While all groups exhibited
some level of caspase-3 positive staining (WT tau protein: 4.9 ± 3.5%, Thr175Asp tau protein:
38.5 ± 9.7%, Thr175Ala tau protein: 6.3 ± 1.7%, GFP: 3.8 ± 1.7%) showed that Thr175Asp tau
protein positive neurons expressed a higher proportion of cleaved caspase-3 expressing cells than
all other groups (p=0.004 vs GFP, p= 0.003 vs WT tau protein and p= 0.005 vs Thr175Ala tau
protein after one way ANOVA with p= 0.002 and F= 10.518; Figure 5.6B).
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Figure 5.6 A
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Figure 5.6 B

Figure 5.6: Caspase-3 cleavage occurs in Thr175Asp tau protein-expressing hippocampal
neurons. A) Thr175Asp tau protein inoculated brains exhibited caspase-3 positive GFPexpressing neurons to a greater extent than all other groups. Scale bar = 20 µm. B) Blinded
counts revealed that Thr175Asp tau protein-expressing neurons express cleaved caspase-3
significantly more than all other groups. *denotes p<0.05 by Tukey’s post hoc test after
significant one-way ANOVA. Data are representative of 4 rats per group.
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5.5 Discussion:
We have shown that the expression of Thr175Asp tau protein, a pseudophosphorylated
construct mimicking pThr175 tau protein, in the adult rodent hippocampus is capable of inducing
fibrillar tau protein pathology. Furthermore, this is associated with induction of pThr231
immunoreactive neuronal cytoplasmic inclusions, which may be occurring through activated
GSK3β which is ubiquitously expressed through the cytosol in GFP-expressing neurons.
Thr175Asp tau protein expression was associated with increased markers of apoptosis.
That pThr175 toxicity is evident in this animal model builds on our previous in vitro
observation of pThr175 tau mediated neurotoxicity and confirms that this phosphoepitope on tau
protein is directly responsible to setting off a cascade of phosphorylation events that are toxic in
an intact brain (Moszczynski et al., 2015). Additionally, it shows that onset of expression in the
adult brain will lead to pathological fibril formation as well as apoptotic cell death. Therefore the
pThr175 pathology observed in those neurodegenerative diseases that we have thus far
investigated, including ALSci, CTE, and CTE-ALS suggests a common mechanism of tau
mediated neurotoxicity across a broad range of tauopathies (Moszczynski et al., 2017a;
Moszczynski et al., 2017b).
Although the animal model we utilized in this study did express pathology, it was
localized to the discrete region bearing the GFP-tau construct. Most specifically, tau pathology in
this experimental model was limited to the hippocampal region CA2, a region for which the
behavioural testing paradigm was insensitive. Moreover, it is also quite likely that the load of
tau deposition and the extent of neuronal death or dysfunction was insufficient for a phenotype to
be expressed. A similar argument can be made for the failure to observe pathology using high
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resolution MRI. To address this, future behavioural studies will employ testing paradigms that
are more sensitive to deficits in CA2 (such as social memory) in evaluating Thr175Asp tau
protein-mediated behavioural changes (Hitti and Siegelbaum, 2014). With respect to the
neuroimaging studies, it is known that ex vivo imaging methods have a much higher resolution
than the in vivo imaging used in these studies (Dyrby et al., 2011). As such, future studies using
this model will require more sensitive measures of behaviour and imaging.
Alternatively, using a genetic model with more widespread expression of Thr175Asp tau
protein may be a useful tool now that the pathogenicity of this tau protein construct in vivo has
been confirmed. This may be the more useful tool for assessing therapeutic potential due to the
possibility of a more aggressive pathology and behavioural phenotypes that will be more easily
measured over time.
To varying degrees, we observed axonal damage in all 4 groups, likely a result of the
invasiveness of surgery. That Thr175Asp tau protein expressing brains had more axonal pathology
and was the only group showing fibrillar tau protein inclusions with a widespread nature in every
animal indicates that the results are due to the expressed construct. This is consistent with our
previous in vivo studies of Thr175Asp tau protein constructs which also demonstrated increased
fibril formation relative to other groups (Gohar et al., 2009; Moszczynski et al., 2015). Finally,
the induction of caspase-3 cleavage indicates apoptotic cell death which was only observed in
this group. This is consistent with our previous reports that Thr175Asp tau protein expression in
vitro leads to caspase-3 cleavage (Gohar et al., 2009).
Given the evidence of toxicity and the known mechanism by which this is exerted
downstream of Thr175 tau phosphorylation, the inhibition of GK3β may be a useful therapeutic
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strategy in neurodegenerative diseases bearing pThr175 tau protein pathology. The potential
efficacy of GSK3β inhibition will be the focus of future studies in animal models of pThr175
toxicity. There is already evidence of GSK3β inhibition reducing tau protein based pathological
processes in vitro (Hong et al., 1997; Moszczynski et al., 2015) and in vivo (Noble et al., 2005).
Additionally, evidence from bipolar disorder patients on Lithium treatment suggests that chronic
Lithium administration is associated with reduced rates of Alzheimer’s disease, indicating
therapeutic potential as a strategy of preventing tau protein phosphorylation-based pathological
processes (Kessing et al., 2010; Nunes et al., 2007).
5.6 Conclusions:
Taken together, these data suggest that pThr175 tau protein is capable of inducing fibril
formation, tau protein-based pathology, neurotoxicity and death in vivo. Further investigation
using GSK3β inhibitors will determine therapeutic potential to inhibit pThr175 based tau protein
toxicity in a complete physiological system and whether this may be effective in human
tauopathies.
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Chapter 6: Discussion
6.1 Summary of results
Thr175 tau which has been implicated in the pathogenesis of cognitive impairment in ALS
is toxic and capable inducing tau aggregates both in vitro and in vivo. This toxicity is mediated
through increased activation of GSK3β and is dependent on phosphorylation at Thr231 in a
process which can be fully prevented in vitro by inhibition of GSK3β pharmacologically or
through molecular knock-down.
In this thesis, I have expanded the relevance of Thr175 phospho-tau and the cascade
triggered by pThr175 tau protein in the induction of pathogenic tau fibrils from ALSci and
Alzheimer’s disease to other tauopathies. I have proposed that this pathway of pathological tau
protein fibril formation may represent a common mechanism of toxicity in these disease
processes. Most critically, Thr175 tau is phosphorylated only in diseased states and appears to be
a specific indicator of pathological tau, unlike other phospho-tau variants. The pThr175 containing
pathology is associated primarily with neuronal cells and not glial cells. Notably in all of these
diseases, Thr175 tau phosphorylation is always associated with Thr231 tau phosphorylation and tau
oligomerization, further emphasizing the importance of this pathway.
Although the initiating mechanism is unknown, I have shown that Thr175 tau
phosphorylation and pathology can be induced by traumatic brain injury in a rat model of mild
traumatic brain injury. This pathology is observed in human CTE and CTEM in hippocampal
and motor neuron populations, and is associated with activated GSK3β as well as tau
oligomerization. In this model, pThr175 tau protein and pathology can be induced by a single
traumatic brain injury in wild type rats and persists 3 months after injury. In traumatic brain
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injury and CTE, GSK3β activity appears to shift from a primarily nuclear to an even distribution
through nucleus and cytosol.
6.2 Implications
6.2.1 Mechanism of toxicity
The toxicity observed downstream of Thr175 phosphorylation relies on increased
activation of GSK3β beyond baseline levels of activity. There are three potential mechanisms by
which this may be induced by tau protein, all of which rely on tau functional changes, likely
promoted by a conformational shift from its global hairpin structure. Firstly, opening of the
hairpin may simply provide increased substrate for GSK3β by exposing more Ser and Thr
residues on tau protein for phosphorylation by GSK3β. It has been shown that increasing
substrate availability can increase the activity of kinases including GSK3β (Frame et al., 2001).
Secondly, opening of the hairpin may expose the proline-rich domain, allowing for tau
interactions with other signaling molecules. These occur through SH3 homology domains which
have been shown to interact with Fyn kinase (Klein et al., 2002). This in turn has been
demonstrated to phosphorylate GSK3β at Tyr216, enhancing its activity, leading to increased tau
phosphorylation in vitro (Lesort et al., 1999). Finally, opening of the tau protein hairpin
conformation may expose the N-terminal phosphatase activating domain (PAD), consisting of
amino acids 2-18. The PAD domain has been shown to directly activate GSK3β related pathways
(Kanaan et al., 2011). While each of these possibilities is dependent on opening of the hairpin
loop structure, it is unknown whether the effect of Thr175 phosphorylation can directly cause an
opening of the global hairpin conformation or if this is mediated by a downstream effect.
However the location of this phosphoepitope on the Pro-rich domain/ hinge region of the hairpin
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suggests that this is possible based on previous reports of phosphorylation in the proline rich
domain (Jeganathan et al., 2006; Jeganathan et al., 2008).
The trigger for Thr175 phosphorylation remains unknown. However, the upstream cascade
of kinase activation that would lead to the phosphorylation of Thr175 tau was not the focus of this
thesis; rather it was to determine whether pThr175 tau was a pathogenic post-translational
modification, and if so, how. In future studies, it will be key therefore to use the rat model of
mild traumatic brain injury to understand this process further (discussed in future directions
section). It is interesting to note however that Thr175 tau protein has been shown to be
phosphorylated in situ by several kinases including MAPK, JNK/SAPK, GSK3β, and LRRK2;
hence, there are several candidates (Atzori et al., 2001; Hanger et al., 1998; Hanger, 2017;
Reynolds et al., 2000). Of note, the MAPK family of kinases, specifically JNK has exhibited
increased activity after traumatic brain injury (Tran et al., 2012), in which case it is a strong
candidate. In fact, JNK inhibition has been previously reported to reduce tau pathology after
traumatic brain injury in a rodent model (Tran et al., 2012).
One possible means of tau phosphorylation by activated JNK is spatial proximity (Zeke
et al., 2016). Neuronal injury requires microtubule remodeling (Kleele et al., 2014; Tang and
Chisholm, 2016; Tang-Schomer et al., 2010). This would be a circumstance in which tau protein
must disengage the microtubule to enable microtubule disassembly before re-polymerization.
While unbound, large proportions of tau could be re-localized to the soma. Here tau may be
situated in proximity to stress-activated JNK, which could phosphorylate tau by this stochastic
process. If this happens to occur at Thr175, the downstream pathogenic process of GSK3β
activation and Thr231 phosphorylation would lead to an inability of tau to return to the
microtubule, and fibril formation. It is also possible that phosphorylation of Thr175 can occur
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through different pathways. For example LRRK2-induced phosphorylation in Parkinson’s
disease linked to mutations in LRRK2 (Shanley et al., 2015) or already elevated GSK3β activity
in Alzheimer’s disease (Guerreiro et al., 2016). Given this, it is reasonable to propose that there
may be multiple pathways of Thr175 tau phosphorylation, with varying degrees of generalizability
to cellular injury response or disease specificity. This may explain the heterogeneity of diseases
associated with pThr175 tau.
6.2.2 Pathology vs. physiology
An important observation is that pThr175 tau was only observed in pathological or injured
states. As mentioned above, the likely pathways to Thr175 induction are all abnormal and may
occur in “primed cells”. It is possible then that pThr175 represents a tipping point in pathological
tau metabolism and further study of the regulation of pThr175 dephosphorylation is required to
establish whether it is a reversible event. The pathological state specificity of pThr175 implies that
beyond its direct role in toxicity itself, pThr175 tau appears to also be an indicator of toxicity and
neuronal damage. Because of this, pThr175 tau may be useful as a biomarker of tauopathy, being
more specific than other tau phosphoepitopes that have been investigated previously as CSF
biomarkers of disease such as pThr181 (Mattsson et al., 2009). If this proves true for general
tauopathies, it may be useful to investigate the ratios of pThr175 tau and other proteins that have
previously been investigated such as14-3-3 (Foote and Zhou, 2012), and neurofilament proteins
(Li et al., 2016) in CSF or blood. These ratios may provide utility in distinguishing between
different neurodegenerative diseases or stratifying patients with the same clinical diagnosis as
candidates based on molecular pathology for specific interventions or combinations of
interventions. The utility of combination therapy for treatment of neurodegenerative disease is
discussed further in the Future Directions section.
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The pathological specificity of pThr175 was in contrast to pThr231 tau which may be of
both pathological as well as physiological significance. As mentioned above, it has been shown
that microtubule dynamics are more plastic after axonal damage (Kleele et al., 2014), in which
case tau protein would need to disengage the microtubule. This physiological response may be
regulated by Thr231 phosphorylation (Cho and Johnson, 2004; Lin et al., 2007; Schwalbe et al.,
2015; Sengupta et al., 1998). As such, Thr231 phosphorylation must be carefully regulated by the
cell as anything leading to dysregulation, such as incorrect isomerisation about the phosphate
group (causing inability of dephosphorylation) can cause cell toxicity (Nakamura et al., 2013). If
kinase activity is enhanced and Thr231 phosphorylation is driven by an external factor, it may be
that it is phosphorylated at a faster rate than it can be dephosphorylated, leading to an inability to
return to the microtubules, further tau phosphorylation, and tau-mediated toxicity culminating in
apoptotic cell death. This dysregulation may be mediated by pThr175 making the pathogenic state
of Thr231 phosphorylation dependent on Thr175 phosphorylation, even though pThr231 normally it
is an innocuous epitope due to tight regulation.
That tau pathology is inducible by traumatic brain injury brings into question the origin
of tau pathology in tauopathies as a whole. In instances where disease is induced by tau protein
mutations such as FTDP-17 it clear that tau protein is the primary cause of the disease. In other
states such as Alzheimer’s disease where tau tangles are observed concomitantly with other
pathologies, it is much more difficult to discern what the origin of neuronal toxicity may have
been. In the case of CTE it is thought that tau pathology is induced by shear forces and axonal
injury brought about by traumatic brain injury (Gavett et al., 2011). The same may be true of
progressive age related tauopathy (PART). Beginning in the entorhinal cortex, tau tangles have
been observed to increase with age in patients without overt dementia, and it has recently been
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shown that the burden of tau pathology in PART post-mortem correlates strongly with rate of
cognitive decline displayed in life (Jefferson-George et al., 2017). It is possible that in the
absence of other pathological processes, tauopathy induced by stress over time is a slowly
developing cognitive deficit. Tau deposition can therefore be thought of not as a function of
normal ageing, but as a toxic byproduct of wear and tear on the brain over the lifespan. There is
nothing physiological about tau deposition as it is a departure from homeostasis.
6.2.3 Affected cell populations
The pathology associated with Thr175 tau was contained primarily within neuronal cells
suggesting that there may be divergent toxic processes responsible for tau pathology in neuronal
and glial cell populations and is consistent with the hypothesis that glial tau pathology is a
separate process influenced by the cellular environment within glia, which is distinct from the
neuronal cellular environment due to differential protein expression (Kahlson and Colodner,
2015). Indeed, it has been suggested that neuronal and glial tauopathic processes are driven by
separate mechanisms and kinases (Ferrer et al., 2001). One example of differential kinase
expression affecting tau pathology is casein kinase 1 (CK1). Although the δ isoform of CK1 has
been implicated in tau pathology in multiple neurodegenerative diseases, this isoform is not
expressed in glial cells (Lohler et al., 2009). It is thus not surprising that CK1 associated tau
pathology is not observed in glial cells (Li et al., 2004; Schwab et al., 2000). Additionally, glial
and neuronal cells have been shown to exhibit opposite responses in MAPK activation after
exposure to external signals such as cAMP due to differential B-raf receptor expression (Dugan
et al., 1999). Of note, the B-raf signaling cascade has been shown to induce JNK activity when
activated, and inhibition of this pathway reduces JNK activation (Park et al., 2005). Additionally,
kinases that have been shown to phosphorylate tau protein such as CaM kinase II have much
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lower expression in glia than neurons (Ferrer et al., 2001). If Thr175 phosphorylation is a
stochastic process driven by cellular stress, it is conceivable that differential kinase activation or
expression patterns would have a completely different likelihood for Thr175 phosphorylation.
This may explain the disparity in phosphorylated residues between glial tau and neuronal tau.
The preferential layer pathology expression between superficial layers in the entorhinal
cortex and deeper layers in frontal and anterior cingulate cortex (ACC) suggests an origin in
entorhinal cortex which spreads along connections to the ACC. Superficial deposition throughout
the entorhinal cortex with preferential localization to layer III may indicate that this is driven by
mechanical cellular stress as observed in CTE. The occurrence of tau in superficial regions in
CTE has brought about the hypothesis of a “wear and tear” source of origin due to mechanical
disturbance to the neurons. This has also been suggested in hippocampal sclerosis of ageing
(Nelson et al., 2013) and PART (Crary, 2016). Superficial neurons are characterized by more
laterally oriented projections connecting neighbouring cortical columns. If tau protein spread
occurs trans-synaptically as has been suggested, (Wang and Mandelkow, 2016) it is plausible
that this process would spread laterally through the entorhinal cortex between columns remaining
largely in layer III, with a lower likelihood of spread to other regions. Tau protein deposition in
deep layers however, is more likely to spread inter-regionally. It is possible therefore that there is
a critical mass of tau pathology needed to be reached before the spread will occur to other layers
by chance and then to other regions. Layer IV and V neurons in the ACC receive inputs from the
perforant pathway via thalamic hubs. These ACC neurons then send projections to distant brain
structures, providing a route for tau spread to distant structures. Therefore, once tau protein
accumulation in deep layers begins, it is possible for this process to perpetuate itself further in a
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seemingly random process. That tau is consistently observed in the entorhinal cortex and other
limbic structures, and then next most commonly in the ACC, is consistent with this finding.
ACC pathology was most frequently observed in diseases associated with cognitive
impairment and has been observed to a greater extent in ALSci than ALS (Yang and Strong,
2012). Indeed, dysfunction of the ACC has been implicated in cognitive impairment in ALS
through multiple studies (Ambikairajah et al., 2014; Byrne et al., 2012; Kew et al., 1993;
Mohammadi et al., 2009; Van Deerlin et al., 2008). This region has been linked to language
processing, emotion (Bush et al., 2000), motor imagery (Grezes and Decety, 2002), motor
function (Basha et al., 2013), pain processing (Naro et al., 2015), error detection (Hyman et al.,
2013; Wang et al., 2005) and conflict monitoring (Kerns et al., 2004; Wang et al., 2005). This
may imply that the variability of frontal symptom progression in ALSci could result from
differential ACC regional involvement. Furthermore, the ACC is also a highly connected region
of the brain with the midcingulate cortex (MCC) subregion alone having cortical projections
with amygdala, parietal cortex, insula, dorsolateral prefrontal cortex (dlPFC) (Vogt, 2016) and
direct connections to spinal motor neurons (Dum and Strick, 1991).
Of further interest to neuronal pathology of the ACC, there are two unique classes of
neurons known as spindle neurons and fork cell neurons which may be linked to social behavior
localized specifically to the ACC and insula. These neurons appear to be affected preferentially
in frontotemporal dementia (FTD) (Kim et al., 2016; Santillo et al., 2013; Seeley et al., 2006).
Fork cells and spindle neurons are large neurons, localized to layer V of the anterior cingulate
cortex, analogous to pyramidal upper motor neurons (Kim et al., 2016). It may be no coincidence
then that ALS and FTD share such pathology and comorbidity. They show physical similarities
(size), similar predisposition to pathological processes, and are contained within structurally
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connected regions. If neurodegenerative disease is even partially stochastic in nature, the link
shared by these cell populations would suggest that a higher than expected number of cases
should develop both diseases especially in diseases bearing more aggressive pathology.
In the case in both Guamanian ALS as well as CTE, which bear intense tau pathology
through the brain and spinal cord, the critical mass hypothesis may be relevant. The reduced
frequency of tau pathology in spinal cord in other variants of ALS and tauopathies may be
because motor neurons have a different molecular sequalae making tau inclusions harder to drive
in them even though tau dysfunction can occur. In fact it has been suggested that neurofilament
may serve as a phosphorylation sink in spinal motor neurons which may hold off tau pathology
resulting in a higher “barrier to entry” (Nguyen et al., 2001). Nevertheless, animal models of
tauopathy and even SOD1 (Nguyen et al., 2001; Spittaels et al., 1999) have been shown to
exhibit abnormal tau protein metabolism and pathology in the spinal cord, suggesting that there
is a possible role of tau in these neurons as well when dysfunction does occur in motor neurons.
The spinal cord tau pathology I observed in CTE cases that did not exhibit motor impairment
may indicate an early stage of tau pathology with phosphorylation preceding sufficient neuronal
death to initiate clinical findings. It has been observed in ALS-Parkinsonism dementia complex
(ALS-PDC) of Guam that spinal cord pathology was present even in 35% of cases with
Parkinosnism without motor symptoms (Rodgers-Johnson et al., 1986). Tau dysfunction
therefore may be relevant to motor neuron toxicity in diseases bearing a heavy tau burden to a
much greater extent than those with relatively limited tauopathy. It is possible that it is one of the
key toxic mediators of motor neuron degeneration in these cases.
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6.2.4 Recognition of tauopathy
I noted divergence between AT8 and pThr175 tau pathology in the frontal cortex. Whereas
AT8 only recognized frontal tau pathology in Alzheimer’s cases selected on the basis of late
stage tauopathy, pThr175 recognized tau pathology in the frontal cortex in 80% of ALSci cases
studied. This is notable because AT8 is a primary antibody used in neuropathological study and
the detection of phosphorylated tau protein in tauopathies. If tau can be toxic without
phosphorylation at Thr202 (the AT8 epitope), AT8 may miss tau pathology resulting in false
negative reporting. This highlights a need for sensitive methods to detect tau pathology in nonAD neurodegenerative diseases, using antibody panels or other methods.
Alternatively to antibody specificity, the thinness of paraffin embedded tissue sections
routinely used for neuropathological analysis presents an additional limitation of tau detection.
One method that has been applied recently to both Pick’s disease (Irwin et al., 2016) and FTDTDP (Brettschneider et al., 2014) is to use 70 µm sections (Feldengut et al., 2013) allowing for
more detailed anatomical characterization. However, this technique also has a higher false
negative rate as more cells and structures are present on each slide. Braak staging has been used
since 1991 (Braak and Braak, 1991) as the gold standard in staging of neurofibrillary pathology
related to AD. Recently (Irwin et al., 2016), a series of Pick’s disease cases were stained using
the thick section method. Their traditionally identified thin section Braak stage was a maximum
of I/II, corresponding with what is considered to be a mild tau pathology which may be
associated with ageing. However, upon further inspection using this sensitive technique it was
apparent that tau pathology was widespread and found in regions spanning from limbic and
frontal structures, to visual cortex. This paired with our finding that tau pathology may be
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underestimated by one tau antibody, or silver staining alone, indicates that thorough investigation
may be required before writing off tau pathology as a contributing factor to disease.
6.2.5 Tau as a central player in NDGs
Tau protein phosphorylation can be induced as an initiator of or response to a stressor.
Thr175 phosphorylation is observed in neuronal pathology in all tauopathies investigated thus far
and may play a role in the toxicity of tau protein. It may be that Thr175 phosphorylation can be
induced by multiple factors such as axonal stress, other protein-induced stress, or other cellular
dysmetabolism. In fact, it has been suggested that within neurodegenerative disease, the rate of
mixed pathologies and number of combined neuropathological substrates may be very high
(Rabinovici et al., 2017; Rahimi and Kovacs, 2014). Therefore, aberrantly phosphorylated tau
protein may be one part of a pathological network of disease-related proteins capable of reenforcing pathology in each other, propagating the toxic processes underlying neuronal death.
Tau protein may therefore be a central player in many neurodegenerative disorders, contributing
to pathology and toxicity. It is possible that it interacts with other components of this
pathological network in a synergistic manner. This is discussed further in the Future Directions
section.
6.3 Caveats
The results from my studies have shown that pThr175 tau protein is pathogenic and
associated with multiple disease states. However, these studies do not shed light on the induction
of this process. That traumatic brain injury was capable of inducing this pathology suggests that
other forms of cellular stress may be capable of inducing it as well. This suggests that Thr175
phosphorylation happens downstream of cellular stress, raising the issue of whether or not this is
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a cause or consequence of neurodegenerative disease. Regardless, it may be a specific marker of
neurodegeneration and it is a clear contributor to toxicity which may require intervention even if
other contributors to toxicity are present in the diseased brain. Alternatively it may be an aberrant
response to stress representing a tipping point, driving a physiological stress response to a
pathological, out of control, toxic state of cellular dysfunction.
Another limitation of these studies is the inability to determine the order of
phosphorylation of Thr175 and Thr231. The cell culture and rat model expresses a construct
mimicking pThr175, and we therefore were only able to determine the downstream changes
required for toxicity. It is possible that Thr175 phosphorylation locks pThr231 into place, or pushes
equilibrium of phosphorylation to dephosphorylation in the favour phosphorylation as it is likely
that Thr231 would be phosphorylated already as tau may need to be off the microtubule to be
phosphorylated at Thr175. Future studies in the TBI model can be used to shed light on this
sequence of events.
The lack of behavioural or imaging correlate in the in vivo studies of pThr175
pathogenicity appeared to be related to insufficient levels and regional spread of expression. This
suggests that a different mechanism of delivery or a longer period of time is required to induce
widespread pathological effects. In other words, pThr175 requires more time to induce pathology
in the brain and needs to be expressed in multiple areas at higher levels to induce behavioural or
large-scale changes. It may very well be that multiple hits are required, and that the toxicity of
pThr175 tau is made worse by another contributor. This will be the focus of future studies.
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6.4 Future directions
One current study is addressing the synergistic toxicity of tau protein and transactive
response DNA binding protein of 43 kDa (TDP-43). I am using the same somatic gene transfer
as in chapter 5 to express 1) Thr175Asp-tau, 2) wild-type human tau, 3) rAAV9-GFP in the
hippocampus of either wild-type or transgenic rats expressing human mutant TDP-43 (NEFtTA/TRE-TDP-43M337V) (Huang et al., 2012; Zhou et al., 2010). Interactions between these two
pathological proteins may be synergistic in the neurodegenerative process, as individual
pathology is rarely observed, and comorbid pathologies are frequent (Amador-Ortiz et al., 2007;
Josephs et al., 2014a; Josephs et al., 2014b; Smith, 2017). The association of TDP-43 pathology
to ALS and ALS-FTD spectrum diseases is well described (Neumann et al., 2006) and comorbid
TDP-43 pathology is frequent in tauopathies such as AD and CTE (Josephs et al., 2014a; Josephs
et al., 2014b; McKee et al., 2010). Both TDP-43 and tau protein may contribute to neuronal
death in ALSci, and tau protein toxicity has previously been shown to act synergistically with
other neurodegeneration-associated toxic proteins (Zabrocki et al., 2005). It is possible that one
pathological process primes the other, in which case the toxicity of Thr175Asp expression may be
enhanced by the coexpression of TDP-43 serving as a second hit to the CNS.
The induction of pThr175 by traumatic brain injury in wild type rats provides an
opportunity to study the upstream events leading to Thr175 phosphorylation. A time series study
where pathological analysis is conducted at the time of injury, hours, days, and weeks after
injury would allow for the characterization of tau fibrillization relative to phosphorylation status.
Investigating this along with kinase activation status and co-localizing phospho-tau with these
kinases would allow for the characterization of underlying kinases. Administering inhibitors of
the identified kinases at the time of injury and following injury could be utilized to confirm
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mechanistic involvement as well as determine the efficacy in blocking fibrillization of tau in this
model. Additionally, GSK3β inhibition should be conducted in this model to characterize its
therapeutic potential for blocking pThr175 toxicity as observed in vitro. This is particularly
attractive as lithium is currently used in the treatment of psychological disorders (Geddes et al.,
2004) and would therefore be easily repurposed for clinical use, expediting therapeutic use if
they prove efficacious.
A detailed characterization of pThr175 in the tauopathies would elaborate further on my
findings. This should be extended to tau mutation carriers including spicing modifying mutants
and MPR affecting mutations. A more detailed account of the types of inclusions and pathology,
as well as a further quantification with a larger cohort for each disease would shed light on the
extent of pThr175 pathology in the disease process.
The mechanism by which pThr175 tau induces GSK3β activity remains unknown. As
mentioned above, it is possible that this occurs through opening of the hairpin conformation of
tau protein to expose the PAD domain. Expressing a pThr175 construct lacking the first 18 amino
acids of tau should therefore abolish the upregulation of GSK3β activity and should not lead to
fibril formation, cell death, or Thr231 phosphorylation.
The redistribution of activated GSK3β likely represents changes in the location and
homogeneity of GSK3β activity in the cell. This warrants further, detailed investigation, and
assays of GSK3β activity should be conducted. In situ activity assays of GSK3β in the presence
and absence of pThr175 could be used to further delineate the nature of tau based GSK3β
activation, (whether it is direct or indirect). Cellular fractionation could be used to investigate the
activation status of GSK3β in multiple organelles. Finally, GSK3β isolation from different states
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(injured/ uninjured) and organelles could be used to assay catalytic activity of the kinase in each
subcellular region.
Tau protein pathology has been observed in a plethora of neurodegenerative diseases.
Regardless of whether tau is a primary or secondary cause of disease, the clear demonstration of
tau protein toxicity in many in vitro and in vivo models suggests that once tau pathology is
induced, it is a contributor to neuronal death. Therefore, tau protein based toxicity may need to
be considered for future attempts at effective therapeutic interventions for neurodegenerative
disease. It is also therefore likely that effective therapies will need to be based on individual
molecular contributors possibly recognized through in vivo imaging of different pathological
markers to account for co-morbid underlying molecular diseases. Therapies attempted thus far
have failed, possibly due to multiple contributing sources of toxicity not being addressed in
strategies attempted. Future attempts may require one inhibitor per molecular contributor. The
concept of combination therapy has been applied with great success to treatment of cancer
(Bayat et al., 2017) and has been suggested as a possible path for neurodegenerative disease
(Bredesen and John, 2013; Schmitt et al., 2004).
6.5 Conclusions
pThr175 tau protein is toxic and may play a role in neurodegeneration. The extent to which
this phosphoepitope is involved in tauopathies appears widespread and requires further
investigation. Thr175 phosphorylation and tau pathology is induced by traumatic brain injury.
This warrants further investigation to examine the upstream mechanism underlying pThr175
phosphorylation as well as whether other stressors can induce this event. Therapeutic
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intervention may be effective in mitigating this source of toxicity, and may be required in
conjunction with other toxicity blockers for comorbid pathologies.
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Chapter 9

Cortical Manifestations in
Amyotrophic Lateral Sclerosis
A.J. Moszczynski, M.J. Strong
Western University, London, ON, Canada

BACKGROUND
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset neurodegenerative disease of the motor system. Although the earliest clinical description of ALS appeared in the thesis of Aran (1850), it was Charcot J.M. and
Joffroy A (1869) who coalesced the findings of progressive degeneration of
both upper (descending supraspinal) and lower motor neurons into a single
diagnostic entity. The net effect of this degeneration is a progressive loss of
motor function, culminating in paralysis and death generally within 3–5 years
of symptom onset (Strong, 2003).
Although neuropsychological changes in ALS were historically considered
to be rare (Hudson A.J., 1993), the contemporary view is that 45–55% of
patients with ALS will develop a neuropsychological syndrome reflective of
frontotem-poral dysfunction, including a frontotemporal dementia (FTD),
behavioral or cognitive impairment (ALSbi and ALSci, respectively),
language impairment, or deficits in social cognition (Abrahams, Newton,
Niven, Foley, & Bak, 2014; Elamin et al., 2011; Montuschi et al., 2015; Oh et
al., 2014; Strong et al., 2009; Strong, Grace, Orange, & Leeper, 1996). The
presence of a neuropsychological syndrome in ALS is prognostically relevant
because affected patients will have a significantly shorter survival than if ALS
occurs in isolation (Elamin et al., 2011; Hu et al., 2013).

NEUROPSYCHOLOGICAL MANIFESTATIONS OF
FRONTOTEMPORAL DYSFUNCTION IN
AMYOTROPHIC LATERAL SCLEROSIS
The neuropsychological manifestations of ALS can range from impairments in
cognition or behavior, deficits in social cognition or theory of mind (ToM), or as
an FTD consistent with either the Neary or Hodges criteria (Hodges & Miller,
The Cerebral Cortex in Neurodegenerative and Neuropsychiatric Disorders.
http://dx.doi.org/10.1016/B978-0-12-801942-9.00009-4
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2001; Neary et al., 1998; Strong, 2008; Strong et al., 2009). Rare presentations
can include progressive nonfluent aphasia or semantic dementia, suggesting a
continuum with FTD. Approximately 2–4% of patients who have ALS will
develop concomitant Alzheimer disease (AD) (Consonni et al., 2013).
Impairments in language, including deficits in naming, comprehension, and
spelling, occur in upwards of 35% of patients (Abrahams et al., 2014). Defi-cits
can be further subdivided into impairment in action verbs but not cognitive verbs,
with the former showing a positive association with impairments in exec-utive
functioning (York et al., 2014). These latter findings are associated with
significant gray matter atrophy in the left precentral gyrus, left cingulate gyrus,
and right medial frontal gyrus. As will be discussed, these observations begin to
highlight the regional selectivity of the frontotemporal dysfunction in ALS.
Impairments in verbal fluency are commonly observed. In a meta-analysis
of published studies, Raaphorst and colleagues observed that among those
indi-viduals with cognitive impairment, impairments in verbal fluency, visual
mem-ory, and immediate verbal recall each had a significant effect size
(Raaphorst, De, Linssen, De Haan, & Schmand, 2010).
Behavioral dysfunction has been observed in upwards of 40% of patients with
ALS and can include apathy, behavioral disinhibition, irritability, loss of
sympathy/empathy, perseverative or stereotypic behavior, or changes in eat-ing
behavior (Abrahams et al., 2014; van der Hulst, Bak, & Abrahams, 2014; LomenHoerth et al., 2003). An increased incidence of psychotic symptoms has been
observed in those individuals with ALS-FTD (Lillo, Garcin, Hornberger, Bak, &
Hodges, 2010). Deficits in ToM have been described in a significant proportion of
patients who have ALS and are characterized as an inability to represent others’
intentions and beliefs and thus the ability to predict others’ behavior by attributing
independent mental states to them (Adenzato, Cavallo,
& Enrici, 2010). These deficits can be observed even in the absence of overt
evidence of dementia (Meier, Charleston, & Tippett, 2010). Consistent with
pathology of the orbitofrontal cortex, impairments range from apathy through to
greater difficulty in identifying emotional expression or reductions in emotional
attributions while sparing intentional attributions (and thus a reduced ability to
recognize others’ emotional states) (Cerami et al., 2014). ToM deficits cor-relate
with diffuse cortical atrophy [determined by magnetic resonance imaging (MRI)]
with a specific accentuation in the left superior precentral gyrus, left paracentral
gyrus, and right precentral gyrus (Agosta et al., 2012).

MOLECULAR, CLINICAL, AND NEUROPATHOLOGICAL
CORRELATES OF FRONTOTEMPORAL DYSFUNCTION
IN AMYOTROPHIC LATERAL SCLEROSIS
Approximately 10% of ALS cases are genetic in origin (Al-Chalabi et al., 2012;
Renton, Chio, & Traynor, 2014) (Table 9.1). Although the mechanism(s) by which
many of these mutations induce neuronal degeneration are uncertain,

237

TABLE 9.1 Genes Associated With Amyotrophic Lateral Sclerosis and Their Overlap With Frontotemporal Dementia

Gene

OMIM

Functional
Changes

PLS/
Other

References

Superoxide
dismutase 1

SOD1

147450

Oxidative stress

+

+ (SBMA,
PMA)

Rosen et al.
(1993)

Senataxin

SETX

608465

DNA/RNA
processing

+

+

Chen et al.
(2004)

Spastin

SPAST

604277

NFL,
cytoskeleton,
microtubule
deficits

+

+

Munch,
Rolfs, and
Meyer, 2008;
Wharton et al.
(2003)

Fused in sarcoma

FUS

137070

Cell death
(closely related
to TDP)

Vesicle-associated
membrane protein–
associated proteins
B and C

VAPB

605704

Altered axonal
transport

+

Angiogenin,
ribonuclease,
ribonuclease A
family

ANG

105850

DNA/RNA
processing

+

FTD

+

ALS

+

ALS-FTD

+

+

Mackenzie,
Rademakers,
and Neumann,
2010; Vance
et al. (2009)
+ (SMA)

Nishimura
et al. (2004)

+ (PBP)

van Es et al.
(2009)

Continued

Cortical Manifestations in Amyotrophic Lateral Sclerosis Chapter | 9 225

Protein

238
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FTD

ALS

ALS-FTD

+

+

+

PLS/
Other

Gene

OMIM

References

TAR DNA binding
protein (TDP-43)

TARDBP

605078

DNA/RNA
processing

Factor-Induced
gene 4 (FIG4)
homolog, SAC1
lipid phosphatase
domain containing
(Saccharomyces
cerevisiae)

FIG4

609390

Cell death/
protein
degradation

+

+

Chow et al.
(2009)

Optineurin

OPTN

602432

Cell death/
protein
degradation

+

+ (PDB)

Maruyama
et al. (2010)

Ataxin 2

ATXN 2

601517

Oxidative stress

+

+ (SCA2)

Elden et al.
(2010)

Valosin-containing
protein

VCP

601023

Protein
degradation

+

+

+

+

Forman
et al. (2006),
Johnson et al.
(2010), Weihl,
Pestronk,
and Kimonis
(2009)

Ubiquilin 2

UBQLN2

300264

Protein
degradation

+

+

+

Davidson
et al. (2007),
Sreedharan
et al. (2008)

Gellera et al.
(2013), Ugwu
et al. (2015)
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Functional
Changes

Protein
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Ion channel
regulation

Profilin 1

PFN1

176610

NFL,
cytoskeleton,
microtubule
deficits

Chromosome 9 open
reading
frame 72

C9orf72

614260

Charged
multivesicular body
protein 2B

CHMP2B

609512

Unc-13 homologue
A (Caenorhabditis

UNC13A

609894

d-amino-acid

DAO

124050

Oxidative stress

+

Dynactin 1

DCTN1

601143

Altered axonal
transport

+

Neurofilament,

NEFH

162230

NFL,

+

elega ns)

+

+

+

+

+

Vesicle
trafficking

+

+

Synaptic
neurotransmitter

+

+

–

Al-Saif,
Al-Mohanna,
and Bohlega
(2011), Belzil
et al. (2013)
Smith et al.
(2015), van
Blitterswijk
et al. (2013)

+

Renton et al.
(2011)
Cox et al.
(2010)

+

Shatunov et al.
(2010)

releas e

Mitchell et al.
(2010)

oxidase

heavy polypeptide

cytoskeleton,
microtubule
deficits

+ (Perry
syndrome)

Farrer et al.
(2009), Munch
et al. (2004)
Al-Chalabi
et al. (1999)

Continued

p
t
e
r

601978

Scle
rosi
s

SIGMAR1

t
i
o
n
s

Sigma nonopioid
intracellular
receptor 1
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Functional
a

PLS/

Protein

Gene

OMIM

Peripherin

PRPH

170710

NFL,
cytoskeleton,
microtubule
deficits

Sequestome 1

SQSTM1

601530

Protein
degradation

TAF15 RNA
polymerase II, TATA
box binding protein
(TBP)–associated
factor, 68 kDa

TAF15

601574

DNA/RNA
processing

+

Spastic
paraplegia 11

SPG11

610844

DNA damage
repair

+

Elongator
acetyltransferase
complex subunit 3

ELP3

612722

Projection
neuron
maturation

+

Changes

FTD

ALS

ALS-FTD

Other

+

+

+

References
Corrado et al.
(2011)

+

+ (PDB)

Le Ber et al.
(2013)
Hand et al.
(2002)

+ (HSP)

Daoud et al.
(2012)
Simpson et al.
(2009)

ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; HSP, hereditary spastic paraplegia; NFL, neurofilament; OMIM, Online Mendelian Inheritance in Man;
PBP, progressive bulbar palsy; PDB, paget disease of bone; PLS, primary lateral sclerosis; PMA, progressive muscular atrophy; SBMA, spinal-bulbar muscular atrophy;
SCA2, spinocerebellar ataxia type 2; SMA, spinal muscular atrophy; TAR, transactive response; TDP, TAR DNA-binding protein.
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TABLE 9.1 Genes Associated With Amyotrophic Lateral Sclerosis and Their Overlap With Frontotemporal Dementia—cont’d
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there are three general themes including the induction of oxidative stress (eg,
mutations in SOD1, ATXN2, DAO), alterations in the cytoskeleton and/or
impairments in axonal transport (eg, VAPB, SPAST, DCTN1, NEFH, PRPH),
and alterations in RNA metabolism (eg, TARDP, ANG, FUS, and pathological
hexanucleotide expansions of C9orf72). However, a group of genetic
mutations cannot be readily bundled into these potential mechanisms
including genes thought to directly give rise to ALS and those thought to be
genetic modifi-ers (CHMP2B, VCP, UBQLN2, SIGMAR1, PFN1, UNC13A,
SQSTM1, TAF15, SPG11, ELP3). Ultimately, however, there are few clinical
features that are unique to any of the genes associated with ALS, suggesting
that the motor degeneration and potentially the neuropsychological deficits are
syndromic or, in the latter, reflective of specific neural network dysfunction
that is indepen-dent of the underlying pathological mutation.
The theme of ALS being syndromic is supported by neuropathological
studies. Consistent with the primary manifestation as a progressive loss of
motor function, the hallmark of ALS is a loss of both spinal and bulbar motor
neurons with degeneration of descending supraspinal innervation pathways.
Affected motor neurons demonstrate a range of nuclear and cytoplasmic neuronal inclusions (NNIs and NCIs, respectively). In a blinded analysis of both
sporadic and familial ALS motor neuron pathology, it was not possible to
identify (by light microscopy) a “signature” pattern of neuronal inclusions of
either cytoskeletal proteins or RNA-binding proteins that would allow
differentiation amongst individual genotypes of ALS (Keller et al., 2012). The
exception to this was SOD1 mutations. The presence of frontotemporal
dysfunction in ALS is typically indistinguishable from that occurring as an
isolated FTD in which diffuse frontal and anterior temporal atrophy is accompanied by a vacuolar appearance consistent with superficial linear spongiosis
throughout affected regions (Wilson, Grace, Munoz, He, & Strong, 2001).
Somewhat in contrast to the pathology of affected motor neurons in ALS,
cortical and subcortical neurons in cases with a syndrome of frontotemporal
dysfunction tend to display an increase in transactive response DNA-binding
protein 43 (TDP-43) cytosolic expression and a range of both NCIs and NNIs
(Neumann et al., 2006).
Although an up-regulation of TDP-43 expression can also be seen as a
response to neuronal injury (Moisse et al., 2009), the presence of both an
increased expression of neuronal TDP-43 and TDP-43 immunoreactive NNIs
and NCIs as major neuropathological features of both ALS and FTD suggests
a common pathogenic process across the two diseases. TDP-43 has a range of
activities that map to the regulation of gene expression, including such diverse
functions as anchoring of chromatin, participation in splicing and RNA
granule formation, the regulation of RNA translation, and participation in
RNA deg-radation through the Dicer complex (Droppelmann, Campos-Melo,
Ishtiaq, Volkening, & Strong, 2014).
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The hypothesis of a continuum encompassing both ALS and FTD has been
further reinforced by the discovery of a pathological expansion of a hexanucleotide repeat (GGGGCC) in C9orf72 in both familial and sporadic ALS
(DeJesus-Hernandez et al., 2011; Renton et al., 2011). The RNA associated
with this expansion undergoes a unique type of repeat-associated non–ATGinitiated translation to give rise to dipeptide repeat proteins that can function
as sinks for a range of RNA-binding proteins, effectively sequestering them
from participating in RNA metabolism (Ash et al., 2013; Souza, Pinto, &
Oliveira, 2015). It remains to be fully clarified as to whether the pathological
RNA alone or the presence of dipeptides alone, or a combination of both, are
sufficient to induce cell death (Hukema et al., 2014; Mizielinska et al., 2014).
The neurodegeneration associated with pathological hexanucleotide expansions in C9orf72 is typically more symmetrical than that observed with other
variants of FTD and includes frontal and temporal cortices and the hippocampus, as well as deeper structures such as the striatum and thalamus (Mahoney
et al., 2012).
No single pathological inclusion describes all variants of frontotemporal
dysfunction in ALS. Indeed, there is increasing evidence to suggest the coexistence of several pathological protein inclusions within the same case, including the
presence of both C9orf72 and TDP-43 (Mackenzie et al., 2013) or C9orf72 and the
microtubule-associated protein tau in pathological inclusions (Bieniek et al.,
2013). In lumbar spinal motor neurons, the coexistence within the same inclusion
of the RNA-binding proteins TDP-43, fused in sarcoma/translocated in
liposarcoma, and Rho guanine nucleotide exchange factor has been described
(Keller et al., 2012). The critical point here is that although there is a tendency to
describe the various neurodegenerative syndromes using nomenclature that
reflects either the underlying genetic basis or the preponderance of a single proteinaceous inclusion, upon critical evaluation the syndromic nature of ALS and its
associated frontotemporal syndromes is evident.
The clinical expression of pathological expansions of C9orf72 is heterogeneous, ranging from a rapidly progressive variant with marked neuropsychological abnormalities to an atypically slow progression that may last decades
(Chester et al., 2013; Kandiah et al., 2012; Khan et al., 2012). Such a range of
survival is not only consistent with the syndromic nature of ALS, but also suggests that the phenotypic expression of a pathological expansion of C9orf72
can be modified either by the presence of a second genetic mutation (the basis
of oligogenic inheritance) or alternatively by either exogenous or
environmental factors.
Perhaps the most controversial aspect of the pathogenesis of frontotemporal dysfunction in ALS is whether or not alterations in the metabolism of tau
are present. However, distinct from the presence of a tauopathy among the
previously hyperendemic focus of ALS in the Western Pacific, we have
observed that tau immunoreactive glial and neuronal inclusions are a significant feature of ALSci (Yang, Sopper, Leystra-Lantz, & Strong, 2003; Yang &
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Strong, 2012). Tau isolated from the frontal cortex of patients with ALSci is
typically insoluble with (in contrast to AD tau) all six tau isoforms being
expressed in the insoluble fraction and abnormally phosphorylated at threonine 175 (pThr175-tau) (Strong et al., 2006). Both the pattern of tau deposition and this phosphorylation state render the tau deposition of ALSci different
from primary age-related tauopathy (Crary et al., 2014; Jellinger et al., 2015)
and from normal tau deposition as a function of aging (Yang, Ang, & Strong,
2005). Moreover, pseudophosphorylated tau mimicking pThr175-tau forms
pathological intracellular inclusions in vitro and leads to cell death (Gohar et
al., 2009; Moszczynski et al., 2015).
These observations suggest that the phenotypic expression of both the
motor neuron and cortical or subcortical neurodegeneration of ALS can be
driven by a wide range of pathological processes, sometimes occurring as
isolated meta-bolic syndromes or at times as a confluence of metabolic
derangements. If this is the case, then the motor neuron phenotype would be
expected to be uniform across all biological variants because there is a limited
phenotypic reserve with which to manifest motor neuron dysfunction,
specifically as a loss of motor function. The converse cannot be held for the
neuropsychological manifesta-tions because the phenotypic reserve upon
which to draw for the clinical expres-sion of a specific pathological process
will be considerably greater. However, these latter manifestations are not
limitless and, as discussed, are reflected in a discrete number of well-defined
syndromes of frontotemporal dysfunction. As will become evident, our
postulate is that these syndromes do in fact draw on a limited phenotypic
reserve, but in this case, the reserve is defined by neural networks.
NEUROIMAGING CORRELATES OF IMPAIRED NEURAL
NETWORK FUNCTION AS THE BASIS OF FRONTOTEMPORAL
DYSFUNCTION IN AMYOTROPHIC LATERAL SCLEROSIS
The postulate that the frontotemporal syndromes of ALS are based on perturbations in neural networks finds support across a number of neuroimaging modalities, but most specifically resting state functional MRI (RS-fMRI) and diffusion
tensor imaging (DTI) (see Chapter 3). RS-fMRI correlates brain regions that are
activated concomitantly and has been used to compare functional network alterations in ALS and the behavioral variant of FTD (bvFTD) (Trojsi et al., 2015).
This latter study highlighted the involvement of three major neural networks in
both ALS and bvFTD: the salience network (SN), the default mode network
(DMN), and the central executive network (CEN) (Fig. 9.1).

To visualize the networks more directly and, more specifically, to assess
the integrity of neuronal pathways, DTI can be applied. The basis of DTI is
the measurement of the diffusion of water along neuronal projections. Given
the narrow diameter of neuronal tracts, water is more able to diffuse along the
tract than across it, having an anisotropic motion, which when measured,
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FIGURE 9.1 Three major networks affected in
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Red nodes have been shown to
be dysfunctional in FTD. (A) Default mode net-work
(DMN) areas affected in FTD include the medial
prefrontal cortex (mPFC) and medial tem-poral (MT)
lobes, whereas the posterior cingulate cortex (PCC),
ventral precuneus (VP), and parietal cortex (PC) are
less commonly implicated. The dashed circle
indicates that the PC is superficial to the contained
structures. (B) Salience network (SN) nodes including
the anterior cingulate cortex (ACC), insula (In), and
prefrontal cortex (PFC) are all implicated in FTDrelated dementia processes.

(C) Central executive network (CEN) areas
affected include the dorsolateral prefrontal cortex
(dlPFC), whereas the posterior parietal cortex is
less com-monly implicated.

allows for an approximation of the tract direction to be generated. More
myelination of tracts increases the signal because of higher water content.
Therefore a reduced signal is likely to indicate reduced integrity of the connective pathways. Although not yet applied to understanding the frontotemporal
dysfunction of ALS, DTI is being applied to understanding the degeneration
of the corticospinal tracts as part of the neural network subserving motor function (Brettschneider, Petzold, Sussmuth, Ludolph, & Tumani, 2006; Hendrix
et al., 2015; Karlsborg et al., 2004).
The concept that neural networks mediate not only the phenotypic expression of the neurodegenerative process but also can serve as “highways of
disease propagation” has been supported by staging the spread of either tau
protein or α-synuclein pathosis in AD and Parkinson disease (Braak & Braak,
1995; Braak et al., 2003). These observations suggest that whereas network
connectivity may be affected as a whole, there are specific patterns of vulnerability within these networks. This approach to the study of neural networks
has provided insight into the dysfunctional network systems in a variety of
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disease states in which syndrome-specific patterns of dysfunction are observed
(Seeley, Crawford, Zhou, Miller, & Greicius, 2009). Extending these
methodol-ogies to evaluate the integrity of white matter tracts within the brain
(structural network imaging), mathematical models in conjunction with fMRI
has yielded the capacity to evaluate differences in activated brain areas
comprising nodes in these networks (functional network imaging) and to
ascribe differences to individual disease states (Zhou et al., 2010).
The understanding of neural networks gained through such studies can be
applied to understanding the neuroanatomical origins of the frontotemporal syndromes observed in ALS. The DMN consists of regions in the medial temporal
lobe (memory), medial prefrontal cortex (involved in ToM), posterior cingulate
cortex, ventral precuneus, and medial, lateral, and inferior parietal cortices. The
DMN is active largely during periods of wakeful rest, while the patient is not
focusing on anything occurring in the outside world (ie, daydreaming) (Yan et al.,
2009). Importantly, the DMN has been implicated in social cognition (Schilbach,
Eickhoff, Rotarska-Jagiela, Fink, & Vogeley, 2008). The SN has been implicated
in a number of psychotic disorders (Palaniyappan & Liddle, 2012). In cases of
young-onset FTD, many are first diagnosed as psychotic disorders up to 5 years
before FTD because of the similarity of presentation (Velakoulis, Walterfang,
Mocellin, Pantelis, & McLean, 2009). It is noteworthy then that increased
psychotic symptoms have been observed in ALS with FTD (Lillo et al., 2010).
The SN is thought to act as a switch between the DMN and the CEN (Menon &
Uddin, 2010; Sridharan, Levitin, & Menon, 2008), allow-ing for the focus of
attention to the external world and one’s inside thoughts to be prioritized and
maintained. This network consists of the anterior cingu-late, insula, and prefrontal
cortices. The CEN is implicated in executive control (D’Esposito, 2007; Koechlin
& Summerfield, 2007). The CEN (also referred to as the frontoparietal network)
consists of the dorsolateral prefrontal cortex and posterior parietal cortex, with
particular activity along the intraparietal sul-cus. Importantly, the DMN and CEN
have anticorrelated activations such that activation of one leads to inhibition of the
other (Fox et al., 2005). Supporting dysfunction in these networks in ALS, the
presence of protein inclusions in the anterior cingulate cortex paired with the signs
of both ToM (van der Hulst et al., 2014) and executive control dysfunction (York
et al., 2014) may indicate an SN abnormality because there are dysfunctions across
all three network activities that may indicate a switching and control abnormality.
Consistent with this, both ALS and FTD brains have reduced SN functioning,
whereas patients with AD have an enhancement in this network and a reduction in
activity of the DMN (Zhou et al., 2010).
Beyond describing the basis of the neuropsychological manifestations of ALS,
the analysis of neural networks has provided insight into neural network
dysfunction in ALS before the detection of executive dysfunction (Trojsi et al.,
2015). When both ALS and bvFTD were compared with controls, reduced right
supramarginal gyrus connectivity (reflecting CEN dysfunction) and decreased
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medial prefrontal cortex and insular activation (reflecting SN dysfunction) was
observed in both ALS and bvFTD, although it occurred in bvFTD more than
in ALS. Of note, divergence between disease states was observed, because
ALS cases showed reduced posterior cingulate connectivity (reflecting DMN
dysfunction), whereas bvFTD cases showed an increase in connectivity of this
region along with decreased connectivity in the frontal regions of this
network, indicating more widespread connectivity changes when the cognitive
phenotype was present. The convergence in network dysfunction may indicate
common processes at work in these separate phenotypes. Conversely, the
divergence in DMN activity, along with more severe deficits in other network
connectivity may be responsible for the lack of change in social cognition in
some patients with ALS.
Additional network connectivity studies in patients with bvFTD have
shown a reduced connectivity throughout the brain, including the anterior cingulate cortex, temporal poles, frontal gyri, and insular cortices (Agosta et al.,
2013). This reduced connectivity has been determined to represent a reduction
in connection efficiency and may represent a reduced ability to transfer and
therefore process information (Agosta et al., 2013). Additionally, white matter
integrity is compromised in the same regions as major gray matter loss, with
extension to other regions with no measured gray matter atrophy (Mahoney et
al., 2012). A reduction in the overall connectivity of the uncinate fasciculus
has been implicated in bvFTD in distinction from other dementias, namely
AD, which shares some network connectivity–change overlap with bvFTD
(Mahoney et al., 2012).
Apart from the cognitive involvement, structural brain network imaging
studies of patients with ALS has revealed a motor network dysfunction that
correlates with the severity of disease to a larger extent than total measured
atrophy (Verstraete et al., 2014). Expansion of these deficits is seen with
disease progression, suggesting a spread of pathosis reminiscent of the spread
of protein inclusions (reviewed in Jucker & Walker, 2013). Such a postulate
would also explain a progressive diversification of symptoms, implying that
this spread of dysfunctional activity along brain network paths is a key
component of the disease process.

MODELS OF NEUROPSYCHOLOGICAL DYSFUNCTION
IN AMYOTROPHIC LATERAL SCLEROSIS
Whereas a number of models of the motor dysfunction of ALS have been identified, there are very few that recapitulate the neuropsychological dysfunction
described, and essentially none that address the integrity of neural networks. Thus
although the most commonly utilized murine model for ALS harbors the G93A
SOD1 mutation seen in familial ALS, little is known regarding its impact on cognitive function in the mouse, although these mice do possess shorter dendrites in
the prefrontal cortex and have reduced fear extinction (Sgobio et al., 2008).
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The latter precedes the development of motor deficits. Mice harboring the
G37R SOD1 mutation have spontaneous alternation deficits on a T maze task
(Filali, Lalonde, & Rivest, 2011).
Murine models of TDP-43 pathology have been developed, including the
overexpression of wild-type TDP-43 (Wils et al., 2010). These mice develop
spinal and cortical TDP-43 pathosis reminiscent of ALS-FTD. In a separate
study, the overexpression of human wild-type TDP-43 in mice led to memory
deficits in the Morris water maze as well as fear conditioning tasks (Tsai et al.,
2010). The expression of mutant TDP-43 (A315T) induces both cortical and
spinal motor neuron death in mice in the absence of pathological cytoplasmic
TDP-43 aggregates (Wegorzewska, Bell, Cairns, Miller, & Baloh, 2009). To
attempt to more precisely reflect the human disease state, Swarup and colleagues designed mouse models of human wild-type TDP-43 as well as
A315T and G348C mutants that expressed TDP-43 at levels that more closely
resemble that in the human CNS (Swarup et al., 2011). They found that along
with motor deficits, mice developed cytoplasmic TDP-43 pathosis resembling
that of ALS-FTD. Affected mice developed learning deficits on the Barnes
maze test, indica-tive of cognitive abnormalities.
The discovery of C9orf72 is relatively recent, and thus the development of
models of cognitive dysfunction lags behind that of SOD1 and TDP-43 models.

THERAPEUTIC STRATEGIES
Given the relatively recent increase in our understanding of both the incidence
of frontotemporal dysfunction in ALS and its probable phenotypic basis in
dysfunction of neural networks seemingly independent of the underlying proteinopathy, little is known regarding its treatment. Indeed, at this time, there
are no studies that have specifically addressed pharmacotherapies for this
aspect of the disease process.

CONCLUSIONS AND FUTURE DIRECTIONS
ALS is a clinical presentation of a group of pathologies that happen to affect
the same cells through potentially different mechanisms. When patients
exhibit dysexecutive syndrome, it is the result of specific network activity
malfunc-tion, such as the insula in the SN. Spread of pathosis through these
networks is likely to be responsible for disease progression. Further insight
into the appar-ent selective vulnerability of the motor and frontal cortical
neurons will also be important in determining the etiology of the disease.
Patient imaging with molecule-specific ligands and genotypic analysis to
determine which patholo-gies are the most likely causes of the phenotype will
be crucial for developing strategies to stop disease progression in individual
patients and stratify cases based on possible mechanisms of cell death such as
oxidative, RNA processing, or cytoskeletal abnormalities.
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